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Abstract 
This context statement outlines mypublished research in three themes, adapted from the 
ten criteria for screening established by Wilson and jungner (1968): alanDrki tradxnwý as 
a public health problem; implementation of large-scale chlamydia screening programmes; 
and monitoring and evaluation of chlarnydia screening programmes. These themes are 
supported by seven published papers quantifýing the epidemiology of chlarnydial infection 
in several populations; describing the development, implementation and first year results of 
a national chlamydia screening programme; and demonstrating four methods of 
evaluation- assessment of screening criteria, use of positivityto measure disease changes 
in the population, clinical audits of provider adherence to screening guidelines, and fiscal 
analysis of costs through economic modelling. 
My research utilised a diverse set of study designs and methodological approaches- a) 
confirmatory studies of previously published research; b) cross-sectional studies with 
differing levels of statistical sophistication; c) clinical policy review using questionnaires to 
health care providers; d) economic modelling of budget expenditures, and decision-tree and 
sensitivity analyses; and e) an evaluation of a chlam), dia screening programme combining 
retrospective cross-sectional anal)sis and multivariate logistic regression with sensitivity and 
efficiency anal3res. 
My research has revealed significant levels of cblamydia morbidity in a variety of 
populations and settings in the Urýted States and Uýnited Kingdom and has demonstrated 
consistently increasing trends in rates of diagnosed chlarnydial infections among 
genitourinary medicine (GLM clinic attenders in the UK. These data suggest that 
chlamydial infection is a prevalent disease in both countries and contributes to a significant 
global public health problem. I have examined the genesis of a new national chlamydia 
2. 
screening programme in the UK, and have shown the continued feasibility and 
acceptability of chlam)dia screening, affirmed that screening in high prevalence populations 
is a successful strategy for disease detection, and improved our understanding of the sexual 
behaviours that continue to drive this epidernýc. My evaluation of the longest running 
chlarnydia screening programme in the US has illustr-ated the value of periodic assessments 
in screening protocols and lead to the revision in selection criteria for women screened in 
the north western LJS. I have found utihty in a variety of methods to monitor and evaluate 
chlamydia screening programmes. The application of sensitivity and efficiency thresholds 
to sets of screening criteria proved useful in evaluating criteria performance and increasing 
criteria efficiency. Using chlamydia test positivity as a surrogate measure for prevalence 
could adequately measure programme impact for the National Chlarnydia Screening 
Programme in England. Cinical audits of service providers regarding published guidelines 
for cWam)dia screening in termination of pregnancy services demonstrated practice 
variation for chlam)dia screening in these settings and suggested harmonisation of 
guidelines to increase adherence. Finally, my research of screening programme costs using 
economic models proved a useful tool to explore the average costs of screening and 
variations in estimates as local programmes revise their implementation and operational 
structure for chlamydia screening, and recommends this method be used to inform 




This context statement summanses my research in defining the epidemiology and public 
health significance of Wanodia tradwutis infection, developing and implementing new 
screening initiatives, and monitoring and evaluating existing chlamydia screening 
programmes. Large-scale chlamydia screening programmes began in Sweden and the US in 
the 1980's. At that time, the evidence for the magnitude and the consequences of 
chlarnydial infection was building. Multiple studies of infertility (Cates 1984; Nfabey, 
Ogbaselassie, Robertson, Fieckels and Ward 1985; T)iarn et aZ 1985; Robertson, Ward, 
Conway and Caul 1987; NEettienen, licinonen, Teisala, FIaldMrainen and Punnonen 1990), 
ectopic pregnancy (Chow et aL 1990) and pelvic inflarrunatory disease (PID) Q&rdh, Ripa, 
Svensson and Westrom 1977; Moller, IJardh, Ahrons, and Nussler 198 1; DeMuýlder et aL 
1990; Westrom, joesoef, Rynolds, Hagud and Thompson 1992) were concluding that this 
bacteria was a prime suspect in the aetiology of these conditions. Given the potential 
devastating consequencei to women, research began to focus on how to intervene. 'Me 
initial detection method for C traoOmnais was cell culture, difficult to perform accurately 
and requiring a high level of sIdH in the laboratory (Stamm 1999). The populations infected 
seemed to be diverse, at least from the small epiden-ýologic studies thus concluded 
ývkGormack er aL 1979), but focusing on those at high risk of other sexually transmitted 
diseases seemed most logical. 
Sweden was the first country to organize at the national level to use targeted chlainydia 
screening for those at high risk as a disease control strategy, as well as an approach to 
reduce the occurrences of PID. In Sweden, the programme targeted routine chlamydia 
testing in conjunction with genital examinations already performed at sexual health clinics. 
This approach was nationally implemented across the network of health care settings 
+ 
providing these examinations (Herrmann and Egger 1995). In the US, the programme 
targeted women attending sexually trans mitted disease (STD) clinics (given the high risk 
sexual behaviours within this group) and women attending familyplanning clinics (focusing 
on " infettility prevention") through the use of selection criteria (1-1andsfield etaL 1986). 
Criteria that were found to be predictive of infection were aged 24 years or less, new sex 
partner in the last two months, mucopurulent cervicitis, easily induced endocervical 
bleeding, and use of no contraception or a non-barrier method (Handsfield et aL 1986). Ile 
LS public health care system is divided into ten regions (numbered 1,11,111, etc. to IX, and 
X), and established a demonstration project for chlamydia screening in Region X (north 
western LJS) to test the utility of selective screening as an approach for targeting women at 
high risk for chlarnydial infection. Even though the two strategies were organized and 
implemented in different ways, both the US and the Swedish prograimnes experienced 
appreciable decreases in chlarnydia morbidity after three years of screening (Lossick er aL 
1990; Flerrmann and Egger 1995). Sweden continued in this vein through the 1990's and 
the US expanded its programme across the other regions over the same time. Both 
programmes began to be viewed as 'models of success' and several European cities started 
to explore or implement chlamydia screening based on selecting "at risk" women, including 
Aarhus in Denmark and Amsterdam in the Netherlands (Moeller, Andersen, Olesen, and 
Ostergaard 2003; Westh and Kolmos 2003). In the United Kingdom in 1998, a 
government-sponsored investigation of whether a national screening progrumme for 
chlarnydia should be established concluded genital chlamydial infection met the Wilson- 
Jungner criteria (Wilson and Jungner 1968) for a screening programme focusing on women 
(chief Medical Officer 1998). 
However, given the depth of evidence, screening for chlamydia is still controversial. Many 
unresolved questions remain, namely. 
- Do we really know how much chlam)dia is in the population? 
" Who are the tight populations to screen: women, men, both or onlyyoung adults? 
" Are the complications of infection as severe as we think) 
" Does screening really decrease a woman's chances of becoming infertile? 
" Are our selection procedures for determining who is infected and our laboratory tests 
for detecting the organism sufficiently accurate to not miss infections but also to not 
classify someone as infected when they aren't? 
" Can we develop better diagnostics to improve the detection of infection? 
" Does treatment reallywork and can it reverse the damage already done? 
" Is there a correct way to offer screening: either during a gynaecological. examination, 
by invitation to attend a clinic, or through testing 16ts posted in the maiP 
" Do we really know that screening saves money and can reduce the prevalence of this 
infection in the population? 
'1he findings of my research presented here examine the epidemiology of chlamydial 
infection in several populations (LaMontagne, Fine and Marrazzo 2003; Brown etal 2004), 
sunu-narise the development, implementation and first year results of a national chlamydia 
screening prograrnme (LaMontagne, Fenton, Randall, Anderson and Carter 2004b), and 
demonstrate approaches for monitoring and evaluating chlamydia screening programmes 
(LaMontagne, Patrick, Fine and ý&rz-azzo 2004a; Adams et aL 2004b; LaMontagne, 
Pimenta, Fenton, Mallins on and Hopwood 2004c; LaMontagne et aL 2005; ). My research 
has shown high levels of disease in male and female populations in two countries. In the 
Urýted States, we found prevalence among women from 4-7% and among men 5-18%, 
depending upon the presence of symptoms. In England, chlarnydia positivity in the first 
year of the national screening prograrnme was 10.1% and reported rates of diagnosed 
infections from genitourinary medicine (GLJ4 clinics were 66 per 100,000 for men and 
167 per 100,000 for women. I demonstrated how to implement a national chlarnydia 
screening programme and quantified the results of the first year, confirming previous 
research on the risk factors for infection and ideal populations for screening. My research 
presented in this context statement also examines several methods for monitoring and 
evaluation cMamydia screening programmes, including assessment of selection criteria, 
measurement of sensitivity and efficiency of screening criteria, analysis of programme costs 
for fiscal jurisprudence, use of chlarnydia positivity as an accurate measure to monitor 
reductions in disease in the screened population, as well as clinical audits of service 
providers to ensure adherence to established guidelines. 
Even though each of my seven published manuscripts included in this context statement 
has a team of authors, ' my personal contribution requires explanation. I conceptualised and 
designed four of the studies, including colIection and collation of data, all statistical 
analyses, data interpretation and principal authorship of the manuscripts: LAIontagne et aL 
2003; LaMontagne et al 2004a; LaMontagne er aL 2004b; and LaMontagne et aL 2005.1 
collated, analysed, and interpreted existing data that was originally collected by the study's 
co-authors, and I was the principal author of the published manuscript for LaMontagne et 
aL 2004c. I assisted in conceptualising the methods, colIated data, assisted with data 
analysis, and production and interpretation of results, and I also contributed to writing the 
manuscript and revisions for Adams et aL 2004b. For Brown et at 2004,1 colIated, analysed 
and interpreted retrospective data, and provided substantive written comments on the 
sexuallytransmitted infection (Sn) trend data presented in the manuscript. 
Professional ethics were considered prior to each study. The infringement of patient 
confidentiality and confirmation of patient consent is paramount in any clinical research. 
Five of mystudies consisted of previous collected surveillance data, where patient consent 
was already received for the clinical service provided and information was disseminated to 
patients regarding the reporting of de-identified (pseudo- anonymised) Sn data to local or 
' CD-author statements of my individual contribution to the research are on file at NEddlesex University. 
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national health bodies with the mandate for the surveillance of STIs (LaMontagne et aL 
2003,2004a, 2004b, 2005; and Brown et aL 2004). Because de-identified data were used in 
accordance to the US or UK legal mandates, as appropriate, for handling routine SU 
surveillance data, formal ethical approval for each study was not required. LaMontagne et 
at (2004c) was a policy review, surveyýing clirýc managers; thus, no patient data were used 
and ethical approval was not required. Ile cost analysis of cWam)dia screening (Adams et 
al. 2004b) also did not require an ethics review, as the study utilised previously consented 
patient data in aggregate only, combined with publiclyavailable health care cost data. 
The research included in this context statement employed a diverse set of study designs and 
methodological approaches. LaMontagne et aL (2005), was specifically designed to confirm 
a previously published statistical method of adjusting test positivity estimates for the 
measurement of prevalence to establish its accuracy and usefulness as a programme 
monitoring tool for the National Chlamydia Screening Programme (NCSP) in England. 
Cross-sectional techniques with differing levels of statistical sophistication were used for 
the descriptive epidemiological studies of the trends in sexuallymansrnitted infections 
(STIs) in the United Kingdom (Brown etaL 2004), asymptomatic chlarnydial infection in 
men aaMontagne et aL 2003), and results from the first year of the NCSP (LaMontagne et 
d 2004b). To assess chlarnydia screening and treatment practice patterns among 
termination of pregnancy providers, clinical policy review techniques using questionnaires 
was employed (LaMontagne et aL 2004c). In the study of the costs of operating an 
opportunistic screening programme among 16-24 year old women, economic modelling of 
budget expenditures matched with patient flow quantification in decision-tree and 
sensitivity analyses was used to estimate the costs of screening tests and the components 
that provided the greatest variability in those costs (Adams et aL 2004b). Lastly, I developed 
a unique design for the evaluation of the screening programme in the north western US. 
(Region X) that combined retrospective cross-sectional analysis and multivariate logistic 
regression with sensitivity and efficiency analyses wlýich resulted in a more robust 
evaluation of selective screening criteria (LaMontagne et aZ 2004a). 
Taken in concert, these seven papers robustly contribute to the evidence that chlamydia 
screening fulfils the criteria for public health intervention (V nion and jungner 1968). 1 
have further refined the epidemiology of chlamydia- the magnitude of the problem and 
the factors most associated with infection. The most significant contribution being made to 
the understanding of chlam), dial infection in men. I have taken the best scientific evidence 
available, as well as the best practice lessons learned from other programmes, to develop 
and implement the first nationally coordinated chlamydia screening programme in England. 





I have wed the criteria developed in the 1960's by Wilson and Jungner (1968) as the 
theoretical framework of my research. The principles described in their manuscript 
established the current model by which public health determines whether, when and how 
to screen for disease. Over time, these criteria have been used in infectious disease control, 
as well, to justify a screening response to a perceived threat to the population's health. 
Several examples are cited, including tuberculosis and cervical cancer (Wilson and Jungner 
1968). 
The criteria cover ten general concepts that seek to qualify and quantify the clinical 
intervention of early detection from both the patient's and the provider's perspective. 
Firstly, the condition should be an important health problem. Importance can be relative, 
but suggested evidence includes scope and magnitude of the disease, types of populations 
affected, and the impact on both the individual writh the disease, as well as the population 
at large. 
Secondly, the natural history of the condition, including development from latent to 
declared disease, should be adequately understood. For certain conditions, natural history 
studies have been possible, either in humans or appropriate animal models, especially if the 
condition is new, eg., severe acute respiratory syndrome (SARS), or rare, eg., sickle cell 
anaemýia, or untreatable, eg., certain cancers prior to adequate therapeutic regimens. Given 
modem medicine's climate of studies involving human subjects, the focus on meeting these 
criteria has been on the "adequacý' of our knowledge of the disease, rather than a 
complete understanding of the entire natural history. 
10 
Along with understanding the natural history, Wilson and jungner (1968) argue that a 
recognisable latent or early symptomatic stage of the disease is required for preventive 
public health action- the third criteria. The goal of screening otherwise healthy 
populations is to determine those who are infected and could develop disease 
complications in the future (Friis and Sellers 2004). Basically, there is a need to halt the 
(potentiallý less harmful infection before it becomes a more significant disease. 
Ile fourth and fifth criteria build of this concept of early detection. Ihere needs to be a 
suitable test for detecting who is infected and who is not. TUs relates to the ability of the 
diagnostic test (or examination) to be sufficiently sensitive enough to detect the people 
who really are infected (true positives) from those who are truly uninfected (true negatives); 
thus the diagnostics need to have high sensitivity and high specificity. Fifth, this diagnostic 
test/examination needs to be acceptable to the population. Because screening targets 
"apparently' healthypeople, the potential harm (physical or psychological) of the 
diagnostic test needs to be minirrLed for population acceptance. 
There is potential to do more harrn than good with a screening test if there are no facilities 
for diagnosis and treatment, if the treatment is unacceptable (causes more harm than no 
treatment) byeither the population or the medical care providers, or if there is no 
acceptable and agreed definition of who is a patient. In the sixth, seventh and eighth 
criteria, Wilson and jungner (1968) focus on the health care aspects of the screening 
intervention. 'Mere must be an adequate service delivery infrastructure, either through 
ph)sical clinics/hospitals; or networked outreach of health care personnel that can reach the 
target population. Treatment that is costly, has severe side-effects, or is not efficacious 
might be a deterrent to a population being screened. This might also make it difficult for a 
coherent and clinicaUrsound treatment policy to be developed by health care providers. 
Lastly, if there is no clear definition of who is patient, either inthe selection procedure for 
II 
screening or the interpretation of laboratory diagnostics, there is a potential that a person 
who should have been treated will be missed and those who are not considered to be 
infected will be treated unnecessarily. 
I'lie costs of finding infections, 'case-finding, ' in an otherwise healthy population must be 
balanced with the expenditure for medical care. Costs include supplies, personnel, 
establishing the screening programme, and on-going maintenance of the intervention 
within the health care system. Additionally, there could be societal costs or long-term costs 
in terms of loss of productivity by those undergoing diagnosis and treatment or medical 
costs incurred from not detecting infection before disease or sequelae from disease are 
experienced by the population. The total cost must balance the financial outlays required 
for the screening intervention versus the potential expenditures required in the absence of 
screening. 
Lastly, Wilson and jungner (1968) advocate for screening to be a continual process, as 
single-occasion interventions mayonlyllit a small proportion of the affected popiAation or 
only detects persons infected now, but not those who subsequently become infected. 
]RATIONALE FOR THEORETICAL FRAMEWORK 
Ihe concepts described in the Wilson-jungner monograph are not original; they have 
origins in chronic disease prevention, shaped by earlier works in the 1950's reported in the 
Commission on Chronis Illness (1956-9) and by Chapman (1949), Moutin (1950), and 
Smillie (1952). However, Wilson and jungner were able to synthesise these earlier works 
into a more digestible and comprehensive format, which has enabled the concepts to find a 
broader application in the field of infectious disease. Additionally, the work of Wilson and 
jungner has influenced epiderniologic methods (Mausner and Kramer 1985; Hennekens 
Iz 
and Buring 1987; Friis and Sellers 2004) through an approach that can be applied regardless 
of the "agent" causing disease, whether that is a bacteria, such as Man* tradknutis 
causing pelvic inflammatory disease and infertility, a virus, such as hepatitis causing chronic 
liver failure, or a condition, such as diet contributing to heart disease. Indeed, with the 
grazizz of the World Health Organisation's seal of approval, these criteria have been widely 
used in prograrnines as diverse as diabetic retinopathy (Wilson and jungner 1968), cervical 
cancer (I-lanselaar 2002), skin cancer/melanoma (Rampen, Neumann and Kiemeney 1992), 
and newborn screening (Seymour et aL 1997). 
Even though widely used, some have expressed concern that the criteria are subjective 
(Pollitt 1999) or conflict with evidence-based views (Seymour etal 1997). Pollitt (1999) has 
noted that qualitative descriptors in the criteria are difficult to define and measure. For 
example, what is 'important' in detennining the importance of the public health problem- 
the very first criteria to be met according to Wilson and Junger. Importance could be based 
on the magnitude of the disease or the magnitude of the consequences of the disease. 
However, who determines the thresholds for these? Other words, such as 'adequate', 
'suitable', 'unacceptable', and the Eke, are used throughout the criteria and could be biased 
in measurement or interpretation (Pollitt 1999). These limitations suggest a more judicious 
and cautious use of the Wilson and Jungner criteria. 
Despite these critiques, the criteria developed in the 1960's by Wilson and junger find 
application today. 'Fhey provide a tool for scientists and public health practitioners in 
developing programmes and policies for a wide-range of conditions affecting the health of 
the population, including the review of evidence for newborn screening of in-born 
metabolic disorders which criticised these very criteria (Seymour et aZ 1997). For example, 
the Chief Medical Officer's Expert Advisory Group (1998) structured their comprehensive 
review of the evidence for chlarnydia screening based on these criteria. These ten criteria 
15 
encompass broad themes within the field of chlamydia screening to facilitate review and 
understanding of the current research evidence, as well as to explore gaps in our knowledge 
that require further work 'Mey can be used to provide a logical progression from 
quantifying the problem to surnmarising approaches for resolution to evaluating the course 





The principles of screening outlined in Wilson and jungner's sentinel work have implicitly 
or explicitly guided the development of widespread chlarnydia screening as a method of 
secondary prevention for the control of this prevalent sexually transmitted infection. 
Because of this, it is useful to review the literature following the logic and flow of the 
Wilson and jungner criteria. 
PUBLIC HEALTH IMPORTANCE 
Nam 
. 
Aa tradxnutis is a prevalent and potentially devastating infection (Stamm 1999). 'Me 
scope and magnitude of this infection is adequately understood and quantified (Cates and 
Wasserheit 199 1). Groundbreaking research on the aetiology of tubal factor infertility 
illustrated the critical role of chlamydial infection plays in this devastating sequelae. Cates 
(1984) cites early research from Sweden that first suggested the link between chlampfial 
infection and infertility, via pelvic inflammatory disease (PID), and encapsulates the 
evidence to date to assert the causal pathway of infertility. Women with salpingitis and/or 
PID have a 3-7 fold risk of involuntary infertility (Cates 1984; Nfardh etaL 1977). 
Subsequent studies from 1985- 1987 confirmed these early findings (Nfibey et aL 1985; 
Tjiarn etd 1985; Robertson etaL 1987). However, the exact mechanisms of the causal 
pathway were yet to be elucidated. 'Me intervening step of PID was found to be the 
immediate consequence of untreated chlamydial infection. In a retrospective study of 166 
women with acute PID, Moller (198 1) found that 2 1% of cases had chlamydial organisms 
cultured from the cervix, and at least 25% of additional acute PID was directly attributable 
to infection with Mya*ýznu bgdris (another bacterium). Further research has confirmed 
chlamydia as one cause of PID (DeMuy1der et d 1990; ýAarks, Tideman, Estcourt, Berry, 
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and hTmdel 2000). Additionally, the etiologic role of chlamydial infection with ectopic 
pregnancybas also been documented in several studies Mettinen et al 1990; Chow et aL 
1990; Egger, Low, Smith, Lindblom, and Henn ann 1998; Cates 1999). Lastly, recent 
evidence has come to light to suggest that Want* trad5awis infection is related to 
ovarian cancer, cervical cancer, and male infertility (Ness, Goodman, Shen and Brunharn 
2003; Paavonen et aL 2003; Idahl, Boman, Kumlin and Olofsson 2004). INS empirical 
evidence confirms the severity of the consequences of untreated cWamyxlial infection on 
personal and public health. 
The risk of developing these sequelae can be assessed through measuring the burden of the 
infection in various populations. Prevalence studies have been undertaken to estimate the 
magnitude of infection and project proportions that may suffer sequelae. In an early study, 
McCormack et at. (1979) found nearly 5% of female college students in the US were 
infected. A review of the literature on the prevalence of infection among European women 
byWilson et aL (2002) showed levels of infection from 1% (2,494 Spanish women ages 15- 
35) to 17% (306 French women ages 15-55), depending upon the population under study. 
A meta-analysis of prevalence studies from the United Kingdom byAdams and colleagues 
(2004a) found a consistent 9% prevalence among women attending farnilyplanning clinics. 
Prevalence estimates have varied considerably depending upon the sampling frame, which 
is not surprising because various sampling methods select different populations. For 
example, population-based household probability samples drawn from the general adult 
aged population have tended to find a lower prevalence of infection than clinic-based 
samples, eg., in China female prevalence was 2.6% (Parish er aL 2003), in the US prevalence 
among women ranged from 2.3% in white non-I-Iispanics to 7.5% among non-Hispanic 
black women (Mertz et aL 1998), in Slovenia 4.1% in women 18-24 yvars old (Klavs, 
Rodrigues, Wellings, Kese and Hayes 2004), in the United Kingdom the National Survey of 
i 
Atdtudes and Sexual Lifestyle found 3% among adult women (Fenton et aL 200 1), and in 
Nadu, India a prevalence of 3.3% among 15-45 year old women was reported Goyee etaL 
2004). Ginic-based estimates of prevalence in England have found 1 in 10 young women 
infected (Pimenta et d 2003b). Other researchers have confirmed similar levels of infection 
in various female populations, depending upon setting, laboratory test methods, and age of 
the population sampled (Gerbase, Rowley, Heymann, Berkeley and Piot 1998; SWjeldestad, 
Nordbo and Hadgu 1997; Simms et aL 1997; I-liltunen-Back, Haikala, Kautiainen, Paavonen 
and Reunala 2001; Richardson E etaL 2003). 
Among men, the estimates of the burden of chlamydial infection have also varied; these are 
also dependent upon the population sampled, age of the men, presence of symptoms, type 
of specimen tested, and laboratory test method (Hart 1993; Sutton, ý&rtinko, Hale and 
Fairchok 2003; Ku et aL 2002; Aronson and Phillips 1993; Gunn et aL 1998; Oh er aZ 1994; 
Johnson, Neas, Parker, Fortenberry and Cowan 1993; Qemins etaL 2000; LaMontagne etal 
2003; LaMontagne etaL 2004b). Among male military populations in three different 
countries, prevalence was 4.6% in Denmark (van den Brule et aL 2002), 5.3% in the LJS 
(Cecil etaL 2001), and 9.8% in Scotland (McKay, Cler7, Carrick-Anderson, Hollis and Scott 
2003). Marrazzo et aL (200 1) found a similar level of infection, 5.5%, among asymptomatic 
men attending sexuallytransmýitted disease chrýics in Seattle (US) tested via urine samples. 
I-Egh prevalence of infection in both male and female populations coupled with significant 
reproductive health consequences of untreated infection demonstrate that genital 
chlarnydial infection is an important public health problem. 
NATLT, AL IUSTORY 
Animal models and quasi-natural history studies of infertility have facilitated our 
understanding of the natural history of genital cWaniy&l infection (Patton, Wolner- 
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I-lamsen, Gc)sgrove and Holmes 1990; Cates 1984; Mettinen et aL 1990; Westrom et aL 
1992). DeMuy1der et aZ (1990) showed that untreated lower genital tract infection in 
women leads to upper genital tract infection, which manifests itself as PID. It is estimated 
that PID causes up to 47% of all ectopic pregnancies and 20% of cases of tubal factor 
infertility (Stamm 1999). In men, the consequences of infection seem to be less severe, but 
can include urethritis, epididymitis, and Reiter's syndrome (Cates and Wasserheit 1991); 
and recently, infection has been implicated in male infertility through damage to viable 
semen (Idahl et al. 2004). The precise understanding of the exact pathogensis of genital 
chlamydial infection in both men and women is not fully known; however, the knowledge 
base is sufficient enough for our adequate understanding of the natural history (Stamm 
1999). 
AsYMIPTOMATIC STAGE 
There is a recognizable latent or asymptomatic stage of the infection prior to disease (or 
sequelae) manifestation, which would lend itself to early detection prior to adverse 
consequences. Seventypercent of infected women are estimated to experience no or very 
mild symptoms (Cates and Wasserheit 1991). In men, chlamydial infection seems to be 
more symptomatic, about 50% of men will develop symptoms if infected (Stamm 1999). 
Symptoms suggestive of infection include dysuria (pain in urination), abnormal penile or 
vaginal discharge, abdominal pain (in women), and irregular or intermenstrual. bleeding (in 
women), and can present three to fourteen days after exposure (Stanun 1999). Stamm 
(1999) suggested that people infected at younger ages are more likely to experience mild 
symptoms. Because symptoms generally encourage people to seek medical attention, a 
disease with high frequencyof symptom development among infected persons is not 
considered a good candidate for screening. The goal of screening is to detect unrecognised 
disease in a population of apparently healthy people and sort those with disease from those 
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without (Nlausner and Kramer 1985). Mus, for chlamydia, especiaUy among infected 
women, 70% of the infected population seemingly "apparently well, " i. e., asymptornatic, 
provides a good case for screening. 
DIAGNOSTICTESTS 
As previously stated, the chlarnydia bacteria has been difficult to grow in cell culture (Black 
1997; CDC 2002). However, since its recognition as a potentiallydebilitating infection for 
women, advances in laboratory detection of the organism in clinical samples, such as 
cervical or urethral swabs, have intensified to make laboratory diagnosis easier and more 
sensitive. In the 1970's direct fluorescence assays were the standard (CDC 2002). In the 
1980's more sensitive enzyme immunoassays (EIA or ELISA) became cornmonly used 
(CDC 2002; Watson et aL 2002). However, those tests had sensitivities of 80% at best. 
Currently, the best tests available utilize techniques that amplifyDNA. Called nucleic acid 
amplification tests (NAATs), these new diagnostics have shown sensitivities as high as 95 % 
and specificities approaching 100% (Newhall et d 1999; Johnson et aL 2000; Cheng, 
IvIacaluso, Vermund, and Hook 2001; Battle et aL 2001; Verkooyen, Peeter, van Rijsoort- 
Vos, van der Meijden and Mouton 2002; Ostergaard 2002; Chemesky 2002; Stary 2002; 
Semeniuk, Zentnerr, Read and Church 2002; Verkooyen et aL 2003; Koumans et aL 2003). 
Even though ranges of sensitivity from 49- 100% have been reported by Ostergaard (2002), 
a meta-analysis byWatson etaL (2002) demonstrated a mean sensitivityfor two NAA tests 
of 87-94% (depending upon sample type). When implemented in non-research laboratory 
environments, estimates of 90% sensitivity and 99.5% specificity are considered more 
realistic (Schachter 1999; Schachter 2001). 
Another significant development in diagnostics, which has not only enhanced the 
justification for screening for chlamydia but has also made it easier, is the use of non- 
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invasive specimens (Knox et aZ 2002; Sylvan et aL 2002; Zenilman, Miller, Gaydos, Rogers 
and Turner 2003). In the early years, detection was only available from a urethral or cervical 
specimen; the latter requiring women to undergo a full pelvic examination with 
visualisation of the cervix. The current laboratory methods can be deployed on urine 
samples (for both men and women) or self-collected vulva-vaginal swabs, without 
sacrificing the sensitivity or specificity of the laboratory test (Stary, Najim, and Lee 1997; 
Rompalo et al 2001; Hseih ef aL 2003; Shafer et aL 2003; Schachter et aL 2003). Studies have 
also demonstrated that pooling non-invasive samples can reduce costs -without reducing the 
sensitivity or specificity of the test method (Clark et aL 2001). 
ACCEPTABILITY OF TESTS 
The newer diagnostic methods have been welcomed bypopulations; being screened (Serlin 
er aL 2002; Hsieh et aL 2003; Lane et aL 2003; Gotz et al 2003). Lane et at (2003) found that 
76% of women preferred to collect their own sample via a vulva-vaginal swab, and Gotz et 
aL (2003) showed that home-testing for chlamydia was acceptable- 84% of responders to a 
survey of home-testing agreed to send a urine sample from home. In health care settings, 
especially genitourinary medicine (GLM or sexually transmitted disease (STD) clinics, 
internal examinations for both men and women are standard, as a battery of tests are 
performed, requiting multiple clinical samples to be collected (Clirýcal Effectiveness 
Workgroup 2002). '1hus, in the context of a routine diagnostic work-up, the acquisition of 
a cervical or urethral specimen has not been controversial. However, that does not make 
them anyless comfortable. As screening needs to reach to those who are apparentlywell, 
i. e., those not experiencing genital symptoms that would prompt them to seek a GUM or 
STD clinic, the acceptability of the test becomes more important (CDC 2002). The advent 
of more sensitive laboratory test methods (NAATs) has increased the range of clinical 
specimens that can be used for testing, including non-invasive specimens such as urine and 
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self-taken vaginal swabs. lUs development has allowed screening to expand beyond the 
confines of health care facilities (Garrow, Smith, and Harnett 2002). Studies investigating 
the potential psychological or emotional 'harm' from cWamydia screening have not 
demonstrated severe consequences of providing a urine or vaginal specimen (Lane et aL 
2003; Gotz et aL 2003). Indeed, screening studies have largely utilized non-invasive samples 
for the very reason that they are more acceptable to the target population (Serlin et aL 2002; 
Hsieh et al. 2003). 
FACILITIES FOR DIAGNOSIS AND TREATMENT 
Fkalth care systems in industrialised nations are fortunate enough to have sophisticated 
networks of hospitals and clinics to provide facilities for the provision of diagnostic tests to 
populations screened and necessary treatment to those infected. Large networks of 
specialist clinics, GUM in Europe and STI) in the US, are available specifically for the 
diagnosis and treatment of sexually transmitted infections (Sfls). Increasingly, other health 
care delivery networks focused on women's health services, such as familyplanning and 
contraception clinics, have expanded services to include the provision of screening for 
STIs. Ilese systems are financed through public funds in European countries but through 
private insurance in the United States. Even though the financing of health care is different 
between the two systems, Levine, Dicker, Devine and Mosure (2004) found that the 
chlamydia screening programme in the US. has been able to achieve higher screening 
coverage of the at-risk population (60%), than the 50% cover-age recently achieved in a 
pilot of opportunistic screening in England (Pimenta et al 2003a) or nearly 30% uptake in 
the Danish pilot of postal screening through population registries (van Bergen er aL 2005)- 
Tli. is suggests that, despite differing funding schemes, uptake of chlamydia screening can 
achieve similar levels. 
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TREATMENT EFFICACY AND ACCEPTANcE 
Wilson and jungner (1968, p27-8) argue that this is the most important criterion to be met 
prior to initiating screening. "[Ilt is clearlyvital to determine... whether a better prognosis is 
given bytreating conditions found at an earlier stage... Unless this is so, there can be no 
advantage to the patient. " Studies exploring the pathogenesis and sequelae of chlam)dial 
infection in women have shown that the earlier an infection is treated the less likely that 
infection is to ascend or cause further complications (Honey and Templeton 2002). Other 
studies have additionally found that a woman's chance of developing PID increase 
exponentially with repeated untreated infections, providing additional evidence that the 
earlier the treatment, the better (Hillis, Owens, h4archbmks, Amsterdam and Mac Kenzie 
1997). However, the treatment should not cause harm. Therefore, toxicity of therapeutic 
regimens for chlamydial infection needs to be minimal. Studies of doxyryche and 
azithrom)rin, the two most commonlyprescribed antibiotics for chlamydial infection 
(CDC 2002; Clinical Effectiveness Workgroup 2002) have shown high tolerance among 
infected persons (Lau and Qureshi 2002). Safe, effective and easy thenapy has facilitated 
treatment compliance and acceptability by patients (Martin et aL 1992). 
DEFININGTHE POPULATION 
Screening targets healthy individuals to detect persons who might be infected. Critical to 
sorting out potentiallydiseased persons (true positives) from those without disease (true 
negatives) is the selection procedure for categorizing the healthy population for whom the 
screening intervention is designed (1-knnekens and Buring 1987; Friis and Sellers 2004). 
I'his selection process operates on two levels: the population and the screening test. At the 
population level, the selection process must be sensitive enough to capture persons most 
likelyto be infected, while not over-screening those who are not. And once the screening 
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population is selected, then the screening test must also do the same procedure, this time 
through the laboratory methods employed. In both cases, the ideal is to have a high 
positive predictive value with both the selection of the population to be screened, and the 
determination of the infected population within those screened (Nbusner and Kramer 
1985). 
A vast array of research on chlamAa has focused on determining the appropriate 
population for screening, as the infection is highly as3anptomatic. The most notable being 
the studies by Orr et aL 1994; Mosure, Berman, Kleinbaurn and Halloran 1996; Mosure et 
d 1997; Burstein et aL 1998; Richey, ýAacAluso, and Hook 1999; the Unites States 
Preventive Services Task Force 2001; ýAardh 2002; Sipkin, Gillam, and Bisset Grady2003; 
and Williams, Tabrizi, Lee, Kovnes and Garland 2003. Various locations for screening have 
also been advocated, including family planning clinics qiandsfield et aL 1986) and primary 
care and general practices (Simms, Hopwood, Mallinson, Rogers, and Webb 2000; 
Verhoeven et a4 2003). Ford, Viadro and Miller (2004) provide a summary of screening 
practices in non-clinical locations in the US and Europe and conclude that schools and 
home testing are viable places for screening and ease is facilitated by the use of non- 
invasive specimen collection. 
Specific at-risk populations have been selected using screening criteria to ensure the 
maximum likelihood of finding asymptomatic cases for early treatment. Flandsfield et aL 
(1986) were one of the first to research this aspect of chlamydia screening and concluded 
that using age, clinical symptoms and signs, and sexual risk behaviour for women 
undergoing pelvic examinations in familyplanning clinics was a sensitive method to detect 
infections. Other studies, notably by Marrazzo, Fine, Celum, DeLisle and I-Tandsfield 
(1997a), Howell, Quinn, Brathwaite and Gaydos (1998a), Nfiller etal (2000), and Paukku et 
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al (2003), have demonstrated the consistent performance of selection criteria in screening 
programmes targeting women. 
'llie microbiological aspects of determining chlarnydia-infected persons from non-infected 
persons has undergone the most remarkable transformation over the last decade with the 
development of highly sensitive and specific laboratory methods using new techniques 
targeting chlamydial antigen DNA (CDC 2002). 7hese new methods also allow for non- 
invasive specimens, such as urine, to be used, thus improving the possibility of test 
acceptance to the population targeted for chlamydia screening (Stephenson et at 2000; 
Andersen, Ostergaard, Moller and Olesen 2001; Andersen, Olesen, Moller and Ostergaard 
2002). In a unique study byNovak, Edman, jonsson and Karlsson (2003), the internet was 
utilized for notification of results after an invitation of home-based urine testing was 
accepted. Novak et d (2003) found that 38.5% of young men aged 22 years accepted 
testing. In both selecting the appropriate population for screening and having the ability to 
detect the infection within that screened population, the goal is to maximý finding those 
who need treatment while minimizing missing infections (not screening those who should 
be) and over-treating persons not infected. Striking this balance has been one of the most 
challenging of the Wilson-jungner criteria to meet. 
COSTS OF SCREENING 
Estimating the economic benefits of chlarnydia screening has been particularlydifficult, 
principally because if a prognamme is not in operation, acquiring exact figures of how much 
the programme costs will be imprecise. Initially, programmes in the US were not 
established based on their cost-effectiveness. Only after several 3, rars of screening was a 
rigorous cost-effectiveness study performed; Marrazzo, a aL (1997b) confirmed that indeed 
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the costs of the sequelae were greater than the costs of the screening intervention, given 
the prevalence of infection and population selected for screening. 
There have been additional cost-effectiveness and cost-benefit analyses of chlarnydia. 
screening performed and have concluded that the benefits outweigh the costs and cost- 
effectiveness can be reached in a few years (Kretzschmar, van Duynhoven, and Severijnen 
1996; Paavonen, Puolakkainen, Paukku and Sintonen 1998; Howell, Quinn and Gaydos 
1998; Welte et d 2000; Kretzschmar, Welte, van den Hoek and Postma 2001; Honeyet aL 
2002). In assessing the cost-effectiveness of an opportunistic screening programme in 
England, targeting annual screening for women 16-20 years of age and biennial screening 
for women 21-24 years of age, Townsend and Turner (2000) concluded that cost- 
effectiveness would be achieved after four years of high volume screening. 
Ile conditions for which screening becomes cost-effective have recently been put to 
scrutiny and include such things as: baseline prevalence of the target population, definition 
of the target population, uptake and coverage of screening by the target population, 
estimates of the preventable sequelae of chlarnydial infection such as PID, ectopic 
pregnancyand infertility, economic costs of immediate and future sequelae, and the social 
costs (psychological and emotional impact) of this public health intervention. Many of 
these conditions are either ill-defined or difficult to measure (Washington, Arno, and 
Brooks 1986; van Valkengoed etaL 2004), thus complicating the accuracyof the cost- 
effectiveness evaluation and the mathematical methods employed in such an evaluation. 
SUSTAINABILITY 
The transmission dynamics of s exuaUy transmitted infections are such that their continued 
maintenance in the population is a result of three factors: the biological aspects of the 
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organism and host (virulence, infectiousness, inherent susceptibility and immune response); 
the behaviours of the host (rupidity and/or frequency of changing sex partners and types of 
sex partners); and the duration of infectiousness (asymptomatic infections, health care 
seeking behaviours of the host, clinical infrastructure for diagnosis and treatment). If any 
one of the components in this cycle breaks down, previously treated persons can rejoin the 
pool of susceptible persons in the population, continuing the transmission cycle (Garnett 
and Anderson 1996). 
Wilson and jungner (1968) advocate that, if started, screening should be continuous. 
However, the challenge for chlarnydia screening has been that in order to build the 
evidence that screening is beneficial (reduction in morbidity and s equelae) and cost- 
effective (saves more than spent), the programme must be in operation for a number of 
years. In the United Kingdom it has been difficiAt to garner the funds necessary to invest in 
such a programme, given the scope required to make an impact in the transmission 
dynamic for this sexuallytransmitted infection, in part because there is constant movement 
of the population coming into the risk pool (beginning sexual activity or changing sex 
partners or recently treated patients returning to sexual relations with an untreated partner). 
Programmes in Sweden and the US did not see appreciable reductions in the prevalence of 
infection until several )tars of aggressive screening (Lossick et aL 1990; Herrmann and 
Egger 1995; Mertz, Levine, Mosure, Berman and Dorian 1997), and in an assessment of 
routine testing activities for chlarny1a over five years in Copenhagen by Westh and 
Kolmos (2003), chlarnydia prevalence ranged from 3.6% in 1995 to 4.3% in 1999 with an 
estimate of nearly20% of the 15-49 year old female population screened at least once in 
the period. However, there are now two nandon-ýsed controlled trials of chlarnydia 
screening that demonstrate a 50% reduction in incidence PID cases after one year (Scholes 
et al 1996; Ostergaard, Andersen, Moeller and Olesen 2000). A s3, stematic review of the 
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evidence by Honey and Templeton (2002) also concluded that PID can be prevented 
through controlling chlamydial infections in women. 
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Chapter 4 
Contribution to knowledge 
My contribution to the knowledge base for chlarnydia screening is reviewed in this chapter. 
I follow three basic themes: 1) defining the epidemiology and public health significance of 
alanydia tradxnw& infection, 2) developing and implementing new screening initiatives, 
and 3) monitoring and evaluating existing chlamydia screening programmes. As will be 
demonstrated, my research has increased our understanding of the public health 
importance of chlarnydial infection, the nature of asymptomatic infection, and definitions 
of appropriate populations for screening- three key criteria for intervention; all of which 
combine to further refine the epidemiology of this infection. My research demonstrates the 
establishment of the new National ChIam)dia Screening Programme in England, which is 
bat upon the entire body of evidence and has been shown to meet the Wilson and 
Jungner critezia (CMO 1998). 1 will conclude with how my other body of research can be 
used to facilitate monitoring and evaluation of already established chlaraydia screening 
programmes. 
Ile manuscripts discussed in this section are grouped accordingly (see Appendix 2 for the 
published manuscripts). 
ChlamTdij bwchomads as an important public health problem 
1. Brown, A. E., Sadler, K. E., Tomkins, S. E., McGarrigle, CA., LaMontagne, D. S., 
Goldberg, D., Tookey, P., Smyth, B., Thomas, D., Murphy, G., Pan7, J. V., Evans, 
B., Gill, O. N., Ncube, F. &Fenton, K. A. (2004). 'Recent trends in I-HV and other 
STIs in the United Kingdom: data to the end of 2002'. SexuallyTransrnitted 
Infections. 80, (3), p. 159-166. 
2. LaMontagne, D. S., Fine, D. N. &hbrrazzojM. (2003). 'Mnr* tra&wuds 
infection in asymptornatic men'. American Journal of Preventive Medicine. 24, (1), 
p. 36-42. 
- Implementing large-scale chlamydia screenýing programmes 
3. LaMontagne, D. S., Fenton, K. A., Randall, S., Anderson, S. & Carter, P. (2004b). 
'Establishing the national chlamydia screening programme in England: results from 
the first fuH year of screening'. Sexually Transmitted Infections. 80, (5), p. 335-341. 
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- Monitoring and evaluating cWamydia screening progranunes 
4. LaMontagne, D. S., Patrick, L. E., Fine, D. N. & Man-azzo, JM (2004a). 'Re- 
evaluating selective screening criteria for chlamydial infection among women in the 
U. S. Pacific Northwest'. Sexually Transmitted Diseases. 31, (5), p. 283-289. 
5. LaMontagne, D. S., Fenton, K. A., Pimenta, J. hi, Catchpole, NI, Rogers, PA, 
Randall, S., Hewitt, W. G., Wfinson, H., Underhill, G. S., McLean, L., Gleave, T., 
Fhrindra, V., Ghosh, A. K. & and Tobin, JM (2005). 'Using chlamydia positivity to 
estimate prevalence: evidence from the chlamydia screening pilot in England'. 
International 
- 
joumal of STD and AIDS. 16, (4), p. 323-327. 
6. Adams, E J., LaMontagne, D. S., Johnston, A. R., Pimenta, J. M., Fenton, K. A. & 
Edmunds, W. J. (2004b). Modelling the health care costs of an opportunistic 
chlarnydia screening programme'. SenaUy Transmitted Infections. 80, (5), p. 363- 
370. 
7. LaMontagne, D. S., Pimenta, J. M, Fenton, KA, Mallinson, 11 &Hopwood, J. 
(2004c). Management of genital chlam)dial infections at tennination of pregnancy 
services in England and Wales - where are we now? '. B-M: an International 
journal of Obstetrics and GyLiaecolg". 111, (12), p. 1408-1412. 
CYILAA13DIA TRACHOMA77SAS AN IMPORTANT PUBLIC HEALTH PROBLEM 
G%mdid tradmutis infection and other SUs in the UK 
Contextualising the parallel epidemics of sexuallytransrnitted infections and MV in the 
United Kingdom has become critically important in recent years as the government has 
made specific action plans towards improving the sexual health of the population 
Pepartment of Health 2001). To that end, it is important to inform the poficymakers, 
health care community and general population of the recent trends in diseases contributing 
to sexual ill- health. A detailed understanding of the q iden-ýiology of various STIs, 
particularlychlarnydial infection, can also provide baseline data for comparisons of 
programme impact, as the government increases its prevention activities through the 
phased implementation of the National CWam)dia Screening Progranune. 
In a cross-sectional descriptive study, I collaboratively investigated STI and I-HV trend data 
from 2002 as reported in the major surveillance systems at national communicable disease 
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surveillance centres in the UK (Brown et aL 2004). Specifically for STI trend data, 
diagnosed cases of chlamydia, gonorrhoea, genital warts, herpes, and infectious syphilis 
among GUM clinic attenders reported on the aggregate KG60 statutoty return in the UK 
were analysed. I also utilized enhanced surveillance data from two new initiatives, enhanced 
syphilis surveillance and the Gonorrhoea Resistance to Antimicrobials Surveillance Project 
(GRASP), to further characterise populations infected with infectious syphilis or Neisseda 
goro? bwae. 
Continuing rises in most S'Ils, except gonorrhoea, and I-HV were found across key 
populations. Genital chlam)dial infection rose by 103% from 1997 to 2002, and continued 
to be the most commonly reported sexually transmitted infection in the UK, Chlarnydial 
infection is particularly high among young women with rates of diagnosis among 16-24 
year olds as high as 1,135 per 100,000 population. The highest rate of diagnosis among 
men, 842 per 100,000, was observed in those 20-24 years of age. The importance of these 
preventable infections to populations at Mghest risk especially young people, gay men, and 
black and ethnic minorities was highlighted in this s ummary of the STI trends in the UK. 
These populations continue to be the most affected. Estimates of rates of disease among 
gaymen showed increasing diagnoses since 1999, with appreciable increases in the last two 
years. Young people accounted for over half of all STIs and 10% of new FHV diagnoses in 
2002; women aged 16-24 accounted for 72% of all female chlarnydia diagnoses from GUM 
clinics; and black ethnic minorities, mainly black Caribbeans, accounted for a staggering 
55% of heterosexual male and 44% of heterosexual female gonorrhoea cases reported in 
2002. 
I'his study of the trends in STIs and HV in the UK has strengthened our understanding of 
the burden of disease in the population and has been important in quantifying the scope of 
these epidenýics. This work was particularly important in light of the govenunent's strategy 
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to address this significant health problem. The Department of Health's Natiad Strxqyfor 
SecudHedthandHIV (2001) outlines keytargets for the prevention and control of sexuaRy 
transmitted infections and FRV, and has included recently funded initiatives, such as the 
modernisation of GUM services and laboratory networks and the implementation of a 
national chlamydia screening programme. Periodic assessment of the survefflance data for 
STIs and HV wifl be critical in measuring whether the increase in funding has had an 
impact on the government targets for sexual health as weff as improvements in the control 
of these infections in the population. 
CMarnivdial infection in men 
Characterisation of chlamydial infection as a public health issue can only be done through 
studies quantifýng the magrýitude of the problem, %ithin the population and the 
ramifications if left untreated. Ilere has been an enormous amount of research on 
chlamydia in female populations, principally because the greatest burden for sequelae of 
infection falls within this group. PID, ectopic pregnancy, salpingids, and tubal factor 
infertility are severe consequences of infection in women. However, the epidemiology of 
chlarnydial infection in men was less well characterised. 
Stanun (1999) has surnmarised the knowledge to date concluding that urethritis and dysuria 
are common among infected men and a small proportion of untreated infections can 
advance to Reiter's syndrome, but on the whole, the severity of disease among men is less 
significant. A strong argument can be made for understanding the burden of infection 
among men as they are the primary transmitters of infection to women (Garnett and 
Anderson 1996). Failure to identify asymptomadc infections in men might allow for the 
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maintenance of a reservoir of untreated infection that might hinder efforts to decrease the 
incidence among women. 
Previous studies of chlamydia, especially in asymptomatic male populations, had been 
hampered by relatively small sample sizes (Braverman, Biro, Brunner, Gilchrist and Rauh 
1990; Domenika, Bassiri and Mardh 1994; Moncada et aL 1994). In the north western 
region of the US Ngion X), chlamydia screening of women has been routine since 1988. 
The universal testing of men attending STD clinics -within this region was standard clinical 
practice and utilised the same data collection instrument employtd in the ch1arnydia 
screening programme for women. This data source provided an opportunity to design a 
study that could help characterise the epidemiology of chlarnydial infection in men. My 
research questions were three-fold: 1) how much chlarnydial infýection is in the male 
population?; 2) what is the level of asymptornatic infection in men?; and 3) can this 
evidence be used to develop screening initiatives to target =2 
I designed a retrospective cross-sectional epiderniologic: study of men attending STD clinics 
who were tested for chlarnydia (LaMontagne et d 2003). 1 analysed data from 43,094 men 
universally tested from 1997-1999 at 103 STD clinics and assessed age-specific prevalence 
of chlamy: lial infection, controlling for signs of infection and report of contact to a person 
with an STD. 
Overall prevalence of cWamydial infection in men was 10.3% and varied by age: 16.2% in 
men under 18 years old, 18.3% in men aged 18-19 years, 14.5% among 20-24 year olds, 
10.1% arnong 25-29 year old men, and 4.8% in men over the age of 29 ), ears. '11-iis is similar 
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to the 11.0% prevalence found by Gemins et at (2000) at the STD clinic in San Francisco. 
ýAarrazzoetaL (2001) found men under 25 years of age were three times more likelyto test 
positive than those 25 ytars and older, and the prevalence among 19-20 year old 
asymptomatic men was 10.4%. In this study, peak prevalence among asymptomatic men, 
7.3%, was at 18-19 years of age, and these men were nearly five times as likely as men aged 
over 29 to test positive for chlarnydia. For asymptomatic male populations, no other 
demographic or bebavioural risk factor vms more strongly associated výith infection than 
age. 
In addition to age, prevalence was correlated with the presence of clinical signs suggestive 
of infection, principallyurethritis, and exposure to infection from known sexual contact 
with an infected partner. Over 75% of all men tested had no signs of infection upon 
examination, however, over 70% of men who tested positive for chlarnydia had clinical 
signs of infection. Men without either signs of infection or a history of contact with an 
infected partner had a prevalence of 3.4%, but contributed to over two-thirds of A men 
tested for cWamydia at STD clinics. 
In focusing on clinician assessed signs in conjunction with sexual exposure to someone 
known to be infected, I found gradients of prevalence among all age groups of men. In 
each age strata, men with signs of infection who had contact with someone infected had 
the highest prevalence. For example, among 18-19 yrar old men, 62% of those with signs 
and contact to someone infected tested positive for chlamydia, compared to only 7.3% of 
men without these factors. Among men over 29 years of age, prevalence was 3 1.1% in the 
signs/contact group and 1.6% in those without. Oinician-assessed signs and exposure to 
persons known to be infected were highly correlated with infection. Efforts to detect those 
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men most likely to be infected could be enhanced through utilising signs and exposure, 
combined with age, regardless of seeking care at an STD clinic. These data raise the 
question of whether certain groups of men without signs should be tested routinely by 
virtue of their attendance in the STD clinic. The Yd US Preventive Services Task Force 
(2001) concluded that there was no strong evidence for selective screening strategies 
among asymptomatic males. These findings question the standard approach of testing all 
male SID attenders for chlarnydial infection, especially when resources in publicly funded 
clinics in the US are scarce. 
WHe this studydid not specifical1y address the cost-effectiveness of such approaches, the 
data do suggest that testing men with no signs in an STD clinic could certainly be made 
more efficient by reducing testing in subgroups unlikely to be infected. For example, if only 
the men in this study with signs, contact to infected partner, or those under 25 years of age 
had been tested over the study period, 58% of our subjects would have been tested and 
9 1% of all positives would have been detected. IMer et aL (2000) suggested that this 
approach would be both sensitive and efficient, and similar selective screening approaches 
are currently emplo)vd among female populations (Nbrrazzo et aL 1997b). This results 
from this study suggest that screening criteria could be developed for use in STD clinics to 
select men to test for cWamy&l infection. 
11ris study used a robust data set on a large population of men tested over three years, 
which was a significant improvement in sample size over previous studies of the 
epidemiology of infection among men. Additionally, I uniquely quantified the role of 
clinical signs, rather than symptoms, and exposure to disease in the epiderniology of 
chlamydia among men. This was important in the STD setting, as clinical protocol dictated 
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full genital examinations as the standard of care for all attenders. Ile results from this 
study suggest that in the context of an existing clinical examination, signs could be highly 
predictive of infection in men. Other published studies at the time of mystudy had not 
been able to tease out the different contributions of signs in relation to sexual contact with 
a known infected partner, client age and sexual behaviour to predict infection among men. 
A result from this study of asymptornatic chlamydial infection in men was the lower 
prevalence of chlamydia found among men who reported sex with men (NB4,7.3%, 
versus men who reported sex with women (Mý, 10.8%. At that time, studies of SlIs 
among NBM focused on STD clinic populations and were reporting increasing S11 rates 
among NEM attending those STD clinics (Clemins et aL 2000). Although not published in a 
peer-review journal, I did a follow-up study of chlarnydial infection in asymptomatic men 
that focused on men who have sex with men (LaMontagne, Patrick and Man=o 2001). A 
brief description of this study, its results and implications is provided to illustrate how I 
have continued to investigate questions raised by my own previous research. 
In this study, I used the same methods and data source as the previous study of chlamydia 
in men (LaMontagne et aL 2003) for consistency and comparability, and explored three key 
unanswered questions: 1) what is the epidemiology of chlarnydial infection among hBM 
within and outside of STD clinic settings?; 2) are rates of chlamydial infection among hBM 
increasing?; and 3) are asymptornatic NISM different than asymptomatic hBW in terms of 
risk factors for chlamydia? I analysed records for 8,981 men who have sex with men, which 
was 8% of the total male population tested from 1996-2000. 
I found an overall prevalence of 7.7% among all ýBK and this was correlated with three 
factors; the presence of clinical signs suggestive of infection, the exposure to infection 
from known sexual contact with an infected partner, and young age. Prevalence was higher 
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in ABM tested outside of STD chnics (9.0%). Ihere was a statistically significant temporal 
trend for increasing prevalence of chlarnydia among IýBM from 5.4% in 1996 to 8.5% in 
2000. Risk factors for infection among asymptomatic IZM and asymptomatic ýBW were 
similar, but asymptomatic ýBM tended to be slightly older. The highest prevalence among 
asymptomatic TvBM was 7.3% in those ages 18-19 years old; the same peak prevalence, 
7.3%, was found among ýBW who were 18-19 years of age. 
IUs study of chlamydial infection in ABM confirmed some of our findings from our 
previous study of infection in asymptornatic men. I again found utility in use of clinical 
signs and exposure to divide the male population into risk groups, and quantified 
appreciable increases in likelihood of infection as one progresses from the 'no clinical signs 
and no exposure' group to the population of men 'who had signs of chlaraydial infection 
(urethritis) and reported recent sexual activity with an infected partner. ' Once again, this 
can be an important aid during a clinical consultation in discussing need for testing a 
person with low probability of infection. Seventypercent of the MSM population in this 
study was asymptomatic and not recently exposed to an STD and had a prevalence of only 
4.2%. 
A trend of increasing prevalence of chlarnydia among all 1ZM and among just the 
asymptomatic hISM population was statistically significant; prevalence among 
asymptomatic men increased from 2.2% in 1996 to 5.4% in 2000, even after adjusting for 
signs of infection or recent exposure. These results have broad implications for the control 
of this infection in a population already impacted by the AIDS epidemic. It also raises the 
question of co-factors for acquisition of I-HV. will an increase in cMamydia facilitate a 
concomitant increase in I-HV infection? 
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Additionafly, I found that asymptornatic INEM tested outside STD clinics had a higher 
prevalence, 5.8%, than those attending urban STD clinics (2.70/6), raising the question of 
whether NSM who do not seek services at an STD clinic warrant a different intervention 
to decrease their risk, or conversely, whether these men feel less stigmatised based on their 
sexual orientation and are comfortable attending more general health settings. INs follow- 
up study of chlamydial infection among men confirmed that asymptornatic hBM have the 
same risk factors for chlarnydial infection as asymptomatic men who have sex with women, 
suggesting that prevention campaigns targeting heterosexual men maybe applicable to 
NBM populations or should emphasise that the risks are the same for both groups of men. 
IMPLEMENTING LARGE-SCALE CHLAMYDIA SCREENING PROGRAMMES 
Ile National Chlarnydia Screening Programme in England 
The establishment of a national cWamydia screening progranune in England has its genesis 
in discussions bythe government dating to the mid-1990's. 'Me Chief Medical Officer 
(1998) gathered a panel of experts to review the evidence for chlamydia screening and 
concluded that evidence exists for the effectiveness of cWamydia screening. IEs was 
followed by a call for the government to take action towards establishing a national 
screening programme (CMO 1998). As a first step, the Department of Health (England), 
funded a study of opportunistic screening among women in England to determine the 
feasibility and acceptability of such a programme. Pimenta et aL (2003a, 2003b) illustrated 
that screening was both feasible and acceptable and that high prevalence of disease, 
approximately 10%, existed among sexually active 16-24 )tar old women. 
Subsequent to this successful pilot of opportunistic screening, the Department of Health 
Po" began a phased implementation of the National Chlamydia Screening Progranune 
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(NCSP) in late 2002, %ith selection of 10 programme areas for the first phase Pepartment 
of Health 2004a). 11iis effort was also combined with the Natiowl St-We9VforSeCUa1Ha-&h 
andHIV Pepartment of Ii2alth 2001) to provide a unified platform for addressing the rise 
in rutes of STIs in England (Brown etal 2004). Given the high public profile of this effort 
and the intense interest in the implementation stage of the programme, a description of the 
programme and an analysis of the epidemiological data from the first ytar of screening in 
phase 1 programme areas was performed (LaMontagne et aL 2004b). This paper had three 
main goals: a) to examine the development and evolution of the National Chlamydia 
Screening Programme in England; b) to comprehensively detail the components required 
to implement a nationally- directed chlamydia screening programme on a large-scale; and c) 
to quantitatively analyse the results of screening in the first year to characterise the 
population tested, their risk factors, and the burden of disease across England. 
A descriptive study of the NCSP with retrospective analysis of opportunistic screening data 
for young men (n = 1,172) and women (n = 15,241) under 25 years of age attending over 
300 clinical and non-chnical settings across England was designed. In this, the programme's 
components are elaborated. Using univariate and multivariate statistical techniques, I 
measured chlamydia test positivity and explored factors associated with testing positive. 
'Me statistical analysis excluded tests performed for diagnostic reasons or on contacts to 
known cases, those persons 25 years or older, or those that were missing or had unknown 
data for test result, sex, age, type of test, or inconsistent sample type (for example, male 
tests with self-collected vulva-vaginal swabs). Separate analyses were performed for men 
and women screened opportunistically. 
In the first year of the NCSP, opportunistic screening occurred in a staged approach with 
the number of programme areas and screening venues within progranune areas offering 
chlamydia screening increasing from April 2003 to March 2004. Over 16,400 opportunistic 
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screens for genital chlamydial infection were performed, with nearly 50% occurring from 
January, ýJarch 2004. Positivityamong women was 10.1% (1,538 / 15,241) and 13.3% (156 
/ 1,172) among men under 25 years of age opportunistically screened at 302 venues across 
England, excluding GUM clinics. Women 16-19 years of age were almost twice as likelyto 
be positive than those under 16 and 43% more likely to be positive than women 20-24. 
Other risk factors for women included Black Caribbean, Black British, or mixed ethnicity, a 
new sex partner in the last three months, or two or more sex partners in the last 12 
months. Among men, only age 20-24 years old and Black ethnicitywere associated with 
infection, even after adjusting for covariates; sexual risk behaviours had elevated odds 
ratios, but were not statisticaUy significant. For both men and women, those tested via the 
Becton-Dickinson strand displacement assay (SDA) were more likely to test positive than 
persons tested with another nucleic acid amplification test. 
This manuscript also provided the first detail of the components of the English 
programme in the peer-reviewed literature. To review, the goal of the NCSP is to control 
genital chlamydial infection through the early detection and treatment of asymptomatic 
infections and prevention of sequelae and onward trunsinission. This is consistent with the 
general approach to selective screening employed in other countries (CDC 2003). Screening 
pmtocols for the national programme area contained in a core requirements document 
Pepartment of Health 2004a), and are disseminated to local programmes to standaidise 
local scr-eening activity. Local progmnunes consist of consortia of primý care trusts 
Xfs), which are the geographic and service boundaries of the National Fkalth Service 
(NHS). A regionallyorganised chlamydia screening progmmme operates in the US and has 
acted as a model for the geographic organisation of services. 
The target population for screening is young men and women under the age of 25 years 
who are attending health care facilities not traditionally associated with providing specialist 
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sexual health services. These include contraceptive clinics, geneml practices, young people's 
services, antenatal services, colposcopy and infertility units, and termination of pregnancy 
clirýics. Screening is also encouraged to those VAthin the target age group through 
innovative outreach strategies, such as " pee in a pot" days at military bases, university 
campuses or health fairs, mobile vans or buses for contact with young people, prisons, and 
other non-traditional settings. The target population for the NCSP is different than that of 
the US screening programme (CDC 2002), in that persons out of the age range, those 
attending GUM clinics, and persons presenting with symptoms are excluded from 
opportunistic screening. These persons are usuallydiagnostically or routinely tested for 
cWamydia as a part of standardised chrýcal protocols, and as such are not the primarytarget 
for the "opport-unistic" nature of this national programme. 
All screening is performed using non-invasive samples, urine for men and urine or self- 
collected vulva-vaginal swabs for women, and tested via nucleic acid amplification, the 
most sensitive testing method available (Black 1997). All positive patients are treated 
following established clinical guidelines (Clinical Effectiveness Workgroup 2002), and 
partners of positive patients are contacted for prophýlaxis and/or chlamydia screening. 
Standardised infon-nation about the demographic and behavioural characteristics of the 
population screened, location of screening, laboratory test method used, and test result is 
collected unifonrJy across all programme areas by the use of a test request form and is 
reported in disaggregate nationally to the Health Protection Agency Pepartment of Health 
2004a). 
The first year of the NCSP has also detected similar levels of infection as was observed in 
the original screening pilot in England (Pimenta et al. 2003b). Screening programmes in 
other countries reported chlamydia prevalences ranging from 6% in Sweden (Herrmann 
and Egger 1995) to 12% in the north western US (Britton, DeLisle and Fine 1992). 'Me 
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similar levels of infection at the start affirm that the opportunistic approach is a successful 
strategy for disease detection and justify our continued focus on young women and men 
attending a variety of health care settings. Encouragingly, the second highest volumes of 
screening came from general practices and young people's services, both of which do not 
traditionally provide sexual health services. Oakeshott, I-lay and PaIdanathan (2004) 
recently suggested that GPs would not participate in screening without remuneration. The 
findings from the first year of the NCSP question that assertion. Over 10% of all screening 
tests were done within general practice (without payment), and increased over the course of 
the first year. This was due in part to the create ways in which the service was delivered 
locally, such as patients self-selecting screening whilst waiting in practice reception areas, 
invitations to screerung made bypractice nurses rather than GPs, and shifting responsibility 
for notification of results and follow-up to a local chlarnydia screening office (LaMontagne 
er al 2004b). However, the devolved nature of generul practice provision in England means 
that efforts to encourage local involvement of primary care in chlam), dia screening need to 
be strengthened and robustly supported to maximise participation. 
My anal3, sis of the population screened in the first year of the NCSP confirmed that the 
epidemiological profile of both men and women screened is nearly identical to that found 
in other studies of UK populations (Adams et aL 2004a) and those in Europe (Wilson et aL 
2002), with highest chlamydia positivity among women 16-19 )tars of age and men 20-24 
Itars; old. Additionally, I found that women who had acquired a new sex partner in the last 
three months or who had two or more sex partners over the past 12 months were about 
50% more likely to test positive. 'Me NCSP is the-first large scale sexual health programme 
to include behavioural Surveillance, and allows for monitoring changes in sexual behaviours; 
that contribute to the acquisition and spread of chlamydia. 
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Because the NCSP is in the early stages of implementation, it is important to place in 
context the screening volume and its impact on coverage. Economic models have shown 
that one of the most critical aspects to ensure the success of a widespread screening 
progrumme is uptake (Paavonen etaZ 1998; Welte etaz 2000; Kretzschmar etal 2001; 
Honey et d 2002). Recent estimates from the US by Levine et aL (2004) suggest that 
screening coverage was highest in areas that experienced reductions in prevalence after 
several years of aggressive screening. Data from the first few years of routine chlamydia 
testing in Sweden also reflect the impact of Mgh screening volumes (1-krrmann and Egger 
1995). It will be imperative for the NCSP to continue to r-apidly increase the offer and 
uptake of screening throughout all participating local programme areas to maximize the 
impact of the intervention. 
I'his manuscript and the analysis of the population screened in the NCSP fills an important 
gap in the existing literature because it comprehensively explains the genesis of a national 
screening programme, iflustr-ates the individual progmmme components necessary for 
actual implementation in local communities, assesses what can be expected in the first Year, 
outlines some of the pitfalls in embarldng on such an immense effort, and most 
importantly, reaffirms the importance and necessity of this public health problem by 
quantifying the magnitude of infection among young people in England. 
MONITORING AND EVALUATING CHLAMYDIA SCREENING PROGRAMMES 
Chlarnydia screening seeks to reduce the prevalence of infection in the population and the 
severe sequelae of untreated infection. There is strong evidence from two randomised 
controlled trials that incident PID can be reduced from screening (Scholes et al 1996; 
Ostergaard et aL 2000). As previously mentioned, several programmes implemented in the 
United States and Sweden observed decreases in prevalence after several years of screening 
+Z 
(Lossick et aL 1990; Addiss, Vaughn, Ludka, Pfister and Davis 1993; Herrmann and Egger 
1995; Mertz et al 1997). Prior to observing these long term outcomes, screening 
programmes require close monitoring to ensure the service is appropriately administered, 
the target population is screened, the outcome is measured correctly, there is sound value 
for money, and the clinical providers are adhering to the guidelines. There is a general 
dearth in the literature on programme monitoring and evaluation for cwam)& screening. 
The majority of published studies cover aspects of selecting or ensuring the target 
population is correctly identified and screened (Paukku etaL 2003; Marrazzo etd 1997a; 
Miller et aL 2000), and the cost-effectiveness of such approaches QvIamzzo et d 1997b; 
Howell et aL 1998; Welte et aL 2000; Kretzschmar et aL 2001). It is within this context that 
myprogramme-related research is discussed below. 
Evaluating selective screening criteria 
Since 1988, annual systematic chlamydia screening of women under 25 years of age and of 
older women based on behavioural risks has been in operation in the north western region 
of the US (Region X). 'Ms was the first large-scale chlamydia screening programme in that 
country. Screening, based on these selection criteria, occurs in conjunction with a pelvic 
examination during attendance at familyplanning chnics (Center for Health Training 2003). 
From 1988 to 1993 the selective screening criteria remained unchanged. These criteria were 
evaluated in 1995 with few changes resulting from that evaluation (Marrazzo et aL 1997a). It 
is not unusual to periodically evaluate the selective screening criteria. Assessments of such 
criteria had been made by other researchers Wer et aL 2000). Using selection criteria to 
detem-line how to direct scarce screening resources had been a cornerstone of the US effort 
to control genital chlarnydial infection (CDC 2003). All public health regions in the country 
(numbered I, II, etc. ) have a selection procedure in their programme. 
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Several developments in the field that could impact the performance of existing selective 
screening criteria suggested the criteria required a re-evaluation, specificallydeclines in 
prevalence observed in the first eight 3, tars of screening were not sustained after 1997; the 
introduction of more sensitive laboratory detection methods in the mid-199os (Gudgel and 
LaMontagne 1999; Dicker, Mosure, Levine, Black and Berman 2000); and assurance of 
programme credibilityand efficiencyin the face of increasing budgetary pressures was 
needed. I set out to re-evaluate the programme with three goals: assess the performance of 
the existing screening criteria in Region X, explore whether the risk factors for infection 
had changed since 1995, and evaluate whether the criteria could be optimised to improve 
sensitivity or efficiency (LaMontagne et aZ 2004a). 
Using cross-sectional screening data of tests performed on women from 1998-2000, a 
prograrn. me evaluation was designed. Data analysis included multivariate logistic regression 
to quantify risk factors for infection, and sensitivity and efficiency analyses to measure the 
performance of the existing criteria and assess optimisation strategies. The dataset 
comprised 409,8 82 chlarnydia test records for women attending 252 family planning, 123 
STD and 251 other clinics, including communýity/rnigrant, college health, public health 
nursing, and adolescent clinýics, in Region X from 1998-2000. To define the perfonmnce of 
the current selective screening criteria in Region X, all tests were analysed for the sensitivity 
and efficiency of the criteria. Sensitivity was defined as the percentage of positives detected, 
and efficiency was the percentage of tests that met the criteria Wer et aL 2000). 
Thresholds of 60% efficiency and 90% sensitivity were used as performance benchinarks 
to identify the most positives (high sensitivity) while testing the fewest nurnber of women 
(low percentage for efficiency). To define risk factors associated with infection, data from 
women universally screened at STD clinics were used. Odds ratios for independent 
associations were calculated with chlarnyidia positivity as the dependent variable, and 
adjusted in multivariate logistic regression models. Using the results of the risk factcr 
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anal)ýsis, five different sets of selective screening criteria were developed to evaluate for 
sensitivity and efficiency to determine whether the current criteria in Region X could be 
simplified. 'Mese five sets of criteria were also compared with recent recommendations 
from the US Preventive Services Task Force (2001). 
The positivity among women attending STD clinics was 7.0%; 4.1% among FP attenders 
and 3.8% among women attending a variety of community clinics. The strongest predictor 
of infection was young age, especially those under 25 years old, regardless of clinical signs 
or exposure to an STD. The selective screening criteria used in Region X were very 
sensitive, detecting 95.6% of all infections in the female population, but were less efficient 
than the target benchmark, requiring testing 85.6% of women. Ile sensitivity of the criteria 
remained high and exhibited little variation (range, 94.5-97.5%). Even after stratifying by 
test type within clinical settings, the sensitivity remained above 90% (range, 90.8-98.7%). 
'Me five sets of selective screening criteria developed from multivariate modeffing showed 
marked dffferences in sensitivity and efficiency. On average, age-only based criteria 
required testing the fewest number of women, but were just over 80% sensitive. 
Conversely, the recently recommended criteria from the Task Force resulted in over 98% 
sensitivity, but would have required testing over 93% of the women in our study, clearly 
less efficient than our benchmark. These findings suggested that the selective screening 
criteria in Region X could be optimised by focusing on those populations found to be at 
highest risk, mainly all women under 25 years of age and women 25 and older with clinical 
signs of infection or exposure to a sex partner with chlamydia. 
There are several significant aspects of this study with implications for existing and newly 
established chlarnydia screening programmes. First, this studywas timely, since it had been 
over five years since publication of the last evaluation of the Region X screening 
programme (Marrazzo er aZ 1997a), and that evaluation had used data from the early days 
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of the programme when less sensitive laboratory tests were emplo), ed and the baseline 
prevalence of infection in the population was high. As the first comprehensive chlarnydia. 
screening programme in the US, Region X has a unique position of leading the field, but 
also setting the example of good practice. Furthermore, it is recommended that periodic 
evaluations be a part of any population- based intervention (Mosure, Berman, Dicker and 
Levine 1998), as new developments occur or programme impact begins to plateau. This is 
critical for the credibility of the programme and can influence the operations of other 
screening efforts. 
Secondly, this evaluation re- affirmed that the risk factors for chlarnydial infection for 
women have remained stable in recent years, even after adjusting for the use of more 
sensitive testing methods. The strength of age as the number one predictor of chlarnydial 
infection in women, although known from other studies (Handsfield et aL 1986; Simms et 
aL 1997; Mertz et d 1998; Wilson et at 2002; Adams et aL 2004a), was a surprising finding, 
principally because of the very high odds ratios for younger women, even after adjusting 
for all other major factors. Women 17 years and younger were nearly 8 times more likely to 
be infected than those over 29; but even 20-24 year old women were almost 5 times more 
likely to be infected. Additionally, the finding that recent exposure was more predictive of 
infection than clinical signs reinforced the asymptomatic nature of this infection in women 
(Stamm 1999). Age, clinical signs and recent exposure were the same factors elucidated in 
my two previous studies of chlamydia infection in men and IZM (LaMontagne et aL 2001; 
LaMontagne et aL 2003). 
Thirdly, this study confirmed that the selection criteria used in Region X to determine 
which women should be screened were sensitive- the criteria accurately detected positives. 
However, the criteria in use were not particularly efficient, requiring testing a high 
percentage of women attending clinical settings. Other studies Wer et al 2000) have used 
a similar approach in measuring criteria performance, but used lower thresholds for 
sensitivity (80%) which allowed for up to 20% of positives to go undetected. 'Me 
programme managers in Region X thought that threshold was too low for adequate disease 
control, and looked to build criteria that could detect 90% of positives while screening 
about 50% of the target population. Although we could not find criteria that would result 
in that level of efficiency, we did conclude that the criteria currently in use could be 
optimised by focusing on the populations most likely to be infected: young women, those 
with clinical signs, women recently exposed either through sex with a symptomatic partner 
or report of sexual contact to a partner with an STD, and women with a positive chlarnydia 
test in the last year. 
Most importantly, this research had immediate practical application in policy decisions by 
the programme. Ile Region X screening programme initiated this evaluation study, and 
agreed to incorporate the studyfindings, regardless of the outcome. This willingness to 
directly apply research findings forpolicyand programme change illustrates the leadership 
role this programme sets for the other regions in the US. Based on the findings of this 
study, the Region X screening programme changed their selective screening criteria for 
women attending the clinical venues participating in the programme (Center for Health 
Training 2003). 
Using cWamydia test positiviiy for progranune monitgning 
Another aspect of monitoring gains made through chlamydia screening is assessing the 
impact on prevalence (Addiss et aL 1993; I-lerrmann. and Egger 1995; ý&n-azzo et aL 1997a). 
Prevalence of genital chlarnydial infection in women in the United Kingdom varies widely 
depending upon the study population selected, methodology employed, clinical setting and 
laboratory test method (Adams er al. 2004a). Pimenta et aL (2003b) have noted the difficulty 
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in measuring prevalence in large cohorts of women, principally due to the need to track 
individuals and their testing behaviour over time and geographic and clinic locations. 
Individuals may have more than one test and may attend a variety of clinical settings over 
the testing period. In the implementation of larger screening programmes based on an 
opportunistic approach, as is currently the design of the National Chlarnydia Screening 
Programme (NCSP) in England, the ability to measure prevalence becomes increasingly 
difficult due to the lack of a national unique identifier. The Department of Health in 
England (2004a) has proposed to use positivity as a surrogate measure for prevalence. 
Mmydia test positivity has been used in the U screening programme and has shown to 
be a useful tool in programme monitoring (CDC 2003). This approach has been validated 
in only one published study Picker, Mosure and Levine 1998). However, in that study data 
were collected from limited health settings and women were screened with less sensitive 
enzyme immunoassays, so questions regarding the ability to generalise results using this 
method remain. I sought to re-examine the original chlamydia screening pilot data to cross- 
validate whether positivity could be used as a proxy measure for prevalence and to assess 
the appropriateness and utility of using positivityto monitor the NCSP 4-1montagne et aL 
2005). 
Using the testing episode data from the cohort of women enrolled in the original chlainydia 
screening pilot (Pimenta et aL 2003a), positivity within the populations for which 
prevalence had already been measured (Pimenta etaL 2003b) was recalculated. Data analysis 
included 16,595 tests from 16-24 year old women attending familyplanning, GUK general 
practice, and youth clinics from September 1999 - August 2000. Positivity, defined as the 
number of positive tests divided by the total number of tests, was calculated with 
accompanying 95% confidence intervals. Positivity estimates were compared to prevalence. 
Prevalence for each health care setting and bysymptoms wit* health care setting had 
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been previously published (Pimenta et aL 2003b) and was used as the comparison estimate; 
however, prevalence by single years of age within the study locations was recalculated 
because the published age-specific prevalence included a 'Rider selection of testing 
locations. Two-sided binomial probability tests were conducted to confirm no difference 
between the estimated positivity and measured prevalence. 
Overall positivity was 9.4% (95% Cl: 8.9-9.9) in Portsmouth and 11.0% (95% CI: 10.1- 
11.9) in the Wirral. 1his was marginally lower than the published prevalence but not 
statistically different. Additionally, slight and non-statistically significant differences were 
found between positivity and prevalence by health care setting, age and reason for test. 
Absolute differences between positivity and prevalence within health care settings ranged 
from -1.43 to 0.04 and the percentage difference between the two ranged from -8.58% to 
0.47%, neither of which were statistically significant. In general, positivity underestimated 
prevalence, possibly due to the frequency of testing within the population. However, even 
in spite of this limitation, the estimates of positivity among a population tested using very 
sensitive laboratory me&ds varied little from prevalence and did not change the 
interpretation of the outcome data. This study demonstrated that measuring positivit3ý in 
lieu of prevalence, would not sacrifice the accurate measurement or the interpretation of 
disease trends and would be easier to implement within a large-scale national screening 
programme. 
lEs re-exarrýination of the data from the original screening pilot to assess positivitywas 
significant in two ways. First, it validates a measurement technique that has only been 
through one scientifically rigorous review process Picker etaL 1998). Gc)nfirmatory studies 
have a critical role to play in research, as isolated findings from one study may not apply 
more generally. Particularlyif a methodologyis advocated, the assumption that the 
methods applyacross studysettings requires validation. I confirmed the method proposed 
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byDickeretaZ (1998), even though the setting of this study was radicaRy different than 
theirs: the screened population was from outside the US, tested in a wider variety of clinical 
venues, provided only urine samples, and utilized more sensitive laboratory techniques 
Second, there has been some criticism that the National Chlam), dia Screening Programme 
was not going to be able to measure its effectiveness because it could not directlymeasure 
prevalence (Low, h1acleod, Salisbury and Egger 2003). This study demonstrates that this is 
not necessary for large-scale programmes, as positivity is a robust surrogate. Therefore, 
changes in positivity are reflective of changes in prevalence in the population. 
Ile implications of my study for programme monitoring are two-fold: 1) the programme 
monitoring method proposed for the NCSP is backed by sound scientific evidence; and 2) 
this method reduces the reporting burden for clinical providers participating in the NCSP. 
The collection of data in a large national programme can be politically sensitive, as the 
balance needs to be struck between gathering the data required to make robust evaluations 
of the programme's impact whit not overburdening the clinical staff in communities who 
are implementing the programme locally. It is a delicate balance as the former requires 
strict and accurate data collection standards and the later might not participate in a 
prograrnme with such stringent data collection needs. By proposing to use positivity as the 
outcome measurement for programme monitoring, the NCSP has been able to find a 
middle ground whereby the scientific rigour is maintained and the local burden of data 
collection is minimised. 
Estimating the costs of opportunistic screening for cWamydia 
In the CMO's (1998) review of the evidence for chlam)dia screening, the cost-effectiveness 
of such progranunes came under particular scrutiny. The key concerns expressed were that 
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previous cost-effectiveness studies over-estimated the sequelae of untreated infection and 
under-estimated the unit costs of the screening programme. These studies also used 
approximated prevalence levels were not verified in population-based studies in England, 
and utilised testing modalities, principally opportunistic or postal-invitation, that maynot 
be feasible in this country. Further, the published cost-effectiveness studies failed to 
adequately account for the dynamism involved in the transmission cycle of this sexually 
transýmitted infection. Specific calls for more research into the cost-effectiveness of 
chlarnydia screening have also come from others in the field (Roberts et aL 2004). 
However, without knowing specific unit costs of items used in an organised opportunistic 
screening programme, it is difficult to estimate these parameters for a more detailed cost- 
effectiveness study. Because the National Chlamydia Screening Programme is currently 
being phased in throughout the country, it is also timely to assess the cost of screening and 
examine in detail the relative contribution of cost elements, such as personnel, supplies and 
overheads. A study of the costs of chlamydia screening was performed (Adams et aL 
2004b). The goals of this cost studywere: 1) to estimate the average cost per test offer, 
cost per testing episode, and cost per chlarnydia positive episode, based on the costs 
incurred bythe health care system; and 2) to run a series of 'what if'scenarios to illustrute 
cost changes vis-a-vis practice changes and screening implementation strategies (Adams er 
aZ 2004b). 
The study design utilised a decision-tree model to mirror the patient flow of the original 
chlamydia screening pilot and to reflect the current clinical flow of patients screened in the 
NCSP. Empirical data on women screened in the chlamyfia pilot were analysed for 
parameter estimates in the model. Patient flow was based on urine samples tested with 
nucleic acid amplification tests and follow-up of positive patients and their partners by 
nurse health advisers. Separate decision-trees were constructed. for patients and partners, as 
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partner notification focused on prophylaxis nather than the 'test then treat' approach used 
with screened patients. The ovemll health care costs were estimated from direct 
expenditures recorded in the original screening pilot for test Mts, reagent, personnel, 
materials, supplies, eqiiipment, office space, treatment and contact tracing. Additionally, 
costs bome by the health care s3, stem for chriical staff involvement and administration in 
the programme were included to reflect activities not receiving direct remuneration from 
the NCSP funding. Planning and set-up costs and overheads were also fixed and 
incorporated into the model. Variable costs were added at each step in the decision-tree 
model and summed to acquire total cost. Sensitivity anal)Ses were performed to assess 
which costs and patient flow values were most important to the outcomes, and to explore 
the r-ange of possible outcomes for this screening progmnune. This facilitated ninning the 
model through several 'what if' scenarios that reflected practice variations reported in phase 
1 of the implementation of the NCSP Pepartment of Health 2004a; LaMontagne et aL 
2004b). 
Ile estimated overall annual cost of opportunistic screening for over 33,000 women ages 
16-24 was overL493,000. Eightypercent of the costs were variable Patient costs, 5% were 
associated with partner notification activities, and 15% were overhead costs for running the 
programme. Each screening episode cost was estimated to be L21.83, inclusive of all 
downstream healthcare costs associated with testing. 'Me cost per offer was underL 15 and 
cost of a positive episode was less than L40. In sensitivity analyses, three keyparameters 
had the greatest impact on the cost per screening offer. 1) the proportion of the population 
accepting screening- as test acceptance increased, so did costs; 2) the involvement of the 
GP versus the practice nurse in patient recruitment- costs decreased with less GP 
involvement; and 3) the amount of time spent by either receptionists or clinicians in the 
screening episode- cost decreased as clinicians spent less time explahiing screening. 
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These findings illustrate that the proportion of the population accepting screening has the 
largest impact on costs. VVhile a high test acceptance rate accounts for higher costs, it may 
help identify the greatest number of infections if the correct population is tested; indeed, 
this is the goal of the NCSP. The laboratory test cost was important to the total cost of 
screening, which suggests that stabilisation of the cost through contractual arrangements of 
bulk-purchasing test kits and reagents, combined with efficient use of laboratorystaff to 
process specimens, could facilitate reductions in overall costs. 
Partner notification activities contributed to only 5% of the overall programme costs. INs 
was expected given the results of the screening pilot which showed that partners only 
comprised about 5% of all persons tested (Pimenta etaL, unpublished data). Although 
partner contacting is critical to the spread and control of chlamydial infection (Garnett and 
Anderson 1996), it was less resource intensive in this study, providing convincing evidence 
that this component of a chlamydia screening programme may not be financially 
burdensome. 
Ibis study also highlights areas of uncertainty in the data that influence the costs of 
screening. For example, the time spent by clinicians in explaining screening had a large 
impact on the costs because of its high vatiabilityand impact on all screening offers. 
Reduction in the time for the screening offer, such as through a patient self-selection 
process, could also reduce the overall costs of the programme. 
This research provided significant contribution to the body of evidence in four ways. 
Firstly, this studyis the only recently published analysis to explicitlyestimate the time and 
costs at each step of a chlarnydia. screening programme. Previous studies have estimated 
the time and involvement of health care workers for different outcomes, such as PID, 
ectopic pregnancy, and infertflity (Welte et al 2000), but, %ithout the precision of costs at 
each step in the process as afforded by this study. 
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Secondly, this study quantified the health care-associated costs of opportunistic cblamydia 
screening in England, directly responding to a keycomponent of the Wilson and junger 
criteria (1968). 'Mey advocate the need to know the costs of a screening intervention in 
order to assess the economic effectiveness of the programme (1968). Thirdly, the use of 
empirical patient flow data and exact cost data from the original chlarnydia screening pilot 
strengthened the interpretation of our model. 
Additionally, utilising decision analysis was novel in assessing the uncertainty of various 
parameters and how those parameters impacted costs at each stage of the screening 
episode. T1-1is allowed the model to reflect actual screening practice and provided flexibility 
to simulate other screening scenarios as they arise. This can be a powerful tool to explore 
the aver-age costs of screening and variations in estimates as local programmes revise their 
implementation and operational structure for chlamydia screening. This also provides an 
oppomu-ýity to estimate costs based upon locallrderived figures for time and staff mix 
involved in the programme as well as the actual costs incurred for equipment, supplies, 
personnel and overheads. 
Lastly, this study demonstrated the utility of employing the lessons learned from this model 
to advise on the appropriate cost of screening for the National Chlamydia Screening 
Programme, and potentially similar programmes being explored in other countries. Indeed, 
the NCSP has used the results of this study to develop "cost templates" that suggest a 
standardised budget for local programmes based on projected testing volume for new areas 
applying to be a part of the next phase of the programme. 
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CMcal audits for assessing adherence to screening giýdehes 
Monitoring and evaluating chlamydia screening programmes can occur at many levels. 
Assessing adherence to screening criteria (LaMontagne et aL 2004a), measuring changes in 
the disease burden (LaMontagne et aL 2005), and ensuring fiscal prudence (Adams et aL 
2004b) are three approaches I have previously researched. For most prograrnmes 
addressing sexual health, clinical standards and guidelines exist. In England, the British 
Association for Sexual I-kalth and I-HV (BASF" published care and treatment guidelines 
for genital chlamydial infection (Clinical Effectiveness Workgroup 2002). For the NCSP, 
the Department of Health (2004a) has published core requirements as guidelines for 
screening implementation. Assessing adherence to these published guidelines will provide 
an additional programme monitoring tool for nationall), organised chlarnydia screening 
efforts. 
For women seeking termination of pregnancy, the Royal College of Obstetricians and 
Gynaecologists (RCOG) (2002) have published guidelines for appropriate chlamydia 
screening and treatment, which allow for either prophylactic treatment of all attenders or a 
'screen then treat' approach for women testing positive. Women undergoing termination 
procedures are an ideal population for chlarnydia screening because studies have found 
higher prevalence levels than other populations of women screened (Skjeldestad et aL 
1997). Moller et aL (198 1) have found women who have surgical terminations were at 
increased risk of ascending upper genýital tract infection and demonstrated a high incidence 
of PID in chlamydia-positive women following termination. In England, over 180,000 
medical or surgical terminations are performed each year (Office of National Statistics 
2000) and mayplace this population of women at increased risk of ascending upper genital 
tract infection. Because of this risk clear guidelines for the detection and management of 
infection among women seeking termination are necessary. 
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In addition to the RCOG guidelines, the Cl-ýief Medical Officer (1998) has advocated all 
women seeking terminations should be screened for chlamydia. Investigating the adherence 
to either of these guidelines by clinical providers of pregnancy termination services through 
clinical audits can be beneficial in understanding practice patterns to address any non- 
compliance or deviations in practice that maybe harmful. This study sought to explore the 
pohcy and practice for chlamydia testing and treatment at termination of pregnancy 
providers in England and Wales, and examined variations by region and service size as well 
as the degree to which practices and policies followed either of the recommended 
guidehes. 
A survey questionnaire was distributed to all providers reporting terminations to the 
Department of Health in 1999. The questionnaire queried current policies for screening 
and treating genital chlarnydial infection, assessed testing and treatment behaviour to client 
populations, gathered information on patient treatment and follow-up, and recorded 
perceived barriers to implementing chlamydia screening. Assessment of practice was 
collected separately for surgical and medical terminations, as medical terminations usually 
do not employ an invasive procedure. I analysed survey responses in themes: policy, 
practice for screening, and practice for treatment. Variations in policy and practice by size 
of service, geographic region, and NHS and non-NHS Providers were explored in statistical 
analyses. 
All 284 identified termination of pregnancy providers were invited to participate, of which 
48% (138/284) responded. All NHS regions except the West Midlands were evenly 
represented in services of different sizes. Most services (87%) were NfE funded. Nina), - 
six services (70%) reported a written policy for screening and/or treatment of chlarnydia. 
No practice differences between surgical and medical terminations were found. 
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Slight regional differences in practice were uncovered. For example, surgical terminations 
in Yorkshire and Htunberside and the North East were more likelyto provide prophylaxis 
without testing (p <. 05). Practice differences were found between NIB and non-NIB 
providers and between small and medium-large services. Over 50% of termination 
providers collected cervical swabs as the specimen of choice for chlarnydia testing. The use 
of less sensitive non-amplified laboratory tests was noted by 50% of providers surveyed. In 
general, clinical pr-actice for screening and treating of chlamydial infection followed three 
patterns: providers screening prior to termination and treating if warranted (over 70% of 
services); providers administered antibiotic prophylaxis without screening (about 25% of 
services); or providers did neither screen or treat for chlamydial infection (less than 5% of 
services). 'Mese practice variations might be due to the diverging recommendations from 
the RCOG and CIAO. 
Among the nearly 70% of providers that engaged in chlamydia screening before 
termination, over 90% tested everyone. 'llie RCC)G and CMO guidelines are most similar 
on this point but the RGOG guidelines do not explicitly recommend testing all patients. 
Most providers who did screen, did so prior to termination, as recornmended; however, 
less than half used the current NAAT diagnostic standard Pepartment of Health 2004a). 
For A services, differences in the treatment regimen administered were apparent. 
Inconsistency in the recommended treatment regimens between the RCOG and CMO 
guidelines maybe influencing these providers' practices. Lastly, the most divergent point 
between the CMO and RCOG is the practice of prophylaxis without screening, which 
occurred among 25% of providers surveyed but is not advised by the CMO (1998). 
This study found that over 95% of responding tennination of pregnancy providers 
reported practice consistent with either the RCOG or CMO guidelines for chlatn)dia, 
although there were discrepancies. Specifically, this study reconunended guideline 
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clarification and harmonisation on three points: (1) whether antibiotic prophýlaxis should 
be offered to all termination of pregnancy attenders without screening for chlarnydia; (2) 
the appropriate treatment regimen for both prophýactic and curative regimens; and (3) the 
laboratory test standard for both the sample and the test platform. 
This studyhas provided two direct and relevant insights for consultation within the 
programme implementation of the NCSP. Firstly, this studywas beneficial in quantifying 
the behaviour of clinical providers regarding chlarnydial screening to a high-risk population. 
Ile uncovering of discrepancies between policy and pructice, as well as between the 
guidelines from two national bodies, highlights the importance of understanding how 
services are delivered in the field and can act as a monitoring technique for adherence to 
guidelines. Because the risk of sequelae from infection is increased by the invasive nature of 
the termination procedure, sound clinical practice that ensures the health of the patient is 
paramount. Women attending for termination of pregnancy are more likely to have 
chlarnydia, even after considering age and sexual behaviour risk factors. Therefore, the 
clinical management of women undergoing pregnancy termination requires a clear and 
consistent policyfollowed-up with sound clinical practice. 
Secondly, by surveying the practice patterns of screening for chlarnydia within this high risk 
population, this study has illustrated service delivery areas that might need strengthening by 
the NCSP. For example, invasive samples tested using tests with lower sensitivity were 
cornmon. 'Me NCSP funds screening based on non-invasive urine or self-collected vulva- 
vaginal swab samples using the highly sensitive tests (Department of Health 2004a). As 
tem-dnation providers join the programme, they wifl be able to access these more 
acceptable testing methods. IUs may increase the termination providers' adherence to 




My research into various aspects of chlamydia screening has covered three broad themes 
across two countries. Individually, these studies have strengthened the evidence base for 
determining whether chlamydia screening meets the criteria for public health intervention, 
as outlined byWilson and jungner (1968), by enriching our current knowledge of the 
epidemiology of genital chlanlydial infection and demonstrating several approaches for 
monitoring and evaluating existing screening programmes. As diverse as these studies are, 
there is a thread that brings them together, and that is the National Chlamydia Screening 
Programme (NCSP). My early work for the Region X screening programme in the US 
(LaMontagne er aL 2004a) and my research on chlarnydia, infection in men (LaMontagne et 
aL 2003) has provided me the academic foundation and critical experience for my role as 
the lead scientist in the NCSP in the UK. Additionally, the research I have performed since 
arriving to the UK has been done to provide critical input on several facets of the NCSP 
(Brown et d 2004; LaMontagne et aL 2004b; Adams et aL 2004b; LaMontagne et aL 2004c; 
LaMontagne et aL 2005). How these diverse research studies in two different countries have 
influenced the field, in general, and the development of the NCSP in the UK, specifically, is 
the focus of the discussion below. 
LaMontagne et aL (2003) has provided the field with a more robust understanding of the 
epidemiology of chlamydial infection in men. This study has raised again the question of 
whether men should be screened. The high prevalence of infection found in asymptomatic 
men suggests they should. Two recently published papers have argued for the inclusion of 
men in screening efforts and have cited this study as evidence (Peipert 2003; Stamm 2004). 
Additionally, this research questioned the utility of testing all men attending STD clinics, 
especially since over two-thirds of male attenders had no signs of infection and were not 
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contacts of known cases. 'Me study explored screening str-ategies for men and suggested 
that age, clinical signs of infection (principallyurethritis), and recent contact to a known 
case would be sensitive in detecting infections and greatly reduce the number of men 
requiring testing. The challenge for the field is to test this hypothesis. The logical outcome 
from this work would be for Region X, where the study was done, to trial different 
selection criteria in various STD and non-STD locations and critically evaluate their 
efficiency and sensitivity, as has been done for screening criteria for women (LaMofitagne 
er aL 2004a). Unfortunately, I left my post shortly after this study was completed, and was 
not able to see through this next step; however, as a peer-reviewer for the journal &xuafly 
TramnitW Ijrk-tibm, I have assessed a study from Australia that has tested screening criteria 
in men, reflecting that with time, the influence of my research will be observed. 
LaMontagne et aL (2004a) has provided the field with the second evaluation of the long- 
standing cWamydia. screening programme in Region X As noted in Chapter 4, this 
programme has set the tenor and pace for chlamydia screening in the LTS. My evaluation of 
the prognunme's selective screening criteria resulted in a direct change in programme 
policy and structure. This study found that the criteria previously in use could be optimised 
for efficiency without a significant loss to criteria sensitivity. This result was taken forward 
to the programme's advisory committee after the study's end, and the new criteria were put 
into programme we beginning January 2003 (Center for Health Training 2003). 
Four of my studies from the UK have helped shape the establishment and structure of the 
National Chlamydia Screening Programme. My first task when joining the programme in 
early 2003 was to develop the data collection system and programme monitoring and 
evaluation components. Using experience with the Region X prograrnme and existing 
research that suggested positivity could be a surrogate measure for prevalence, I proposed 
to collect data for all tests, rather than data on all women Pepartment of Health 2004). 
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Ihis study (LaMontagne et aL 2005) has already been reviewed in Chapter 4. Ile important 
influence of this work was two-fold. Firstly, I demonstrated that the suggested plan to 
monitor test trends for positivity was appropriate and could act as a surrogate measure for 
prevalence. 'Ihis helped advance the data collection system for the prograrnme, and greatly 
eased local implementation of data collection instruments as well as reporting requirements 
for local screening prograrnmes. Secondly, this research provided a significant contribution 
to the knowledge base by confirming a method, that although was widely used, had only 
been verified in one peer-reviewed published study. As is often the case with research, it is 
important that the findings from one study are replicated in others, enhancing the validity 
of the study and confirming the studys conclusions. 
LaMontagne et aL (2004c) has shaped the discussions at the national level of what clinics to 
include in the NCSP. Even though studies of chlamydia prevalence in women attending for 
termination of pregnancy have shown levels of infection as high as 14% (Pimenta. et aL 
2003b), the inclusion of providers of pregnancy terminations into the screening programme 
was not automatic. Conflicts with existing policies and practices and the potential for 
additional training for these providers were areas of concern. My work examining the 
current policies and practices of termination providers illustrated what baseline pr-actices 
were being employed and what training would be needed for providers that were not 
already adhering to a screening guideline. This study also showed the divergent policies 
between the CMO (1998) and the Royal College of Obstetricians and Gynaecologists 
(2000), and suggested harmonising the two guidelines. Since the publication of this study, 
questions of how to take the issue forward have been discussed by those involved in the 
NCSP as well as external agencies, such as the Health Protection Agency and the National 
Institute for Clinical Effectiveness. How to continue to take this issue forward is one of 
many current topics on the agenda of the NCSP. 
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'Me Adams et aL study (2004b) of the cost of chlamydia screening has provided the first 
published analysis of the actual costs of screening at each step in an organised programme, 
from screening offer to treating the partners of positives. Previous cost studies were only 
focused on 'health care costs' more generally, and have not detailed the costs for each 
component. I'his has enhanced our knowledge base significantly. Additionally, the 
sensitivity analysis performed in this study has helped define the most variable costs. INS is 
important to the NCSP because it has provided a tool for financial audits, has illustrated 
where money might be saved, ag., through the reduction of physician involvement, and has 
informed the NCSP on specific costs in the programme that are not terribly expensive, e-g. 
partner notification and treatment. The NCSP has already used the results from this study 
in two important ways. Firstly, the programme has used the average costs of screening 
from this paper to analyse budget proposals by the local programmes included in phase 2 
of implementation, which will also form the basis of yearly financial audits. Secondly, the 
average cost of screening from this studywas used in conjunction with the estimated 
number of sexually active young people in England to determine the funding required for 
full national coverage of the NCSP. 
Brown et aZ (2004) reconfirmed how prevalent SUs are in the UK, examined observed 
trends in increased diagnoses, and was in the top ten frequently downloaded articles from 
the journal's website in 2004 (hqp: //sti. bmjjoumah. com/nýsc/topten04. shtmD. The 
presentation of annual epidemiological statistics for SlIs has provided more evidence of 
the burden of these diseases in the population, especially among persons aged under 25. 
'Mis study provided additional confirmation that the NCSP is targeting the appropriate age 
group for chlarnydia screening. Often reports of this magnitude can act as a catalyst for 
greater attention by the public and by government. The English government has recently 
announced its current health priorities and have earmarked. C300 million to tackle the rising 
trends in A sexually transmitted diseases, including chlamydia Pepartment of Health 
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2004b). Certainly, this study is not the only evidence used to influence the govenunent's 
recent decision, rather the research literature taken in total, of which this paper has made a 
significant contribution, has provided the evidence base. 
Ultimately, these six research papers have lead to the most recently completed study-- the 
description of the establishment of the National Chlarnydia Screening Programme in 
England and analysis of results from the first year of screening outside GUM clinics 
&aMontagne et at 2004b). My work in establishing this programme has utilised all of my 
prior research, in addition to the existing body of evidence. The NCSP has benefited from 
the lessons learned by other programmes and from the enriched body of knowledge that 
was not available at the time programmes were established in the US. The progrumme has 
been able to robustly build its structure and components from the best available evidence, 
as well as from the additional research that I have performed whit the NCSP has evolved. 
'Me programme has confirmed that opportunistic screening for genital chlamydial infection 
is feasible and acceptable and can occur in a wide variety of settings, without loss to quality 
care for persons testing positive and their partners. Most importantly, the first )tar of the 
NCSP has shown that chlamydial infection is highlyprevalent among young people in 
England. 
Ile evidence for the magnitude of this disease can no longer be in dispute. Action towards 
reducing the burden of disease and the potential devastating consequences of infection can 
no longer be delayed. The establishment of the NCSP has received significant attention 
recently, in the press- popular and academic, and by the government. Popular press has 
included lengthy articles in broadsheets and interviews with the BBQ Reuters and others 
by myself and NCSP staff. 'Me academic press has shown its interest in the NCSP by fast- 
tracking the paper describing the first year's results (Ward H and Miller R 2004). 1 believe 
that the work of the NCSP to date has had direct influence on the recent decisions by the 
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govenunent to make sexual health a prioiity and to specifically allocate L80 million to fully 
fund the National Chlamydia Screening Programme for national coverage by Alarch 2007 




'11iis; context statement considered the structure and context of chlamydia screening in two 
different countries, the United States and United Kingdom. I have critically examined the 
epidemiology of chlamydial infection in several populations across both countries, detailed 
the development, implementation and first year results for the newly established National 
Chlarnydia Screening Programme in England, and have demonstrated four methods for 
monitoring and evaluation of chlamydia screening- assessment of screening criteria, use of 
positivity to measure disease changes in the population, fiscal analysis of costs through 
economic modeffing, and clinical audits of provider adherence to screening guidelines. My 
research was developed within the framework of the Wilson and jungner (1968) criteria, 
which are used to examine the case for screening as a public health intervention. 
My research has been chronological with increasing sophistication over the 3tars. The 
lessons learned from each study have been taken to the next, as illustrated by my 
investigation of the epidemiology of chlamydial infection among men and MSK The 
combination of all seven papers has provided additional support for the Wilson and 
Jungner (1968) criteria and has had direct influence on policies and screening programmes 
in the U and the UK. The studies from the US have shown significant disease burden in 
men, and suggested selective screening criteria might be beneficial. Additionally, my 
evaluation of the Region X screening programme lead to direct programme change for 
screening criteria used to test women. The lessons learned from this evaluation have been 
incorporated in the programme monitoring structure of the NCSP in the LJK, particularly 
through the use of positivity as a surrogate measure to monitor prevalence changes as 
screening becomes increasingly wide-spread. 'Ihis is just one example of how I have been 
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able to bring my experience in the LS and expertise in chlarnydia screening to bear on 
components of the NCSP; others have been Iiighfighted throughout this context statement. 
Even though the scientific evidence presented, both my own and that of the published 
literature, covered many aspects of chlamydia screening, there is still more work to be 
done. I continue to be intimately involved in contributing to gaps in our knowledge of 
chlamydia screening progrummes. 
For example, there are two questions that are stifl inadequately studied and consume a 
portion of the debate about chlarnydia screening in England today. First, do we know how 
frequently women should be screened for chlarnydia to reduce prevalence? One published 
study (Burstein et al. 1998) of adolescents in Baltimore (US) suggests young women with 
negative results on their first chlamydia test should be screened every six months. To date, 
three prospective cohort studies of chlarnydia re-infection from the US have suggested 
wornen, %ith positive results on their first chlarnydia test should be re-screened every three- 
to-six months (Oh et al. 1996; Fortenberr7 et aL 1999; VVhittington et aL 200 1). 
Because these studies were unable to assess the long-term impact on cmamydia prevalence 
of their recommended screening intervals for women testing negative and those testing 
positive and are limited in their inference outside the US, I am studying chlamydia. 
incidence and re-infection in women aged 16-24 years in England. Myprospective cohort 
study has recently concluded and showed an incidence rate of 5.8 per 100 woman-years and 
a re-infection rate of 24.0 per 100 woman-years (LaMontagne, Emmett, Baster and the 
Chlarnydia Recall Study Advisory Group 2004d). Women with multiple partner changes 
over the preceding six months were at highest risk of both infection and re-infection. Most 
infections occur-red within 14.4 months of follow-up for initiallynegative tests; most re- 
infections occurred within six months of follow-up for initially positive tests (LaMontagne 
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ef al 2004d). We are currently modelling these data to calculate the optimal screening 
interval for initially negative and initially positive women to reduce cWamydia prevalence in 
the population. 
The second question under debate is whether screening women for chlarnydia is cost- 
effective. Even though several cost-effectiveness analyses have been published in the LIS 
(Nfarrazzo et aL 1997b), Europe (Welte et aL 2000; Krtzschmar et al. 2001), and England 
(rownsend and Turner 2000), some have suggested methodological shortcomings of these 
studies (Roberts et aL 2004), principally the lack of empirical data to verify the mathematical 
models developed and the inability of previously published models to account for the 
unique dyrmrr&s of cWamydia transmission in the population. My colleagues and I are 
performing economic analyses based on a recently developed transmission dynamic model 
of cWamydia (Turner, Garnett, Ghani, Sterne and Low 2004) using data from our incidence 
and re-infection study to more accurately estimate the scenarios of chlarnydia screening 
that are most cost-effective. Various strategies of screening are being explored including 
those operating on an invitation-to-screen or'call/recall' basis, those arising from 
opportunistic screening in clinical settings, and those that include a variety of age cut-offs 
for both men and women. 
The results of the chlam), dia incidence and re-infection study and the subsequent modelling 
of screening intervals and cost-effectiveness will be a great addition to our understanding 
of how to improve upon current approaches to chlamydia screening. The results from 
these studies will also be used by the National Chlamydia Screening Programme in 
developing scientifically robust screening frequency recommendations to enhance the 
progranune's impact on the morbidity and sequelae of this preventable public health 
epidemic. 
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Sexual health in the United Kingdom has deteriorated in 
recent years with further increases in HIV and other 
sexually transmitted infections (STIs) reported in 2002. This 
paper describes results from the available surveillance data 
in the United Kingdom from the Health Protection Agency 
and its national collaborators. The data sources range from 
voluntary reports of HIVAIDS from clinicians, CD, 4 cell 
count monitoring, a national census of individuals living 
with HIV, and the Unlinked Anonymous Programme, to 
statutory reports of STIs from genitourinary medicine 
(GUM) clinics and enhanced STI surveillance systems. In 
2002, an estimated 49 500 adults aged over 15 years 
were living with HIV in the United Kingdom, of whom 31 % 
were unaware of their infection. Diagnoses of new HIV 
infections have doubled from 1997 to 2002, mainly driven 
by heterosexuals who acquired their infection abroad. HIV 
transmission also continues within the United Kingdom, 
particularly among homo/bisexual men who, in 2002, 
accounted for 80% of all newly diagnosed HIV infections 
acquired in the United Kingdom. New diagnoses of syphilis have increased eightfold, and diagnoses of chlamyclia and 
gonorrhoea have doubled from 1997 to 2002 overall; STI 
rates disproportionately affect homo/bisexual men and 
young people. Effective surveillance is essential in the 
provision of timely information on the changing 
epidemiology of HIV and other STIs; this information is 
necessary for the targeting of prevention efforts and 
through providing baseline information against which 
progress towards targets can be monitored. 
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Group on Sexual Health; greater investment in 
genitourinary medicine (GUM) clinics, and 
phased implementation of prevention interven- 
tions, such as the National Clilamydia Screening 
Programme, aimed at specific population risk 
groups. There have been similar strategies in 
other UK countries Wales, ' Scotland 7 and 
Northern Ireland)! Tile Health Select 
Committee report on Sexual Health, ' the All 
Party Parliamentary Group on AIDS report on 
Migration and IIIV, ` and most recently the 
government's response to the Health Select 
Committee's report on sexual health" have all 
drawn attention to the need for greater political 
will and investment in tackling IIIV and STIs in 
the United Kingdom and globally. 
Surveillance data have a key role in such 
strategies. The collection and analysis of data, in 
conjunction with the monitoring of trends with 
timely feedback provides information for the 
implementation and evaluation of these initia- 
tives. Specifically, by highlighting where preven- 
tion efforts should be targeted and through 
providing baseline information against which 
progress towards targets can be monitored. 
The immediate public health challenges facing 
sexual health in the United Kingdom include 
increasing incidence and prevalence of IIIV and 
STIs; rising costs of IIJV related care, variation in 
disease determinants and distribution; and the 
associatcd long term morbidity and mortality of 
these conditions. This paper suniniarises recent 
trends in the UK surveillance data for HIV and 
other STIs tip until the end of 2002. " 
DATA SOURCES 
in the United Kingdom, the majority of STIs, 
including HIV, irc diagnosed and treated in 
GUM clinics which form part of the National 
Health Service. Although diagnoses of many STIs 
(particularly chlanlydia) occur in primary care 
and other community settings, " only GUM 
clinics have statutory reporting of STIs to the 
Health Protection Agency and its collaborators by 
clinicians. The detailed methods of the IIIV and 
STI surveillance systems in the United Kingdom 
have been described elsewhere" and are briefly 
summarised here. 
HIV/AIDS reporting 
New diagnoses, of HIV infections, AIDS cases, 
anti deaths" (IIIV/AIDS reporting) are reported 
by laboratories and clinicians through voluntary 
reporting systems. The annual Survey of 
Prevalent HIV Infections Diagnosed (SOPIIID)" 
provide.,; a census of the number of individuals 
160 
living with diagnosed IIIV infection and receiving care in 
England, Wales, and Northern Ireland. Longitudinal data on 
CD4 T lymphocytes" (CD4 surveillance) are reported from 
laboratories in England. Wales and Scotland and are uscd to 
monitor trends in imninnosuppression associated with nIV 
infection. In Scotland, these data are used to gauge the 
number of people in specialist IIIV care. 
Unlinked anonymous HIV surveys 
The unlinked anonymous (UA) IIIV surveys" measure the 
prevalence of IIIV, including undiaynosed IIIV infections, in 
selected subgroups of the population. The unlinked anon- 
ymous survey of GUM clinic attendees (UA GUM survey) 
measures IIIV prevalence in a high risk population (attendees 
of sentinel GUM clinics in the United Kingdom). " In 
England, Wales, arid Northern Ireland the incidence of HIV 
infection in homo/bisexual men included in the UA GUM 
survey has been determined by application of the Scrological 
Testing Algorithm for liecent 111V Seroconversion 
(STARHS). '9 
Prevalence in the general population is measured by sur- 
veys of pregnant women (UA pregnant women surveys- 
pregnant women attending antenatil care and women giving 
birth in England arid Scotland). Live births to diagnosed IIIV 
infected women in the United Kingdom are reported to the 
National Study of IIIV in Pregnancy and Childhood. "' These 
reports are aligned with the overall prevalence estimates for 
IIIV in pregnant women by geographical area, to produce 
estimates of the proportion of women giving biitli who were 
diagnosed before antenatal attendances, diagnosed through 
antenatal testing, and who remained undiagnosed at 
delivery. " 
STI surveillance 
Statutory KC60 returns frDIII all GUM clinics" in England, 
Wales, and Northern Ireland provide aggregate data oil the 
total episodes of diagnosed STIs by sex and age group (and 
sexual orientation for selected conditions). The ISD(D)5 
returns system provides disaggregate data on all STI 
diagnoses in GUM clinics in Scotland. " NHS laboratories 
throughout the United Kingdom provide voluntary electronic 
disaggregate reporting oil laboratory diagnoses of selected 
STIs with age and sex information. Enhance(] Syphilis 
Surveillance (ESS) collects further dernoggraphic and risk 
factor data in the United Kingdom, and is designed to 
improve interpretation of the incidence and distribution of 
infectious syphilis. 22 Tile Gonococcal Resistance to 
Antimicrobials Surveillance Programme (GRASP) is a senti- 
nel surveillance system for monitoring gonococcal anti- 
microbial resistance and collects detailed behavioural 
information on diagnoses ofgonorrhoea in England. " 
Related surveillance techniques 
Estimates of the total number of IIIV infected people in the 
United Kingd OM24 were cakulated by combining data from 
SOPHID (for diagnosed HIV infections) and the unlinked 
anonymous surveys (for undiagnosed IIIV infections), with 
estimates of the size of the population in various exposure 
categories derived from the National Survey of' Sexual 
Attitudes and Lifestyles (Natsal 2000), " and census 2001 
population estimates (Office for National Statistics), 
Annual rates (cases/population) of diagnoses of STIs %vere 
calculated per 100 000 people. The 2002 rates for all regions 
and countries in the Unitcd Kingdom were calculated by 
dividing the number of cases reported from GUM clinics in 
each area in 2002 by the mid-2002 population estimates from 
the office for National Statistics (for horno/bisexual men 
population estimates vvere derived from Natsal 2000"). 
Descriptive epidemiology i% the locus of the paper, but 
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Previously undiagnosed HIV infection 
This includes both HIV infected individuals who v*eire 
I Id is 
iogric 
, 
With HIV of the ep; sode of clinical core,. 'bncl'ý 
iýncl VI who left clinical care remaining unaware of their, 
infection, but excludes individuals whose HIV infection %Y'CIS .n-- diagnosed 6efore the episode a 'linical care c 
hypothesis tests have been used to supplement the data 
where appropriate using Stata 7 (StataCorp, 2001). 
OVERALL HIV/STI SURVEILLANCE TRENDS 
Estimates of the total prevalent infections indicate that at the 
end of 2002,49 500adults aged over 15 ivere living with 111V 
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Figure I Prevalence of previously undiagnosed HIV infection in 
England, Wales, and Northern Ireland, 1993-2002. (A) Previously 
undiagnosed* HIV rifection in homo/bisexual ment by clinical 
presentation and age group. (8) Previously undiagnosed* HIV infection 
in heterosexualst and overall HIV prevalence in women giving birth. 
('Excludes HIV infected attendees who were previously diagnosed. fAttendees at 15 GUM clinics in England, Wales, and 
Northern Ireland (seven in London, eight elsewhere). tAcute STI is defined as presenting with one of the following diagnoses: infectious 
syphilis, gonorrhoea, chancroid/donovanosis/LGV, chlomydia, NSU, 
trichomoniasis, scobies/pediculasis, HSV/HPV first attack or molluscum 
, 
2, iosum. §Tbrough unlinked anonymous testing of neonatal dried conto bloo pots. ) Data source: Unlinked Anonymous Programme. 
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Table I Subcategory of HIV infections diagnosed in the United Kingdom that were probably acquired heterosexually, 1992- 
2002 
1992 or 
][ýýI subca" earlier 1993 1994 1995. 1996 1997 1998 1999 2000 2001* 2002*, 
Exposure to "high risk" partnerls) infected through: 
Mole homosexual intercourse 109 24 21 12 11 10 11 12 13 23 17 
Inieding drug use 199 37 31 At 33 49 48 23 22 36 16 
B6od/b6od products 75 5 2 4 9 6 4 5 2 4 3 
Exposure to presumed heterosexually infected partner(s): 
Exposure abroad 
in Africa 1938 506 534 559 SA9 642 745 99A 1478 2151 2338 
in Latin America/Cari6bcon 62 24 27 14 25 28 32 62 67 82 108 
in Asia 66 28 18 39 44 53 78 76 110 97 95 
in North America 56 16 9 8 8 10 15 7 6 9 4 
in Europe 127 38 36 42 A2 50 42 49 46 46 A] 
in Australasia 6 2 0 2 1 2 4 6 2 5 2 
in courdry(ies) not known 24 0 0 2 7 3 17 0 2 1 1 
Exposure in the UK it) partrieris) presumed infected 
ouhicle Europe 91 17 38 48 42 71 81 90 127 155 153 
within Europe 108 42 44 38 29 39 41 48 47 51 35 
in oountry(ies) not known 152 28 30 32 28 31 25 30 27 56 87 
Porlnerl[s) exposure category undetermined: 
Investigation continuing/closed 2A 2 6 10 7 11 17 25 32 113 252 
Total 3037 769 796 851 835 1005 1160 1427 1981 2829 3152 
'Numbers for recent years will rise as further reports are received. The table will include some records of (a) the same individuals, which are unmatchable because 
of differences in the information supplied and (b) individuals who leh the United Kingdom of some date after diagnosis. 
Data source: HIV/AJDS Reports. Reports received by the end of June 2003. 
in the United Kingdom, of whorn 15 200 (31%) were 
unaware of their infection. There were 5542 new IIIV 
diagnoses reported for 2002: double the 2735 diagnoses in 
1997. 
At the end of 2002, overall HIV prevalence among homo/ 
bisexual men in the United Kingdom was estimated at 7%, 
with estimates of total prevalent infections indicating that 
22 600 horno/bisexual men were infected with IIIV, of whoin 
5500 (24%) were unaware of their infection. of Elie newly 
diagnosed HIV infections that were acquired in the United 
Kingdom, 80% (1500/1850) were among horno/bisexual men. 
The UA GUM survey found 4% (27/672) of honio/bisexual 
men aged under 25 in London had a previously undiagnosed 
HIV infection in 2002, indicating continuing transmission in 
this population (fig IA). Annual incidence in GUM attendees, 
measured using STARIIS, rose to approximately 3.5% in 
2002. " 
However, the recent increases in reports of new IIIV 
diagnoses have largely been driven by lieterosexually 
acquired infections, which accounted for 57% (3152/5542) 
of all those reported in 2002. Of these infections, three 
quarters (2338/31521 were probably acquired in Africa 
(table 1). Estimates of the total prevalcnt infections indicate 
that by the end of 2002,15 400 AfriCan heterosexuals aged 
over 15 were living with HIV in the United Kingdom, of 
whorn 4800 (31%) wcre undiagnosed. 
in 2002, one third (185015542) of new IIIV diagnoses were 
probably acquired in the United Kingdom. Although 80% 
(1500) of these infections were dLignosed in homo/bisexual 
men, since 1997 there has been a steady increase in the 
number of diagnoses of heterosexually acquired JIIV infec- 
tion in the United Kingdom. In 2002,275 such IIIV infections 
were diagnosed compared to 141 in 1997 (table 1); 56% (153/ 
275) of these diagnoses were acquired through partners who 
were probably infected outside Europe. in England, Wales, 
and Northern Ireland, although remaining low, the pre- 
valence of previously undiagnosed IIIV infection rose 
significantly among UK born heterosexual males from 
0.12% (30P24 465) to 0.3% (72/24 040) between 1997 and 
2002 (p<0.0001); prevalence in UK born women was 
unchanged. 
Major acute STI diagnoses reported through KC60 returns 
have continued their rising trend since the mid-1990s. From 
1997 to 2002, there was a 103% increase to 82 206 chJamydfa 
diagnoses (rates were 138/100 000 in males and 167/100 000 
in females); a 97% increase to 24 958 gonorrhoca diagnoses 
(males: 66/100 000, females: 167/100 000); a 716% increase 
to 1232 syphilis diagnoses (males: 41100 000, females: 0.51 
100 000); a 9% increase to 69 449 genital warts diagnoses 
(niales: 141/100 000, females: 118/100 000); and a 17% 
increase to 18 379 genital herpes diagnoses (males: 26/ 
100 000, females: 421100 000) in England, Wales, and 
Northern Ireland. Laboratory reports of STIs have also 
increased recently in Scotland; 12 392 chlarnydia positive 
isolates were reported in 2002, a 161110 increase on 2001 
(10636). 
Infectious syphilis (primary, secondary and early latent) 
Uncomplicated gonorrhoea 
Genital chlomyclial infection 
x --- Genital warts (first allock) 
New HIV diagnoses 






Figure 2 Trends in rates of major ocvte STIs in horno/bismal men*, 
United Kingdomt, 1995-2002. (*Rates are based on an estimated 
ýulafion of 310 000 homo/b; sexvol men resident in England, Wales, 
Scotland 
. 
21 t2001 and 2002 data not available for Scotland for 
KC60 and ISD(D)5 data. ) Data sources: KC60 statutory returns and 
ISD(D)5 data, and HIVAIDS Repods, reports received by the end of 
June 2003. 
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Fiqure3 Trends in the roles of selected acute STIs in young females and 
males aged 16-24 in the United Kingdom% 1995-2002. (Al Males. (B) 
Females. (*2001 and 2002 data not available for Sc6tlond. ) Data 
source: KC60 Statutory returns and ISDID)5 data. 
STIs have risen markedly among homo/bisexual men 
(fig 2). in this population, cases of gonorrhoea have almost 
doubled from 1842 in 1999 to 3363 in 2002, and cases of 
syphilis have increawd from 52 to 007 over the same period; 
this latter rise is as a result of ongoing outbreaks in urban 
centres in the United Kingdom. " 
Among heterosexuals, young pcople -, in(] black minority 
communities continue to be disproportionately represented 
in STI statistics. Rates of diagnoses of chlainydia in GUM 
clinics have increased by 215% in Nvornen aged 16-24, from 
529/100 000 in 1997 to 1135/100 000 ! it 2002 in England, 
Wales, and Northern Ireland (fig 3). In the 2002 GRASP data 
collection, black ethnic groups, mainly black Caribbeans, 
accounted for 55% (516/936) and 44% (249/563) of gono- 
coccal isolates collected from heterosexual males and females 
respectively (fig 4). 
100- 0 Females (n - 563) 
80- Heterosexual mates (n - 936) 
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Figure 4 Proporfion of new diagnoses of uncomplicated gonorrhaea 
by ethnicity, England and Wales, 2002. Data sovrce: Gonococcol 
Resistance to Antimicrobials Surveillance Programme (GRASP). 
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POPULATION SUBGROUPS 
Homo/bisexual men 
Since IIIV/AIDS reporting began in the United Kingdom in 
the early 1980s there have been 29 890 IIIV diagnoses 
reported in homo/bisexual men, 12 284 (if whom have 
progressed to AIDS, and 8761 of whom have died. IIIV was 
the third most commonly diagnosed major STI in horno/ 
bisexual men in 2002 (fig 2). 
In 2002, the UA GUM survey found that 6.50,6 (97/1495) of 
previously undiagno%ed HIV infected lionio/bisexual men 
were co-infected with an acute STI; the equivalent figure in 
Scotland was 2.9% (12/416) and elsewhere in England, 
Wales, and Northern Ireland, 3.5% (25nl9). Such individuals 
are of particular concern since they may be at higher risk of 
passing on their HIV infection to others. in London, 4% (27/ 
672) (if liomolbisexual men under 25 years attending GUM 
clinics had a previously undiag gnosed HIV infection a clear indication of continuing HIV transmission at relatively high 
levels. Application of STARIIS found that annual IIIV 
incidence among horno/bisexual men rose to approximately 
3.5% in 2002, " compared to 2-3% froin 1995-2001,27 
although this difference is not statistically significant. The 
highest incidence was seen in those aged 35-44 (5.9%, 95% 
confidence intervals 3.7 to 8.8). This increasing trend 
occurred in a period when there were intensive health 
promotion campaigns and when 60-70% of diagnosed HIV 
infected hoino/bisexual men were on antiretroviral therapy 
(ARV). 
Since 1999, considerable increases in the rate of acute STI 
diagnoses in hoino/bisexual nien attending GUM clinics have 
been observed (fig 2). Rates of gonorrhoca diagnoses doubled 
between 1999 and 2001, from 612/100 000 to 1242/100 000. A 
slight decrease was observed overall in 2002, but there was no 
decrease in nien aged 16-24 where rates increased from 648/ 
100 000 in 1999 to 1194/100 000 in 2002. In 2002, rates of 
hortiosexually acquired infections syphilis have shown a 
marked rise since 1999 (61604). This has been associated with 
a series of large localised outbreaks in Brighton, Manchester, 
Newcastle upon Tyne, London, " central Scotland, '" and 
Northern Ireland. "' Data collected between April 2001 and 
September 2003 from the ESS programme indicate that 46% 
of hoino/biscxual men diagnosed with infectious syphilis in 
L, ondon were co-infected with IIIV. increases in genital 
chlainydia infections in homo/bisexual men were also 
observed in 2002, tip 144% since 1999. 
Factors influencing transmission 
Behavioural surveillance data aniong honio/bisexual men in 
(he United Kingdom have denionstrated increases in rates of 
unprotected anal intercourse (UAI), and specifically, UAI 
involving JJIV discordant or unknown status partners. 'o Data 
from Natsal 2000" suggest that there have been increases in 
the prevalence of male homosexual behaviour in the general 
population, and increases in some high risk behaviours 
among lionio%exually active men. " The reasons for this rising 
risk are unclear. However, continued liberalisation of 
attitudes towards homosexuality, " and "safer sex" fatigue 
in the cra of ARV, 'I coupled with expansions in opportunities 
which facilitate partner acquisition (for example, the inter- 
net, saunas)" may be contributing factors, 
Young people 
People aged 16-24 accounted for just over 10% (58815542) of 
all reports of new IIIV diagnoses ill 2002; a proportion that 
has remained constant over time. Their risk exposure 
distribution was similar to that of people aged over 24. 
Heterosexual IIIV acquisition accounted for 63% (370/588) of 
jie%v IIIV diagnoses in 2002 in those aged 16-24, with the 
www. sfiiournal. com 
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majority of individuals (659A'), 242/370) probably infected in 
Africa. 
Rates of STIs hive risen markedly among young people 
(fig 3) and this population subgroup bear a disproportionate 
burden of STI diagnoses. In 2002, women aged 16-24 
accounted for 72% (33 205/46 140) of all fernale chlainydia 
diagnoses, 66% (5031/7569) of gotiorrhoea, 62% (50/137) of 
syphilis and 61% (19 792/32 544) of genital warts reported 
from GUM clinics in England, Wales, and Northern Ireland. 
Rates of diagnoses front GUM clinics for chlarnydia, 
gonorrhoea, and genital warts were highest aniong fernales 
aged 16-19 and males aged 20-24. The highest rates of 
chiamydial diagnoses wcre seen in woolen aged 16-19 and 
men aged 20-24 at 1209 and 8421100 000 respectively. These 
figures are likely to underestimate the total number of 
infections because most infection% in wonien ire asympto- 
niatic, and thus care an(] ireatmeni are not sought. 
Chlainydial infections diagnosed in primary care and other 
community settings" are not reported in the KC60 returns 
and also contribute it) (his underestimation. Of wornen 
diagnosed with gonorrhoea, 40% %vere tinder 20. In men, 
rates of gonorrhoea were highest in those aged 20-24 in 2002 
(296/100 000), an increase of 231% since 1997. Similarly, 
rates of genital herpes simplex infection remain highest 
among inales and females aged 20-24 (93/100 000 and 296/ 
100 000 respectively). Unlike other bacterial STIs, rates of 
syphilis among young people remain low. 
Factors influencing transmission 
Young people are behaviourally more vulnerable to STI 
acquisition as they generally have higher numbers of sexual 
partners, more concurrent partnerships, and change partners 
more often than older age groulis. "Although consistent and 
proper use of condoms reduces the risk of STI transmission 
and unintended pregnincy, many young people may not 
have developed the skills and confidence to implement this 
successfully, " 
STI re-infection is a particular concern in this population. 
In a study of three GUM clinics, " young age was a key 
determinant of STI re-infection within a year of initial 
diagnosis. Studies in the United States have also found that 
re-infection rates are high among adolescents and young 
adults, particularly ivornen, "hicluding those aged tinder 15. " 
Black and ethnic minority populations 
The number of HIV infected black African adults born in the 
United Kingdom is increasing but currently remains low. It is 
estimated that in 2002, black African adults accounted for 
63% (15 400) of the total of prevalent IIIV infections in 
heterosexuals, and 51% (4800) (if heterosexuals who are 
unaware of their IIIV infection. In 2002, of tile 12 203 111V 
infected heterosexuals reported to SOPHID, 68% (8262) of 
those for whom ethnicity was reported were black African (a 
330% increase since 1997), 4? '.. (501) black Caribbean, and 
21% (2580) white. The UA pregnant women surveys found all 
HIV prevalence of 2.5ýf, (239/47 075) in wonlen born in sub- 
Saharan Africa who gave birth in 2002. This compares with a 
prevalence of 0.03% (42/121 833) in their UK born counter- 
parts (fig JB). These data reflect the focus of the IIIV 
pandemic in sub-Saharan African countries and the impact 
of population movement oil tile UK statistics. 
Undiagnosed IIIV infection continues to be a feature of the 
treatment histories of black heterosexuals. Among sub- 
Saharan born heterosexuals included in the UA GUM survey, 
the prevalence of previously undiagnosed IIIV infection rose 
to 4.2% (159/3752) fit f. ondon and 7.9% (60/757) outside 
London (fig 113). The latter figurc may be due to the recent 
dispersal to areas outside London (it' inigrant populations 
originating frorn high 111V prevalence countries. In Scoiland, 
the prevalence of previously undiagnosed IIIV infection was 
163 
5.7% (9/157) in heterosexuals of African nationality, com- 
pared to 0.1% (13/133 314) in heterosexuals of British 
nationality. 
STI diagnoses disproportionately fall on the United 
Kingdom's black minority populations. "" In the 2002 
GRASP" data collection (fig 4), black ethnic groups, mainly 
black Caribbean, accounted for 55% (516i936) and 44% (249/ 
563) of gonococcal isolates in heterosexual Inales and 
females respectively. The ESS programme in London revealed 
that 48% (187/393) of heterosexual syphilis diagnoses Nvere 
among black or black British ethnic group%. 
Factors influencing transmission 
Black and ethnic minority populations in the United 
Kingdom continue to have lx)or sexual health. However, 
few behavioural surveys give insight into sexual health 
aniong ethnic minority groups. Variations in the burden of 
STIs among these populations ire known to be influenced by 
a number of behavioural and social factors. " Qualitative 
community based studies highlight variations in sexual 
socialisation, attitudes and community norms related to 
sexual behaviour; sex, religious beliefs, and degree of 
. acculturation are all influential factors. " Although qualitative 
studies suggest that variations in high risk behaviour do exist 
across ethnic groups, " " these alone cannot explain the 
observed disparities. Factors such as patterns of sexual 
mixing, differential access to curative services, and back- 
ground disease prevalence in the communities concerned 
may also be contributing. " " Data frorn population based 
surveys and mathematical modelling will be needed to 
further elucidate these associations. 
HIV SCREENING AND TREATMENT 
There has been sonic success in interventions aimed at 
reducing IIIV transmission in the United Kingdom. Diagnosis 
at an earlier stage of IfIV infeclion presents the opportunity 
for treatment to postpone further illness and to reduce viral 
load which, along with changes in sexual behaviour, may 
reduce the risk of onivard IIIV transmission. 
The number of GUM clinic attendees accepting a voluntary 
confidential IIIV test (VCT) can be measured through the UA 
GUM survey, which collects KC60 dara in addition to limited 
demographic information. Voluntary confidential IIIV testing 
(VCT) has increased in honio/bisexuil men and heterosex- 
uals respectively, from 45% (2724/6019) and 25% (16 886/ 
66 880) in 1997, to 62% (4604f7372) and 54% (40 746/ 
74 935) in 2002 in England, Wales, and Northern Ireland. 
From 2003, modified KC60 data will allow better monitoring 
of VCT uptake. In Scotland, dita indicate that uptake of VCT 
has increased in horno/bisexuil men and heterosexuals 
respectively, from 47% (454/959) and 23% (2624/11 223) in 
1997, to 59% (761/1290) and 36% (5142/14 281) in 2002. 
Similarly, over recent years, CD4 surveillance data show a 
recent trend towards earlier diagnosis for homo/bisexual 
men. Only 24% of lionio/bisexual men had a CD4 cell count 
less than 200 cells xI0"/I at IIIV diagnosis (an indicator of a 
"late diagnosis") in 2002 compared to 28% in 1997. In 
contrast, 43% of ncvvly diagnosed heterosexuals had a "late 
diagnosis" in 2002. This may be because a high proportion of 
heterosexuals were infected, and previously lived abroad. 
Additionally, heterosexuals may perceive themselves to be at 
lower risk from IIIV and may present for testing only when 
they become symptomatic. " " 
In England, the proportion of HIV infected pregnant 
women remaining undiagnosed by the time of delivery has 
declined since the introduction of the universal offer and 
recommendation of an 111V test is a routine part of antenatal 
care in 1999"' "; this policy has now I)ccn introduced 
elsewhere in the United Kingdom. 
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In 2002 there were an estfinatcd 686 births to IJIV positive 
women in England, Wales and Scotland, of whoin at least 
79% (539/686) were reported as diagnosed before delivery. 
overall, HlVdctcction rates in 2002 are currently estimated at 
75% (318/422) for London, 85% (199/234) elsewhere in 
England and Wales and 73% (22/30) in Scotland (fig 5). 
These minlinum estimates are subject to reporting delay and 
are likely to rise as more diagnosed infections in pregnancies 
are reported. 
These improved maternal IIIV detection rates have reduced 
the proportion of exposed children who go on to acquire the 
infection vertically. In London, in 2002 (based on the current 
estimated detection rates), the cstiniated proportion of 
children exposed to IIIV vertically who were themselves 
infected was 8% (35/422) compared with 19% (37/200) in 
1997. In the rest of (lie United Kingdom this proportion 
decreased from 22% (25/113) in 1997 to 0,, (16/264) in 2002. 
A high proportion of IIIV infected people who were eligible 
for ARV were on medication in 2002 in the United Kingdom. 
Of the 1708 homo/bisexull men with CD4 counts of 200 cells 
X10 6 /1 or less, 78% werc on therapy; of the 2433 hetero- 
sexuals, 78% were on therapy; and of the 211 IDUs, 73% were 
on therapy (measured through SOPHID). Equivalent figures 
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I Fi ure 5 Estimated proportion of HfV infected women diagnosed Tere delive * and of exposed children becoming infected with HIVtj, 
1997-2002. 
TA) 
London. (B) Ovtside London-England, Wales, and 
Scotlond. Onclucles those previously diagnosed and those diagnosed 
through onfenotol testing. tAssumes a vertical transmission rate of 
26.5% in undiagnosed women and 2.2% in diagnosed women. ' tTkese data contain reports received by the end of September 2003. Molo far 
2002 should be considered preliminp, 7 minimum estimates, and as the 
number of reports rise, estimates of in ants becoming HIV infected will fall. ) Data source: Unlinked Anonymous Programme and the National 
Study of HIV in Pregnancy and Childhood (NSHPC). 
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were higher for Scotland: 92% (72,1) = 0.006), 94% (84, 
1) = 0.0004), and 92% (98,1) = 0.0002). llowcver, in Scotland 
ARV therapy is ineasured through CD4 monitoring which is 
largely undertaken to assess a patients eligibility for ARV. 
These data confirm that exposure group does not affect the 
level of therapy uptake. 
DISCUSSION 
The surveillance data confirm that 111V and other STIs have 
increased within the UK population. Population subgroups 
that have high rates of sexual partner change continue to 
have higher infection rates, in particular 111V and STIs among 
horno/bisexual men an(] STIs among young people. Black and 
ethnic minority populations (including subgroups born in 
high prevalence countries) arc disproportionately affected by 
poor sexual health. There is some evidence of onward 111V 
transmission rising within the United Kingdom though as yet 
this is limited. 
Health promotion campaigns, targeted 111V and chlamydia 
screening initiatives, and increased sensitivity of diagnostic 
tests may all have played a part in the rising number of HIV 
and STI diagnoses reported in 2002. The well documented 
pressure mounting upon GUM clinics' through increased 
numbers of high risk patients attending has undoubtedly 
contributed to the observed trends. Since KC60 returns data 
are aggregate, it is not possible to determine what proportion 
of attendees are re-attending for follow up and/or are 
becoming re-infected. A disaggregate STI surveillance system 
is currently under development and will lielp interpretation 
of future trends. 
STI diagnoses are mainly reported through GUM clinics 
and voluntarily from NIIS laboratories. The former misses 
cases diagnosed in other settings and the latter reports are 
incomplete. This combined with the requirement for data 
accuracy over data quantity may have led to a general 
underestimate of 111V and STI diagnoses in the United 
Kingdom. 
indications from Natsal 2000" of increasing high risk 
behaviour (including concurrent partnerships and higher 
rates of partner acquisition), the continuing immigration of 
heterosexuals from countries of high 111V prevalence, and the 
suggested rising of 111V incidence, undiagnosed 111V infec- 
tion, anti STI diagnoses in liorno/bisexual men all indicate 
that sexual health is deteriorating and the documented 
increases arc real. 
Through national collaboration, high levels of data report- 
ing, analysis anti feedback performed in conjunction within a 
coin plenien ta ry set of UK surveillance systems, allow the 
data to be used as a powerful toot in providing information 
for action. The role of surveillance has been instrumental in 
the creation and monitoring of successful initiatives such as 
the introduction of the universal offer and recommendation 
of an 111V test in pregnant women. 49 $0 
our data confirm the need for national and local 
prioritisation of sexual health and 111V prevention activities. 
interventions such as those outlined in the English Sexual 
flealth and HIV Stritegy' need to be implemented urgently. 
For lionio/bisexual men this includes 111VIST]. education, 
promotion of sifer sex and 111V testing, and increasing the 
uptake of hepatitis B vaccination in GUM clinics. The strategy 
has also specifically identified young people as a priority 
group for action and (lie Department of Health is currently 
implementing a range of interventions including the National 
Chlarnydia Screening Prograninic. The persistent ethnic 
disparities in sexual health outcomes deserve even greater 
attention, particularly with emerging evidence of increasing 
111V transmission within the United Kingdom among black 
communities. The disaggregate STI surveillance system 
currently under development" will allow ethnic disparities 
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suirVeillance is essential to provide timely 
information on the changing epidemiology of Hly and other. STIs in the United Kingdom 
in sexual health to be monitored in the future and will 
facilitate the determination of where preventive efforts need 
to be targeted. In the meantime, key interventions for 
prioritisation include imprMing aC(CSS 10 treamient and care 
services in hyperendernic areas; raking community IIIV/STI 
awareness; and enhancing secondary prcvention actives 
including partner notification. '-' 
Elsewhere in the United Kingdom, health prornoLion 
campaigns aimed at high risk subgroups are being imple- 
mented and will undoubtedly require scaling up in the near 
future. In Wales, for example, the "Come Clean" multimedia 
campaign has been run by BBC Wales and the Welsh 
Assembly and is targeted at young peoifle. " Effective 
secondary prevention activities are also needed to tackle the 
growing problem of STI re-infection and epidemiological 
synergy between STIs and IIIV infection. Such initiatives 
need to be fully supported and sustained if further 
deterioration in the United Kingdom'- sexual health is to 
be prevented. Finally, although the impact of these initiatives 
can only be recognised over many years it is important that 
medium and long term targets are set and progress 
monitored to ensure the most appropriate, cost effective, 
and efficient use of scarce resources. 
Further information or) HIV/STI surveillance trends can be 
found in a report published by the Health Protection Agency 
and others: Health Protection Agency, SCIEH, ISD, National 
Public Health Service for Wales, CDSC Northern Ireland and 
the UASSG. Renewing the focus. IIIV and other Sexually 
Transmitted Infections in the United Kingdom in 2002. 
London: Health Protection Agency November 2003" 
(vv-w; v. hpa. org. ukfinfectioti!,! Iol)ic!, - a7/hiv-aj)d-s1VpubJica- tions/annual2003/aniiual2OOl. l)df). 
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Chlamydia trachomatis Infection 
in Asymptomatic Men 
D. Scott LaMontagne, MPH, David N. Fine, PhD, Jeanne M. Marrazzo, MD, MPH 
Background: The epidemiology of Chlamydia trachomatis infection in men is not well defined, especially 
among those who are asymptomatic or show no signs of infection. Established C trachomatis 
screening programs for women have demonstrated the benefit of routine screening in 
reducing prevalence over time, but the yield and benefit of screening asymptomatic men 
are unclear. 
Methods: Cross-sectional study of C. trachoinatis prevalence and associated risk factors among men 
tested at sexually transmitted disease (STD) clinics in Alaska, Idaho, Oregon, and 
Washington. We analyzed data from 43,094 men universally tested from 1997 to 1999 at 103 
STD clinics, and assessed age-specific prevalence of infection, controlling for signs of 
infection (urethritis diagnosed by clinician) and report of sexual contact to a person with 
an STD (defined as "contact"). 
Results: Overall prevalence of C. trachomatis was 10.3%. Age-specific prevalence was highest among 
men aged 18 to 19 years and lowest among those aged >29 years, regardless of signs of 
infection upon examination or contact to a person with an STD. If these factors and age 
<25 years had been used to direct C. trachomatis testing at STD clinics, 59% of men would 
have been tested and 91% of positives would have been detected. 
Conclusions: Using either the presence of clinical signs or report of a sex partner with an STD in 
combination with selective screening of all men aged <25 years detects the majority of 
infections and, in our population, would have considerably reduced the number of 
negative tests performed. (ArnJ Prev Med 2003; 24(l): 36-42) 0 2003 Americanjournal of 
Preventive Medicine 
Background 
T he epidemiology of Chlamydia Irachomatis infec- 
tion in men is not well defined, especially 
among asymptomatic men who are not evalu- 
ated in the context of contact with a sex partner with a 
sexually transmitted disease (STD). However, estab- 
lished screening programs have described the epidemi- 
ology of chlanlydial infection in women and demon- 
strated that routine screening of women aged <25 
years is effective in reducing the prevalence of chla- 
mydia over time. ' Screening is critical to tile control of 
chlarnydial. infection because most infeceions in both 
women (a-705vo) and men (ý: 60%) are asymptomatic. 2 
Efforts to screen asymptomatic men have evaluated 
small numbers of subjects; thus, our understanding of 
the epidemiology of chlamydia) infections in this group 
is limited. 5-7 Failure to identify asymptornatic infections 
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in men might allow for maintenance of a reservoir of 
untreated chlamydial infection, consequently hinder- 
ing efforts to further decrease the incidence of chla- 
mydial infections in women. 2 
Previous studies of chlamydial infection among men 
have shown moderately high prevalence, ranging from 
2.8% among asymptornatic 19- to 21-year-olds in Oslo, 
Norway, in 1994 '7 to 18.5% among asymptornatic men in Sweden in 1990.4 In the United States, prevalence of 
chlarnydial infection in asymptornatic men has ranged 
from 4.0% in a 1997 study of male STD clinic attendees 
in San Francisco 8 to 6% among young men in Seattle. 9 
These and other studies have compared asymptomatic 
and symptomatic populations. 2,4,8 -10 However, patient- 
reported symptoms may not be reliable in predicting 
infection. Clinical findings of signs of infection may be 
more reliable in ascertaining which men are most likely 
infected. To date, no study of chlamydial infection 
among men has assessed adequately the relationship 
between clinician-assessed signs and sexual contact with 
a person with a known STD. 
In STD clinics in U. S. Public Health Service Region X 
(Alaska, Idaho, Oregon, and Washington), universal 
screening of male clinic attendees for chlarnydia is 
36 Am j Prev Med 2003; 24 (1) 0749-3797/03/$-see front matter 
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standard practice. Chlarnydia testing data from these 
STD clinics have been systematically collected using the 
same data collection form used in the Region X Infer- 
tility Prevention Project, a screening program for Nvom- 
en. " To better understand the age-specific prevalence 
of chlamydial infection in men using a clinician assess- 
ment of signs of infection, and controlling for the effect 
of sexual contact to a partner Nvith an STD, we used this 
database to retrospectively assess patterns of chiamydial 
infection in a large multi-year sample of men. 
Methods 
We analyzed 43,094 test records from men who attended 103 
STD clinics throughout Region X from 1997 through 1999. 
Region X is a federally defined geographic area of the U. S. 
Department of Health and Human Services that includes the 
states of Alaska, Idaho, Oregon, and Washington. The num- 
ber of categorical public STD clinics included in this study 
varied by state: I in Alaska, 36 in Idaho, 53 in Oregon, and 13 
in Washington. All men who attended these clinics were 
tested for chlamydial infection, regardless of reason for visit 
(universal testing). Data were entered on a standardized form 
by clinicians and included demographics; chlamydia diagnos- 
tic test type and result; site of specimen (urethra, urine, or 
rectum); report of sexual contact (timing not specified) to a 
partner with an STD, specifically chlamydia, Neisseyia gonor- 
rhoeaeý mucopurulent cervicitis, or non-gonococcal urethritis 
(NGU); and clinical findings on physical examination. Sexual 
behavior data were assessed by patient report and included 
new sex Partner, two or more sex partners, or sex with a 
symptomatic partner in the past 60 days; condom use at last 
intercourse; and a positive chlarnydia test in de last year. 
Records were excluded from analysis if data were missing for 
both clinical examination findings and reported sexual con- 
tact to a partner with an STD (n =5169 or 12%). Because only 
one study site reported N. gonorrhoeae test data and compara- 
ble gonorrhea data were not available from all study sites, 
records with a positive gonorrhea test result were excluded 
(n =1071 or 2.5%). A small number of records (n =686 or 
1.6%) indicated "other" for both clinical examination find- 
ings and reported sexual contact to a partner with an STD. 
Because "other" could not be more specifically defined, these 
records were excluded from analysis. The final study popula- 
don analyzed included 84% of all men tested for chlarnydial 
infection (N=36,168). 
To explore the role of reported sexual contact to a person 
with an STD in men with or without clinical signs of infection, 
the study population was categorized into four screening 
groups. These group categories were based on clinician- 
assessed signs and patient report of sexual contact to a 
partner with an STD: (1) signs, contact; (2) signs, noncontact; 
(3) no signs, contact; and (4) no signs, noncontact. Alen were 
classified as "signs" if urethritis or epididymitis was present on 
clinical examination and as "no signs" if neither of these 
findings was recorded. Urethritis was defined by the presence 
of visible urethra] discharge or 2: 5 PAINs per field (XIOOO) 
on Gram stain of urethral secretions (n =8437). Epididymitis 
Was defined as unilateral scrotal pain and swelling (n =174). 
Data on specific symptoms reported by subjects, such as 
dysuria, were not available. Classification as "contact" is a 
common term used by public health practitioners in the field 
of STI)s and was defined as patient self-report of sexual 
contact with a partner who has an STD, as defined above 
(n = 4733). If no sexual contact with these conditions was 
reported, the record was categorized as noncontact. 
Age-specific chlarnydia prevalence, univariate Mantel- 
Haenszel odds ratios, 95% confidence intervals, and multivar- 
iate logistic regression models (forward stepwise procedure) 
were calculated using SPSS 8.0 (SPSS, Chicago, IL, 1998). All 
measures of significance were two-sided and used a statistical 
significance level of p <0.05. 
Results 
Characteristics of All Subjects 
The mean age of men tested was 29 years, and over half 
of the population was aged ; ýt25 years. The racial 
distribution was predominately white (73%) and in- 
cluded 18% African Americans and 15% Latino men. 
Most men reported having had sex with women; 9% 
reported sex with other men. The principal lab test 
employed was enzyme immunoassay (SyvaTrak EIA, 
55%); followed by cell culture (19%); nucleic acid 
amplification test (NAAT) (Abbot LCR, 17%); and 
non-amplified DNA probe (GenProbe Pace, 9%). Be- 
havior consistent with an increased risk of STD was 
common; for example, 77% of all men tested did not 
use condoms at last intercourse. The majority of men 
tested were no signs, noncontact (67%); 207o' were 
signs, noncontacts; 97o ivere no signs, contacts; and 4% 
were signs, contact. 
Overall prevalence of chlamydia was 10.3% and 
increased from 1997 to 1999 (chi-square test for trend, 
p <0.001), not controlling for test type. Variations in 
prevalence across states ranged from 7.8% in Alaska to 
12.1% in Idaho; Washington and Oregon had preva- 
lences of 9.1% and 11.5%, respectively. Men tested at 
STD clinics in rural locations- cities with <25,000 
people-had a higher prevalence than those tested at 
urban STD clinics (data not shown). The highest 
age-specific prevalence, 18.3%, was found among 18- to 
19-year-olds. Men who had signs and who reported 
sexual contact to a partner with an STD (signs, con- 
tacts) were most likely to be infected, with 51 % positive 
for chlamydia. Prevalence otherwise varied from 20.4% 
among signs men with no reported contact, to 22.0% 
among no-signs, contact men, and 3.4% among no- 
signs, noncontact men (Table 1). 
Univariate analysis showed the risk of chlamydial 
infection to be associated with several demographic 
and behavioral factors (Table 1). Men aged <20 years 
were four times as likely to have a positive chlamydia 
test than ivere men aged >29 years. Asian/Pacific 
Islander and African-American men had a two-fold 
increase in risk for chlamydial infection compared to 
white men. Behavioral fýctors-including new sex part- 
ner in the past 60 days, two or more sex partners in the 
Am j Prev Nied 2003; 24 (1) 37 
Table 1. Prcvalence of Chlamydia trachomatis by population characteristics, all men, STD clinics, Region X, 1997-1999 
Number tested Number positive Univariate OR 















Black or African American 




Risk behaviors (yes) 
New sex partner, past 60 days (n=34,712) 
Two or more sex partners, past 60 days (n=35,069) 
Sex with symptomatic partner, past 60 days (n=28,097) 
Positive chlarnydial test last 12 months (n=35,359) 
Condom used at last sex (n=33,973) 
Sex partner (n=35,489) 
Sex with women 
Sex with men 
Sex with men and women 
36,168 (100%) 3,727 (10.3%) 
1,395(3.9) 709(50.8) 29.1 (25.6-33.1) 
7,098 (19.6) 1,448 (20.4) 7.2 (6.6-7.9) 
3,338(9.2) 736(22-0) 8.0 (7.2-8.9) 
24,337 (67.3) 834(3.4) Referent 
1,664(4.6) 270(16.2) 3.8 (3.3-4.5) 
3,245(9.0) 594(18.3) 4.4 (3.9-5.0) 
9,893 (27.4) 1,439 (14.5) 3.4 (3.1-3.7) 
7,486 (20.7) 753(10.1) 2.2 (2.0-2.5) 
13,833 (38.3) 667(4.8) Referent 
21,851 (61.6) 1,663 (7.6) Referent 
6,227 (17.6) 907(14.6) 2.1 (1.9-2.3) 
434(l. 2) 39(9.0) 1.2 (0.8-1.7) 
835(2.4) 136(16.3) 2.4 (1.9-2.9) 
5,468 (15.4) 844(15.4) 2.2 (2.0-2.4) 
631 (1.8) 65(10.3) 1.4 (1.1-1.8) 
17,447 (50.3) 1,928 (11.1) 1.2 (1.1-1.2) 
11,705 (33.4) 1,411 (12.1) 1.3 (1.2-1.4) 
5,826 (20.7) 1,239 (21.3) 3.4 (3.1-3.7) 
1,509(4.3) 235(15.6) 1.7 (1.4-1.9) 
7,785 (23.2) 640(8.1) 0.7 (0.6-0.8) 
31,496 (88.7) 3,401 (10.8) Referent 
3,182(9.0) 232 (7.3) 0.7 (0.6-0.7) 
811 (2.3) 26(3.2) 0.3 (0.2-0.4) 
'For all ORs, P=0.05. 
'See text for definitions of screening groups. 
'Numbers in parentheses represent number of men for whom data on individual characteristics were available. 
Cl, confidence interval; OR, odds ratio; STD, sexually transmitted disease. 
past 60 days, and positive chlamydia test in the last 
year-were also associated with an increased risk of 
infection. Reports of condom use at last sex and of sex 
with other men were significantly -associated with a 
reduced likelihood of clilamydial infection (Table 1). 
The age distribution of chlamyclia prevalence was 
consistent across the four screening groups (Figure 1). 
In all groups, the highest age-specific prevalence oc- 
curred among 18- to 19-yearýold men. Clilamyclia prev- 
alence declined with increasing age, regardless of 
screening group. The lowest prevalence (1.6%) was 
found among no-signs, noncontact men aged >29 
years. 
Chlamydia Prevalence Among Men with No 
Signs and No Reported Contact with STD 
Most tests (67%) were performed among the no-signs, 
r1oncontact group. The demographic and behavioral 
characteristics of this group were generally similar to 
the overall study population (Table 2). However, fewer 
of these men were African American (p <0.001) and 
fewer reported recent sex with a symptomatic partner 
(P <0.001). 
Univariate associations for chlamydial infection 
among no-signs, noncontact men were similar to those 
found among all men tested (Table 2). Age was the 
strongest risk factor for chlamydial infection; men aged 
18- to 19 years were almost five times more likely to have 
a positive test than were men aged >29 years. Other 
associations of infection included African-American or 
Hispanic race/ethnicity, sex with a symptomatic part- 
ner, report of a positive chlamydia test in the last year, 
and two or more sex partners in the past 60 days. 
Reports of condom use at last sex and of sex with other 
men were associated with a reduced likelihood of 
infection. Prevalence did not increase significantly 
from 1997 to 1999 (data not shown), but did vary by 
clinic location. Rural clinics and clinics located in 
mixed urban/rural cities had a slightly higher preva- 
lence of chlamydial infection, at 5.4% and 4.1%, re- 
spectively, than urban clinics at 3.1% (p <0.05). 
In multivariate analysis, among no-signs, noncontact 
men, young age had the strongest association with 
chlamydial infection (Table 2). Men aged <20 years 
were over four times more likely to be infected than 
those aged >29 years. Some racial/ethnic groups had 
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Figure 1. Age-specific prevalence of Chlainydia trachonzatis by screening group, all men, STD clinics, Region X, 1997-1999. 
an increased risk of infection in the model. African- 
American and Hispanic men were nearly twice as likely 
as white men to be positive for chlamydia. Behavioral 
risks of two or more sex partners or sex with a symp- 
tomatic partner remained associated with an increased 
risk of chlarnydial infection, and condom use at last sex 
remained associated with a reduced risk of chlamydial 
infection. When considered with other factors, new sex 
partner, history of chlamydia in the last year, and sex 
with men were not statistically significant in the multi- 
variate model. 
Patterns of Testing in Population Subgroups 
Men with signs of infection and/or reported contact 
with an STD accounted for 33% of all tests performed 
and 78% of all chlamydia detected at STD clinics 
(Figure 2). The remaining 67% of tests were performed 
among no-signs, noncontact men. Of these men, the 
largest percentage tested was aged a: 25 years (62%) 
and had the lowest prevalence at 2.1 % (Figure 2). Over 
40% of all testing was performed in the group least 
likely to be infected with chlamydia-no-signs, noncon- 
tact men aged >24 years. 
Discussion 
Our study found a relatively high prevalence of chla- 
niydial infection, 10.3%, among men attending STD 
clinics in the U. S. Northwest. Clinical findings consis- 
tent with infection, report of sexual contact with a 
partner with an STD, and young age were strongly 
associated with infection. These findings are consistent 
with those of other studies of chlamydia among men 
attending STD clinics. 8-1o In a recent study at an STD 
clinic in San Francisco, Ciemins et al. 8 found an overall 
chlamydia prevalence of 11.0% among men. In our 
study population, prevalence varied by behavioral risk 
factors, race/cthnicity, gender of sex partner, type of 
lab test, and clinic location. 
Previous studies of chlarnydial infection in men have 
been limited by small numbers of asymptomatic men 
and were focused on patient-reported symptoms. Our 
analysis included a very large, universally tested male 
population and focused on clinician assessment of 
signs, an approach that might be more accurate in 
predicting infection. We examined men with and with- 
out signs in the context of their contact to sex partners 
with an STD. As expected, the likelihood of chlarnydial 
infection was highest among men who had both clinical 
signs of urethral infection and report of contact to a sex 
partnerwith an STD. Men with eitherclinical findings or 
reported sexual contact to a partner with an STD had 
similar prevalence of chlamydial infection (20% to 
22%), suggesting that both indicators are important 
tools for clinicians in assessing the likelihood of infec- 
tion. Men who had no apparent signs of infection and 
who did not report a recent sexual contact to a partner 
with an STD (defined as no signs, noncontacts) were 
Ain j Prev hled 2003; 24 (1) 39 
Table 2. Univariate and multivariate associations of Chlamydia trachomalis, no signs/non-con tact men, ' STD clinics, Region X, 
1997-1999 
Number Number Row Univariate OR Multivariate b, c 
Population characteristic tested positive % (95% CI)b OR (95% CI) 
Total 24,337 834 3.4% - - 
Age (years) 
<18 1,031 63 6.1% 3.9 (2.9-5.3) 4.1 (2, &-6.1) 
18-19 1,973 145 7.3% 4.8 (18-6.1) 4.5 (3.4-6.1) 
20-24 6,320 305 4.8% 3.1 (2.5-3.7) 3.1 (2.4-3.9) 
25-29 5,046 159 3.2% 1.9 (1.6-2.5) 2.1 (1.6-2.8) 
>29 9,937 162 1.6% Referent Referent 
Race/ethnicity (n=23,852)d 
White 15,977 414 2.6% Referent Referent 
Black or African American 3,108 136 4.4% 1.7 0.4-2.1) 1.9 (1.5-2.5) 
American Indian/Alaska Native 298 7 2.3% 0.9 (0.4-2.0) 0.3 (0.1-1.4) 
Asian/Pacific Islander 535 17 3.2% 1.2 (0.7-2.1) 1.2 (0.6-2.2) 
Hispanic 3,513 221 6.3% 2.5 (2.1-3.0) 1.9 (1.5-2.3) 
Other 422 14 3.3% 1.3 (0.7-2.3) 1.9 (1.0-3.4) 
Risk behaviors (yes) 
New sex partner, past 60 days (n=23,237) 11,231 421 3.7% 1.2 (1.0-1.4) p=0.51 
Two+ sex partners, past 60 days (n=23,523) 7,356 308 4.2% 1.4 (1.2-1.6) 1.5 (1.3-1.8) 
Sex with symptomatic partner (n= 19,07 1) 2,088 140 6.7% 2.5 (2.0-3.0) 1.9 (1.5-2.4) 
Positive chlamyclial test last 12 months 775 48 6.2% 1.9 (1.4-2.6) P=0.10 
(n=23,797) 
Condom used last sex (n=22,691) 5,679 146 2.6% 0.7 (0.6-0.8) 0.6 (0.5-0.8) 
Sex partner (n=23,819) 
Sex with women 20,909 733 3.5% Referent p= 0.18 
Sex with men 2,265 71 3.1% 0.9 (0.7-1.1) 
Sex with men and women 645 7 1.1% 0.3 (0.1-0.7) 
'See text for definitions of screening groups. 
'For all ORs, p=0.05, except as noted. 
'Variables in the multivariate analysis include items listed in table plus test type, year, and clinic location (data not shown). 
d Numbers in parentheses represent number of men for whom data on individual characteristics were available. 
Cl, confidence interval; OR, odds ratio; STD, sexually transmitted disease. 
the largest group screened, but had the lowest preva- 
lence of chlamydial infection. 
Age was also a significant factor in our study. Chla- 
mydia was most common among older adolescent men 
(aged 18 to 19), as others have noted. 9'-10 As has been 
noted in numerous studies of chlamyclial infection 
among women, young age is the strongest predictor of 
infection. 12-14 Because men aged <25 were three to 
four times more likely to be infected with chlamydia 
than those aged >29 years, even after adjusting for 
clinical signs and sexual contact with a person with an 
STD, age should factor significantly in determining the 
most likely population of men to be infected with 
chlamydia. The largest number of men tested were 
aged >29 years (about 40%), even among the no-signs, 
iloncontact group, and had the lowest prevalence. It 
remains unclear why a large and significant number of 
very low-risk men sought STD testing services at a 
public STD clinic. Perhaps the heal thcare-seeking be- 
haviors of men, in general, and the accessibility of 
healthcare venues for men, in particular, redirects 
: onccrned men away from primary care facilities and 
into public STD clinics. 15 Further study is needed to 
)etter elucidate this phenomenon. 
Our study suggests that combining age with clinician- 
Issesscd signs of infection and patient self-report of 
sexual contact with a person with a known STD could 
greatly enhance efforts to detect those men most likely 
to be infected, regardless of seeking care at an STD 
clinic. In clinical practice, men with signs of infection 
or history of recent sex with someone with an STD 
should receive diagnostic testing for chlamydia. Our 
data raise the question of whether certain groups of 
men without signs should be tested routinely by virtue 
of their attendance in the STD clinic. Currently, there 
are no guidelines on how best to address men who are 
asymptomatic, much less for men with no clinical signs 
of infection and who also have no history of sexual 
contact with an infected person. 
Recently, the third U. S. Preventive Services Task 
Force concluded that there was no strong evidence for 
selective screening strategies among asymptomatic 
males. 16 While our study does not specifically address 
the cost-effectiveness of such approaches, our data do 
suggest that testing nien with no signs in an STD clinic 
setting could certainly be made more efficient by 
reducing testing in subgroups unlikely to have a high 
prevaIence, such as men aged >25 years with no signs 
and no contact with a sex partner xvith an STD. 
Research on clilamydiýl infection among women sug- 
gests that screening in settings with prevalence of 
<3.1% is not cost-effective 17 ; the cost-benefit ratio of 
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Figure 2. Companson of age-specific testing volumes and Chlanýydia trachomatis prevalence among men by screening group, 
sexually transmitted disease (SiD) clinics, Region X, 1997-1999. 
testing men at similarly low prevalence levels might also 
be questionable. fiere 
are several potential limitations to our study. 
First, our population consisted of self-referred STD 
ch-c attendees who may not be a representative 
of men seeking care related to SID; their 
preva. ence may nc-t accurately approximate that of the 
gene, -al comrn un.,.;, an-I our findings may noi apply to 
other clinical Second, we did not have data on 
specific patient-repo. ted symptoms and could not com 
., Lre the relative conuibution of symptoms with clinical 
or pre(:: --t'ng 
infection in our population. Third, 
, ata an! on chlamydia tests; multiple visits by 
ie same cannot be assessed. Fourth, clinks 
participating in our prcýject may be heterogeneous; we 
could not assess possible differe-fýý--es among programs 
operat-g ý-Cer c. ýJerent Ar. i*:, 's--rý, tive or organiza- 
tional , xuc-res, . 
6% of male Lest 
-ý records, of -. )/o were co-infected with 
N gonor- 
rhoeae, may have introduced selection bias into our study. 
Finally, while other studies have confirmed the rode of test 
type in increased deLection oIch1wa-iydia, "6'_'8 we cannot 
confirm to what extent increasing Lise of NAAT increased 
chlarnydia positivity among men over time in tLIý3 F-_C. y. 
Our anallysis supports routine testing of all men w-th 
signs of infection and men who report sexual contact 
with a person With an STD, reorardless of age. While the 
cost-effectiveness of such an approach rec. uires further 
study, our data also support cf routine 
screening among men aged <25 yea, -s who have no 
signs of infection and who report no sexual contact 
with a person with an STD. if these factors and age <25 
years 
ýad Ibeen used to direct chlarnydia testing in our 
sWdy popula Lion, 58% of our subjects would have been 
tested and 91% of all positives would have been de- 
tected, Currently, selective screening strategies based 
on similar indicators are used to test women in family 
Planning clhnýcs and have affected reductions in the 
Arn j Prev Med 2003; 24 (1) 41 
prevalence of chlamydia. 1,17 Use of a selective screen- 
ing approach among men attending STD clinics might 
be able to achieve a similar level of success, and 
identifying and treating infections in men without signs 
may assist in efforts to further decrease the incidence of 
chlamydial infections in women. 
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Establishing the National Cklamydia Screening Programme 
in England: results from the first full year of screening 
DS LaMontagne, KA Fenton, S Randall, S Anderson, P Carter, on behalf of the 
National Chlarnyclia Screening Steering Group 151ýý 
............................................................................................................................... 
Sex Transm hifect 2004; 80: 335-341. doi: 10.1 136/sri. 2004.012856 
Background: The phased implementation of the National Chlamydia Screening Programme (NCSP) 
began in September 2002. The NCSP offers opportunistic screening for chlomyclia to women and men 
under 25 years of age attending clinical and non-clinical screening venues using non-invasive urine or 
vulvo-vaginal swo6 samples tested via nucleic acid amplification. This review describes the implementation 
of the NCSP, reports positivity rates for the first year, and explores risk factors for genital chlamyclial 
infection. 
See end of article for 
Methods: Cross sectional study of the first year's screening data from the NCSP. A stanclardised core 
authors' affiliations clatoset 
for each screening test was collected from 302 screening venues, excluding genitourinary 
....................... medicine (GUM) clinics, across 10 phase I programme areas. We estimated chlomyclia positivity by 
Correspondence to: 
demographic and behavioural characteristics, and investigated factors associated with infection through 
D Scott LaMonta e, MPH, FRIPH, CS, Heolg' 
univariate and multivariate analyses. 
Results: Cklamyclia positivity among people under 25 years of age screened in non-GUM settings was 
Protection A ency, 
Communico8e Disease 
10.1% (1538/15 24 1) in women and 13.3% (15611172) in men. Risk factors varied by sex: for women - 
Surveillance Centre 61 age 16-19, non-white ethnicity, and sexual behaviours were associated with infection; for men-only age 
Colindale Avenue, ionclon 20-2.4 and non-while ell-inicity were associated with infection. 
NW9 5EQ, UK; sco". Discussion: In the first phase of the NCSP, 16 413 opportunistic screens among young adults under lamontagne0hpa. org. uk 25 years of age were performed at non-GUM settings and testing volume increased over time. Rates of 
Accepted for publication 
disease were similar to those found during the English screening pilot and were comparable to the first 
13 August 2004 year of widespread screening in Sweden and the United States. The screening programme in England will 
....................... continue to expand as 
further phases are included, with national coverage anticipated by 2008. 
T hc most commonly reported bacterial sexually trans- 
mitted infection (STI) in the England is Chlamydia 
trachornatis, ' with serious sequelae in untreated infected 
women-for example, chronic pelvic pain, pelvic inflamma- 
tory disease (PID), ectopic pregnancy, anti infertility. ' 
Complications among men with untreated infection include 
urethritis, epididyinitis, and Reiter's syndrome. ' Recent 
evidence has also suggested that infection call cause male 
infertflity. 1 Since a high proportion of chlainydial infections 
are asymptoniatic, ' screening programmes have evolved to 
detect and treat individuals with prevalent undiagnosed 
infections and their partners. '--' These programmes have 
reported reduction.,; in prevalence" '" ind incident PID" " 
after implementation. Other studies have demonstrated that 
screening for genital chlamydial infection is both cost 
beneficial and cost effective. '"' 
In England, a comprehen%ive review of the evidence 
justifying screening for genital chlainydial infection against 
the Wilson-Jungner criteria"' iva. % published by the chief 
medical officcr's (CMO) expert advisory group oil Chlamydia 
trachomalis. " The principal conclusion from this review was a 
call to establish a national clilainydia screening programme, 
focusing on young women attending clinical setting% who 
were at risk of infection. ` This call was strengthened through 
the inclusion of chlainydia screening. in theaction plan of the 
National Strategy for Sewal Health and HIV, which aims to 
reduce the transmission ind prevalence of STI%. " 
In 1998, the Department of Health (DoH) in England 
funded a pilot of an opportunistic screening programme to 
CXPIOTe how best to implement chlamydia screening. The 
investigators of the clilamy(lia pilot concluded it was feasible 
all([ acceptable to opportunistically screen asymptornatic 
women 16-24 years of age attending different healthcare 
settings, including general practices, contraceptive clinics, 
young people's services, womcn's services (for example, 
termination, gynaccology, and antenatal), and genitourinary 
medicine (GUM) clinics. " The screening pilot also reported 
high rates of disease, on average 10% prevalence among 
young women attending general practice and other health- 
care sellings. 3" Based oil this evidence and with the guidance 
from the lessons learned in the screening pilot, the DoH 
agreed funding for a phased implementation of the National 
Chlanlydii Screening Programme (NCSP) for England. This 
paper overvicivs the structure all(] process of the NCSP, 
reports positivity rates by demographic and bchavioural 
charact eris tics, and explores risk factors for chlamydia from 
the first rcliorting year (I April 2003-31 March 2004) of 
opportunistic screening for phase I programmes. 
METHODS 
Programme overview 
The goal of the NCS), in England is to control genital 
chlarnydial infection through the early detection and treat- 
irient of asyniptorriatic infcctioiiý an(] prevention of sequelae 
arid onivard transmission. Funding and national leadership 
Abbreviations: CDSC, Communicable Disease Surveillance Centre; 
GUM, genitourinary medicine; LCR, ligase chain reaction; NAATs, 
nvcleic acid amplification tests; NCSP, National Chlomyclia Screening 
Programme; PCR, polymerose chain reaction; PCTs, primary care trusts; 
PIAG, patient information advisory group; PID, pelvic inflammatory disease; SDA, strand displacement amplification; TMA, transcription 
mediated amplification 
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are provided by the DoH, with scientific support from the 
Health Protection Agency Communicable Disease 
Surveillance Centre (a)sq. The prograinnie is guided by a 
national chlarnydia screening steering group (NCSSG), 
comprising multidisciplinary representation from relevant 
clinical and public health bodies engaged in sexual health, 
including GUM, contraccp6on anti family planning, obstc- 
trics and gyniccology, nursing, health advising, general 
practice, and microbiology. This body advises (lie DoH on 
clinical and laboratory protocols anti procedures for imple- 
meriting opportunistic screening in primary health care 
settings-for example, contraception clinics, young people's 
services, general practices, etc. Screening protocols for the 
national programme are contained in a core requirements 
document, and are disseminated to local programme areas to 
standardise local screening activity. " Phased implementation 
of the NCSP began with 10 programme area% selected in 
September 2002 for phase L` " Programme areas are 
composed of consortia of primary care trusts (PCTs), which 
arc the geographic anti service boundaries of the National 
Health Service (NHS). In January 2004, the second phase of 
the NCSP began with an additional 16 programme areas 
encompassing a further 54 PCT%. This brings current 
population coverage of the NCSP to an estimated 30% ofall 
sexually active young people aged 15-24 years in England. 
Local programme areas implenlent Screening activities 
guided by the national core requirements. Adinini%trativc 
structures vary locally but usually include a local niulti- 
disciplinary steering group, chlamydia screening office anti 
coordinator, programme lead, and clinical staffing, in 
partnership with PCTs, local laboratories, an(] healthcare 
providers. 
Ali local screening activity is coordinated by a local 
chlamyclia screening coordinator, working out of a desig- 
nated chlainydia screening office. A multidisciplinary local 
CSSG oversees the local programme implementation and is 
responsible for ensuring that data are reported to the DoH. 
Mandatory guidelines on the %tructure, process, and outcome 
monitoring for local progranirnes have been produced by the 
national CSSG and are contained in a core requirements 
document (available at www. dh. gov. uk). Also contained 
within the core requirement. % doconicrit are the Ilaticin 
information Advisory Group (PIAG) approved standard 
screening dataset to be collected by all screening sites. The 
core data items are transferred electronically to the Health 
Protection Agency, Colindale, on a quarteily basis for 
national programme monitoring. Local programmes have 
some flexibility to adapt their screening activities to reflect 
local need. All programmes areas are developing locally 
relevant materials to complement nationally available screen- 
ing resources; some areas are examining the feasibility of 
screening chlamydia positive patients for gonorrhoca; and 
other areas plan to include additional screening venues-for 
example, local prisons, in their activities. All such enhance- 
merits are funded locally. As the programme is still in its 
infancy, locally driven research and evaluation will needed to 
inform unresolved operational iNsucs-for example, screen- 
ing intervals and engaging men.: ' 
The target population for screening I-. young men and 
women under the age of 25 years who are attending 
healthcare facilities not traditionally associated with provid- 
ing specialist sexual health services. This approich expands 
the number of location% (that is, screening venues) that 
young people can attend which are offering chlaniydia 
screening as part of their service%. These include contra- 
ceptivc clinics, general praclicc. s, young people's services, 
antenatal services. colposcopy anti infertility units, and 
termination of pregnancy clinics. Screening is also cricour- 
aged to those within the target age group through innovative 
LaMontagne, Fenton, Randall, et al 
outreach strategies, such is "pee in a pol- days at military 
base-.,, university campuses or health fairs, inobile vans or buses for contact with young people, Prisons, and other non- 
traditional settings. People routinely attending GUM clinics 
are already tested for Chlain , %, 
dia trachonralis as a part of 
standardised clinical protocols, and as such are not the 
primary target for the "opportunistic" nature of this national 
programme. People filling within the screening guidelines 
ire offered a chlainydia test when attending a venue 
participating in the programme, regardless of the reason for 
their attendance. The attendance, itself, is the "opportunity" 
created to eductue and encourage the uptake of screening for 
chlaruydia. People under 16 years of age are offered screening 
if they are determined by the test initiator to be "Frazer 
competent. "" Every person offered screening receives a 
detailed patient information leaflet which summarises 
screening procedures and management outcomes. Implied 
consent is acquired by client %elf completion of a test request 
form an(] provision of a clinical specimen for testing. 
Non-invasivc samples, principally urine and self collected 
vulvo-vaginal swabs, are submitted to centralised local 
laboratories and tested using one of three common nucleic 
acid amplification tests (NAATs)*ý-polynierasc chain reac- 
tion (PCR) Aniplicor or Cobas Amplicor (Roche Diagnostics, 
Base], Switzerland), strand displacement amplification 
(SDA) BDProbcTcc (Becton. Dickinson and Company, 
Franklin Lakes, NJ, USA), or transcription mediated ampli- 
fication (TMA) Aptima Combo 2 Assay (Gen-Probe 
Incorporated, San Diego, CA, USA), per the manufacturer's 
instruction%. All positive and equivocal samples are con- 
firmed, either (hrough testing using a different NAAT or re- 
run of the simple using the same platform. " 
All clients arc notified of test results, based on their 
preferred method, such as letter, telephone call, or text 
message. People testing Imsitive are conticted up to three 
times for treatment and partner notification. Treatment is 
provided in accordance with published guidelines, " although 
directly observed izithromycin (I g oral tablets) is the 
preferred option. Alternative regimens are prescribed, as 
clinically necessary. " Clients receive treatment at no charge, 
which trial, be dispensed at the original testing venue, by the 
local chlainydia screening coordinator, via referral to a GUM 
clinic, or other method as negotiated by the client. All people 
testing positive, and especially those who exhibit symptoms 
suggestive of chlanlydial infection, are offered the opportu- 
nity to attend a GUM clinic for further STI testing. Routine 
tests of curc are not performed, unless the patient has been 
treated with erythromycin or there are serious concerns about 
treatment compliance. 
Patient% are offered the choice of notifying their o%vn 
partners (Patient referral), or supplying information for the 
health adviser or local chlarnydia Coordinator to notify the 
partner, without the patient's name being given (provider 
referral). Partner notification activities are also undertaken 
by various trained pcrsonnel-for example, the health 
jdviscr, chlarnydia coordinator, staff based at a GUM clinic, 
Programme lead, arnVor test initiator; according to national 
stindirds. ý' Pfophylactic treatment to partners is provided 
free of charge. All documentation relating Io treatment of 
index paiicni and follow up of partner notification activities 
is collated locally at the central chlarnydia screening office for 
local audit and is reported annually in aggregate summary to 
the Doll. 
......................................................... 
'Even though the Abbott LCx test (Abbott Laboratories, Abbott Park, IL, 
USA) was withdrawn from the UK market in early 2003, one 
)rogromme area in phase I tested specimens via ligase chain reaction rLICR) from April to August 2003 because of an overstock of available 
test kits and reagents. 
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Standardised information about the demographic and 
behavioural characteristics of the population screened, 
location of screening. laboratory test method used, and test 
result is collected uniformly across all local programme areas 
by the use of a test request form and is reported in 
disaggregatc nationally to CDSC. Data reporiing to CDSC is 
approved by the PJAG. 
Sample selection 
in this paper, tests reportcd to CI)SC by 15 June 2004 are 
included. Of those, ive selected only tests performed outside 
of GUM clinics and which were taken for opportunistic 
screening purposes only, as they most closely reflect the 
efforts to, extend chlamydia testing services to people who 
might not normally have been tested and who potentially 
represent a "hidden reservoir" of asymptoniatic infections 
within the young adult population. Tests were categorised as 
opportunistic screening if the reason for the test wis for 
screening purposes. Tests pcrfornicd for diagnosiic reasons or 
because a client was a contact of' a chlainydia positive were 
not included. Ail additionil 4%, (n = 674) of test% were 
excluded from analysis becauw ol'unknown or missing daia 
for test result, sex, age, type of test, or inconsistent sample 
type (for example, male tests withself collected vulvo-viginil 
swabs). 
Data analysis 
We performed cross sectional descriptive analyses of the 
population tested and assessmcnt of factors associated with 
infection. Distributions of demographic. behavioural, and 
testing characteristics within tile population were tabulated. 
X2 tests and univariale odds ratios were calculated. 
Multivariate analyses were performed using logistic regres- 
sion to explore the inter-relation of factors associated with 
infection within the rnale anti fernale populations separately, 
as we hypothesised that the factors associated with infection 
between the two populations inight be diffcrent. ' 
We used chlamydia positivity, rather than prevalence, as 
the dependent variable in our univariale and multivariate 
analyses, as studies have %hown that positivity is a valid 
surrogate measure of prevalence. " " Further, since this is a 
largely naive population to screening and the testing period is 
12 months or less, the likelihood of repeal testers is minimal 
and would not have all appreciable impact oil our estimates. 
All data analysis was performed In SPSS 12.0 for Windows 
(SPSS Inc, Chicago, IL USA) with two tailed significance 
levels of p <0.05. 
RESULTS 
Opportunistic screening in phase I of the NCSP occurred in a 
staged approach with the number of programme areas and 
the number of venues within cach progrannue area offering 
chlarnydia screening increasing from the first quarter of 
Table I Number of programme areas and venues* 
offering opportunistic screening for Chlorn d'a c' 
frachornatis by quarter, National ChlamyYi. Screening 
Programme in England, I April 2003-31 March 2004 
Number of programme Number of screening 
areas venues 
I it, Apr--Jun 2003 A 74 
2nd. J. ý--S#p 2003 5 12) 
3rd, O"ec: 2003 9 184 
At6, ion-Mar 2004 10 2A7 
Total 10 302 
*Does not include GUM clinics. 
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opermions to (fie last ((able 1). For example, in the first 
quarter of the NCSP, four programme areas were offering 
screening it 74 venues outside of GUM clinics; by the end of 
the first full year of reporting, almost -150 non-GUM venues 
across all 10 phase I programme areas were offering 
opportunistic scTcci)ing to young people. A total of 16 413 
opportunistic screening tests were performed outside GUM 
settings during the first full year of the NCSP. Following the 
phased approach, over 1000 chlainydia screens (6% of the 
total) were (lone in the first quarter, and the last quarter of 
tile first year accounted for almost 50% of all screening tests 
(table 2). 
We found 10.1% positivity aniong women less than 
25 years of age opportunistically screened at settings outside 
of GUM clinics in the first year of the NCSP (table 2). The 
population of women screened was primarily white and 
tested at contraceptive clinics. Over half of the female 
population was undcr 20 and the other half 20-24 years of 
age. 11chivioural risks among wornen were common: 44% of 
tile reporfilig population hidicatcd a new sex partner in tile 
last 3 months and/or two or more sex parincrs in the last 
year. SDA and IICR were the most commonly used diagnostic 
platforms in local laboratories. Urine was tile most common 
specimen type, but nearly 30(Xý of' tests were (lone on self 
collected vulvo-vaginal swabs. 
We f. ound 13.3% positivity among men less than 25 years 
of age opportunktically screened at settings outside of GUM 
clinic. in tile first year of the NCSP (table 2). The population 
of men screened was primarily white, with 45% of tests done 
-it contraceptive clinics and 26% done at colleges and 
universities. Tile male population was slightly younger than 
the female population-62% under 20 years of age. 
Behavioural risks ainong men were more common: 56% of 
the reporting population indicated a new sex partner in the 
last 3 months and 60% reported two or more sex partners in 
the past year. Urine was collected from all men. 
Women ages 16-19 years were 43% more likely to test 
positive for chilinydia than those 20-24 years old (table 2). 
Women of black Caribbean ethnicity were nearly twice as 
likely to test positive. Behavioural risks were also associated 
with infection in wornen. even after controlling for covari- 
ates. Women tested with SDA were more likely to test 
positive and this factor also held after multivariate adjust- 
merit (table 2). 
Among men, the groups more likely to test positive were 
somewhat different front (]lose for women (table 2). After 
controlling for all factors in multivatiate analysis, slightly 
older niales, those 20-24 years of age, were more than twice 
is likely as those under 20 to test positive. Sirnflar to women, 
black Caribbean or mixed ethnicity males were also more 
than twice as likely to be infected. Among men, behavioural 
risks were not statistically associated with ail increased risk 
of infection, either in unadjusted or adjusted analyses 
(table 2). Addiiionally, men screened at colleges and 
universities and at young people's clinics had a reduced 
likelihood of infection than those tested in contriceptive 
clinics. Like their female counterparts, men screened using 
the SDA test had a significantly higher likelihood of testing 
positive (table 2). 
To understand why higher positivity was found with tile 
SDA test, an exploratory analysis was pcrfornled, dividing the 
population into those testcd with SDA and those tested using 
another NAAT. (iroups with higher positivity tended to be 
over-reprewracd in tile population tested with SDA (data not 
shown). For example, there were larger proportions of black 
and mixed ethnic groups and people reporting a new sex 
partner among people tested with SDA (1) <0.05), and these 
gjoup% were almost twice. as likely to test positive for 
chlaniydia than white people or those who did not report a 
www. stijournal. com 
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new sex partner in the last 3 inounlis (table 2). Further, there 
were higher concentrations of 20-24 year old females in the 
population tested with LCR, PCR, and TMA and the positivity 
in (his group was less than 16-19 year olds. 
DISCUSSION 
The phased implementation of the National Chlamydia 
Screening Programme in England has begun. The number 
of phase I programme areas, the number of venues within 
prograinnie areas, and the total number or screens performed 
011 11)CMISCd over flryie, reflecting our phased approach. 
Because the pro-rininie has just begun, it is important to 
place fit context the screening volume and its impact on 
coverage. Economic niodefs have shown that one of the most 
critical aspects to ensure the success of a widespread 
screening programme is uptake. " " 2" Recent estimates 
front the Unitcd States by Levine and colleagues suggest that 
screening coverage was liiglic%t in areas that experienced 
reductions in prevalence after several years (if aggressive and 
comprehensive screening. " Data front the first few years of 
routine chlamydia testing in S%vcden also reflect the impact 
of high screening volumes. ' Continued efforts to increase 
screening coverage in England are focused not only on 
expanding the number of prograinine areas involved, but also 
increasing the volume of testing at the screening venues 
within those programme areas. This will be monitored closely 
as. the NCSP continues to expand. 
The first year of screening has also (Ictected similar 
levels 
of infection among people consenting to be screened as was 
found in the original chlaurydia screening pilot. -' Screening 
programmes in tither countries reported chlaniydia preva- 
IC11CCN ranging Irom 61, f, in Swcdcn' to 1214, in the north 
%vestern region of the United States" " in their first year of 
implementation. AlthouOm those same programmes screened 
a larger number of women than thus far accomplished in 
England. the similar rates of infectionat the start affirms that 
the opportunistic approach-w1cctively screening those 
thought to be at higher riik-hav proved to be a successful 
strategy in diwasc detection. The data from the first year of 
the NCSP justify our continued focus on young wornen and 
men attending healthcare settings as performed in the 
original pilot. 
Another Uni(ILIC Outcome Of the first year results is the 
demonstration that opportunistic screening can and does 
occur in a vidde varicty of setting%. Encouragingly, the second 
highest volumes ol'screening were front 131 general practices 
fin five of the progrannne areas) and 16 young people's 
services (in six progarainnie areas), both of which are not 
traditionally centred around sexual health service provision. 
Much has been made recently about the ability or willingness 
of GI's to become involved in the NCSP. Oakeshott el al 
suggest in a recent article that without remuneration GPs 
would not only not participate in screening but also that the 
programme WOUld not succeed. " Unlike the research pilot of 
opportunistic chlainydil screening in which GPs wcre paid on 
a per test basis, " the NCSP funding in phase I did not include 
the same payments to GPs (as it is not a research project). 
The NCSP first year data scern to suggcst that GPs are willing 
to offer chlainydia screening to their clientele without 
reimbursement incentives from the NCSP. Over 10% of all 
screening tests wcre done %vid-iin general practice, and that 
proportion increascd throughout the first year and continues 
to (to so in preliminary data from the first quarter of the 
second year (daia not shown). We are encouraged by these 
numbers, as strong efforts have been made by both the 
national management team, as well as local chlarnydia 
screening coordinators and their teanis, to engage primary 
care and to case the implementation of screening fit those 
settings. Creathe delivery strategies utilised fit phase I 
www. stijournal. com 
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programme areas address soine of the barriers to screening 
within general practice, " and include: (1) allowing patien(s 
to self select for screening and self complete the test request 
form (saving time); (2) training of practice nurses to make 
appropriate invitations for screening (reducing the need for 
expensive medical consultant involvement); (3) covering 
administrative time for specimen and data collection (aug- 
menting costs); (4) shifting the responsibility for notification 
of results and follow up to a local clilainydia screening office 
(reducing workload burden within general practice), * and (5) 
empowering GPs to holistically attend to the physical and 
sexual health needs of their young adult population (cnlian- 
cing the skills and capabilities of general practice staff). The 
lessons learnt about implcmenting screening in primary care 
front the first phase of the prograinnie have informed the 
development of guidelines for clifamyclia screening in general 
practice as well as model local enhanced service contracts 
outlining set standards and outcomes for screening in this 
setting. The devolved nature of general practice provision in 
England means that efforts to encourage local involvement of 
GPs in chlamydia screening will beconle a major challenge of 
the programme in future years. Indeed, phase 2, and 
subsequent phase 3, implementation areas will encourage 
more widespread priniary care involvement than pievious 
phases. 
Data from the NCSP'-% first year confirm that the 
epidemiological profile of both the men and women screened 
is nearly identical to that found in numerous studies in the 
United Kingdom' "' and in Europe, " with highest chlamy- 
dia positivity among %voinen 16-19 years of age and men 20- 
24. The age related difference. -., in chlarnydia positivity 
between women and men screened was expected given the 
results of other studies. ' '"" Additionally, people who have 
acquired a sex partner recently or who have had several sex 
partners were at increased risk of infection. However, the 
association between behavioural risks and infection among 
men did not reach statistical significance in univariate 
analysis or multivariate modelling. This could he the result 
Of a Small S, 1111PIC -i7C for men (less than 1200 mile tests 
reported), an under-reporting of' sexual risk taking aniong 
the female population, or an actual difference in the sexual 
behaviour of men versus wornen. There is cvidence from the 
Natsal study of sexual behaviour in Britain it) support a 
behavioural difference bmvecii men and wonien: men 
reported a greater number of lifetime and recent sex partners, 
as well as more frequent partner change, than women. " 
The sexual behaviour data reported through the NCSP have 
provided additional benefit by further refining our analysis of 
risk behaviours that are associated %vith people testing 
positive for chlamydia. This will allow us to better under- 
stand the behavioural components contributing to the spread 
of STIs, " and monitor behavioural changes in the population 
that inay affect our disease control efforts. Other established 
STI surveillance networks, principally through the statutory 
KC60 returns from GUNI clinics, do not collect sexual 
behaviour data. The collection of these data in the NCSP is 
the first large scale piograinine targeting sexual health to 
include behavioural %urvcillance. The use of this information 
allows us an additional tool in prevention efforts to address, 
and eventually arrest. the observed increase% in STI% in 
England. 
The noted increase positivity iniong those tested with the 
SDA platform is an unexpected mystery. The concentration of 
higher risk people in the SDA tested population and lower 
risk people in the population tested using other NAAT% might 
help explain the variations in positivity between the four 
different nucleic acid amplification tests. However, inter- 
laboratory variation in the use of the testing platforms, 
adjusted sensitivity and specificity of each NAAT fit a "real 
LaMontagne, Fenton, Randall, ef al 
Key messages 
0 The phased implementation of the National Chlamyclia 
Screening Programme has begun: 16 413 chlomyclia 
screens to young men and women during the first year. 
confirm the feasibility of opportunistic screening in non. i GUM settings 
0 The NCSP has demonstrated 10% positivity am'ong',. 
women and 13% positivity among men opportunisti- 
cally screened; this is similar to the findings from the 
original screening pilot and affirms the opportunistic 
approach is a successful strategy for disease detection 
0 30% of specimens collected from women. were self 




0 The NCSP is the first national sexual health initiative to 
include routine behavioural surveillance, which 
improves our understanding of the behavioural factors driving STIs and enhances our ability to design 
appropriate prevention messages 
%vorld" setting, or the 11tilisation of lower cut-off threshold 
for positive confirmation within the laboratory could also 
influen(c the performance anti outcome of the SDA test. it 
would be worthwhile to further analyse this difference. The 
DoH has recently funded the Microbiological Diagnostic 
Assessment Service to carry out a comparative evaluation of 
tile sensitivity, specificity ind performance of PCR, TMA, and 
SDA in three laboratories in England (Department of Health, 
personal communication). This evaluation may also provide 
additional context for explaining our findings. 
Finally, researchers have suggested that targeted annual 
screening of 15-14 year old females, combined with treating 
50% (if partners of ( Iflarnydia positive fernales and increasing 
condom use, could dramatically reduce tile prevalence of 
chlarnydia in the populalion. 2" The NCSP includes dedicated 
funding and guidelines for a strong partner follow up 
activities in local programme areaO to ensure wornen do 
not become re-infected front in untreated partner and that 
parmeri of positive women do not continue to spread 
infection to others. The NCSP provides for the testing and 
free treatment of all sexual contacts, regardless of age, 
through application of rigorous national partner notification 
standards. " In future years, the mirr)ing of partner 
notification data with screening volurne and coverage data 
will provide an enhanced summary of the NCSP's impact on 
the population. We hope to expedite disease reductions 
through the combined approach of screening anti compre- 
lienshc treatment and follow up. 
it is clear from our results that we have soine way to go to 
demonstrate rccinctions in disease similar to what was 
experienced in Sweden anti the United States; however, the 
data from this first year of screening are encouraging. New 
lessow. are being learnt ton the proces% and outcomes of 
opportunistic screening and inethods for enhancing its 
implementation in a (li%-crsc range of healthcare settings. 
Insight,; are being gained into the best methods for engaging 
men fit sexual health; innovation in treatment and partner 
notification in sites outside of GUM clinics; and sharing of 
information on best practice acros% the breadth of the health 
service %ysicni in England. The collection of in expanded and 
disagýregatc sexual health damsel is improving our under- 
standing of the distribution anti (IcEcrininams of genital 
chlarnydill infeciion. The NCSP vvill undoubtedly continue to 
www. stijovrnot. com 
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make inroads into the prevention and control of this infection 
in England. 
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Re-evaluating Selective Screening Criteria for Chlamydial 
Infection Among Women in the U. S. Pacific Northwest 
D. SCOTT LA MONTAGNE, MPH, * L. ELIZABETH PATRICK, MC,, l DAVID N. FINE, PHD, t AND 
JEANNE M. MARRAZZO, MD, MPH, ý ON BEHALF OF THE REGION X INFERTILITY PREVENTION PROJECT 
objectives: Screening women for Chlamydia trachomatis (CT) infec- 
flon using selective screening criteria has been operational in the 
northwestern United States (Region X) since 1988. Changes in the 
field, Including declines In CT prevalence, Introduction of sensitive 
laboratory tests, and budgetary pressures necessitate reevaluating the 
selective screening approach to ensure program credibility and 
efficiency. 
Goals: The goals of this study were to assess 1) performance or 
screening criteria In Region X, 2) predictors of CT Infection, and 3) 
optimization of these criteria. 
Study Design: We conducted cross-sectional analysis of 409,882 CT 
test records or women from 1998 to 2000 using multivariate logistic 
regression and sensitivity and efficiency analyses. 
Results: Young age (<25 yrs), cervical signs of infection, and recent 
exposure to or history of chlarnydial Infection were strongly associated 
with testing positive. Behavioral risks showed a weak association with 
infection. Currently used selective screening criteria were sensitive but 
not effident. Criteria weighted toward young age, exposure to chla- 
mydia, or cervicids would increase criteria efficiency by nearly 25% In 
smne settings while detecting >90% of Infections. 
Conclusion: Evaluating selective screening criteria can result in 
modifications that could increase screening efficiency. 
CHLAMYDIA TRACHOMATIS (CT) is a prevalent and potentially 
devastating infection for women, with over 700,000 cases reported 
annually in the United States; however, up to 3 million total cases 
are estimated when undcrreporting and undcrdiagnosis are taken 
into account. ' Because infection is most often asymptomatiC, 2-4 
untreated gcnital chlarnydial infection can lead to pelvic inflam- 
matory disease, 5-8 cctopic prcgnanCy. 7.9 and infertility. 9-12 Recent 
evidence has suggested that prior CT infection can be linked to 
ovarian canccr. 13 
Detection of infection is challenging because most women do 
not develop symptoms that prompt clinical evaluation. Because 
many women annually attend gynecology or family planning (FP) 
clinics for routine Pap smears, contraceptive services, and repro- 
Funding for this study was made possible through the Centers for 
Disease Control and Prevention, Division of STI) Prevention, Infertility 
Prevention Project and the Department of Health and Human Services, 
Office of Family Planning. The authors thank all the clinical staff who 
Participated in this screening program for their timely and accurate data 
collection and reporting. without them, evaluating the success of the 
Program would be impossible. 
Correspondence: David N. Fine, MO, Center for Health Training, 
1809 7th Avenue, Suite 400. Seattle, WA 98101-134). E-mail: 
ScOtt. lamontagne@hpa. org. uk 
Received for publication September 15,2003, revised December 10, 
2003, and accepted December 11,2003. 
From the *Health Protection Agency, Communicable Disease 
Surveillance Centre, London, U. K., formerly of the Center for 
Health Training, Seattle, Washington; the tCenter for Health 
Training, Seattle, Washington; and the *University of Washington, 
Division of Infectious Diseases, Seattle, Washington 
ductive health checkups, clinic-based CT screening programs were 
developed. 14.15 One of the first large-scale CT screening programs 
in the United States began in 1988 at FP clinics in the Pacific 
Northwest, U. S. Public Health Service (USPHS) Region X, which 
includes the states of Washington, Idaho. Oregon, and Alaska. 14-16 
To both minimize costs and to increase the probability of detecting 
infection among asymptomatic women, selective screening criteria 
(SSQ were developed. 17 'Me SSC initiated in 1988 were based on 
risk factors for infection, including young age, clinical signs, 
having sex with an infected partner, sexual behaviors such as 
frequent multiple sex partners, and previous diagnosis of a sexu- 
ally transmitted infection (STI). 18-21 Using SSC, women attending 
for annual pelvic examinations in publicly funded family planning 
clinics in Region X are routinely tested for CT. For ease of 
implementation in clinical settings outside sexually transmitted 
disease (STD) clinics and to allow for funding of diagnostic CT 
testing in non-STD settings, the selective screening criteria in 
Region X include 2 elements normally interpreted as indications 
for diagnostic testing and/or presumptive treatment: manifestations 
of cervicitis (mucopurulent secretion, cervical friability, and ab- 
normal cervical ectopy) and evidence of recent exposure to CT. 
Beginning in 1993, the Centers for Disease Control and Prevcn- 
tion (CDC) began administration of Infertility Prevention Projects 
based in each federal health region using selective screening 
criteria that were locally developed; this effort has been the cor- 
nerstone of the CDC's programmatic efforts to reduce the mor- 
bidity and associated sequelac from this infection. Each of the 10 
projects receives funding from CDC to administer chlamydia 
screening. Areas in the United States and other countries that have 
been performing clinic- and population-based screening for chla- 
mydial infection have reported declines in prevalenCC. 22-24 and 2 
randomized, controlled trials of screening have shown a 50% 
reduction in the diagnosis of pelvic inflammatory disease. 25-26 
Many studies have evaluated the performance and cost-effec- 
tiveness of this CT control strategy, 27-30 and most have concluded 
that in settings of moderate prevalence, selective screening pro- 
grams are cost-effectivc. 's The most recent (1995) evaluation of 
Region X's selective screening criteria used data from 1990 to 
1993.19 At that time, enzyme immunoassay (EIA) with direct 
fluorescence antibody (DFA) testing was the standard CT diag- 
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postic test. Recently. highly sensitive nucleic acid amplification 
tests have been increasingly used and shown to be a factor in 
observed increases in prevalence in Region X, other parts of the 
United States, and in Sweden. 31-33 Some investigators have sug- 
gested that periodic reevaluation of selective screening should be 
performed when circumstances in the held change 
significantly. ' 8.34 
The current reevaluation of the SSC in use in Region X centers 
on 3 questions: 1) What is the current performance of the selective 
screening criteria now used in Rcgioýn X? 2) Have risk factors for 
the presence of chlarnydial infection changed since the last SSC 
evaluation in 1995? 3) Can the performance of the selective 
screening criteria be optimized? 
Methods 
We analyzed 409,882 CT test records (excluding 4355 or 1% 
where test result or test type was unknown) for women attending 
252 family planning, 123 STD and 251 "other" clinics, including 
commumity/migrant, college health, public health nursing, and 
adolescent clinics, in Region X from 1998 to 2000. STD clinics 
contributed 34,288 records, FP clinics 304,183 records, and 
"other" clinics 71,471 records. Women attending STD clinics were 
universally tested for infection. Women attending family planning 
and other clirfts were tested according to the Region X SSC, 
which were: 1) age S24 years, or 2) age >24 years plus any I of 
the following: nonspecific cervicitis, mucopurulent cervicitis 
(MPC), friability of the cervix, cervical ectopy, clinician-diag- 
nosed pelvic inflarm-natory disease (PID), patient-reported or cli- 
nician-assessed recent exposure to chlarnydia or any other STD, 
including sex with a symptomatic sex partner in the past 60 days, 
C. trachomatis or any other STD in the prior 12 months, or new 
sex partner or 2 or more sex partners in the previous 60 days. 
Diagnostic tests used in Region X were EIA (SyvaMicrotrak), 
ligase chain reaction (LCR; Abbott LCx), nonamplified DNA 
probe (PACE2; Gen-Probe), and cell culture. 
To define the performance of the current selective screening 
criteria in Region X. we analyzed all tests for the sensitivity and 
efficiency of the criteria. Sensitivity was defined as the percentage 
of positives detected, and efficiency was the percentage of tests 
that met the criteria, 35 Thresholds of 60% efficiency and 90% 
sensitivity were used as ideal benchmarks for criteria performance. 
The ideal scenario was to identify the most positives (a high 
percentage for sensitivity) while testing the fewest number of 
people (low percentage for efficiency). Sensitivities and efficien- 
cies for clinic type and test type were calculated separately to 
explore variations in criteria performance in settings of lower 
prevalence or locations where use of the more sensitive nucleic 
acid amplification tests had increased. 
To define risk factors associated with chlarnydial infection, we 
analyzed data from women universally tested at STD clinics. Data 
were gathered on a standardized laboratory test request form in use 
across all clinics since 1993. Patients self-reported demographics 
and behavioral risks in response to questions posed by clinicians 
during the clinic visit. Clinicians reported results of cervical ex- 
an-driations using standard definitions within the program for mu- 
copurulent endoccrvical discharge, cervical friability, abnormal 
cervical ectopy, and PJD, each reported separately. 16 Laboratories 
reported test type and results. With CT positivity as the dependent 
variable, univariate odds ratios for each independent variable were 
calculated. Variables significant in univariate analysis to a level of 
P <0.05 were included in a multivariate logistic regression model 
(forward stepwise procedure with Wald statistical correction). The 
linal model included a variable for type of diagnostic test to 
explore whether risk factors differed between those tested with 
amplified and nonamplified laboratory methods. 
Using the results of the risk analysis, we developed 5 different 
sets of selective screening criteria to evaluate for sensitivity and 
efficiency using the benchmarks of 60% and 90%, respectively. 
Because no new variables were under consideration for inclusion 
in sets of SSC, the focus of the sensitivity and efficiency analysis 
was to assess whether the current SSC in Region X could be 
simplified. Therefore, the resultant SSC were modifications of the 
existing Region X criteria and could be applied retrospectively to 
our study population to address whether the current criteria could 
be optimized. Additionally, the criteria endorsed by the third U. S. 
Preventive Services Task Force (USPSTF) were also applied to 
our study population and compared with the performance of other 
selective screening criteria. This Task Force recommended screen- 
ing for: 1) all sexually active women 25 years and younger; and 2) 
asymptomatic women over 25 years of age at increased risk, 
defined as new or multiple sex partners, prior history of an STD, 
or inconsistent condom USe. 36 
All analyses were performed using SPSS 8.0 statistical software 
(SPSS, Chicago, IL). Measures of significance were 2-sided and 
used a significance level of P <0.05. 
Results 
Chlamydia positivity was highest in STD clinics (7.3%) and was 
approximately 4.0% in FP and other clinics (Table 1). Women less 
than 25 years of age comprised 70% of the FP clinic population 
and 64% of the "other" clinics' population; women attending STD 
clinics were slightly older. EIA and LCR were the most frequently 
used laboratory tests. Almost 50% of tests in STD clinics were 
EIA, whereas in FP clinics, more than 4517b of tests were LCR. The 
higher proportion of LCR tests within FP clinics reflects the wider 
dissemination of nucleic acid amplification tests in that setting. For 
all clinical settings, 97% of samples were clinician-acquired cer- 
vical swabs and 2.5% were urine samples (data not shown), 
reflecting the linkage of the screening program to annual pelvic 
examinations for women. Behavioral risks were common: 21% to 
39% of the population (depending on clinic type) reporting a new 
sex partner in the last 60 days, and nearly one fourth of the STD 
clinic attendees reporting 2 or more sex partners over the same 
period. Not surprisingly. condom use was low; less than 25% of 
women used condoms at last sex, regardless of clinic type. Women 
who attended STD clinics were more likely to demonstrate clinical 
signs associated with increased likelihood of chlarnydial infection 
such as mucopurulent cervicitis or cervical friability (Table 1). 
Univariate analysis confirmed that the factors associated most 
strongly with chlarnydial infection among STD clinic attendees 
were young age. clinical signs, and recent exposure to chlarnydia 
or other STDs (Table 2). Over 80% of all women who tested 
positive were less than 25 years of age, regardless of clinic type 
(data not shown). Behavioral risks such as new sex partner, mul- 
tiple sex partners, or history of chlarnydial infection were associ- 
ated with positivity. but not as strongly. Nonwhite race was also 
associated with infection, but Hispanic ethnicity was not. Women 
submitting urine samples were slightly more likely than those 
submitting cervical swabs to test positive, and those tested with 
culture were less likely to test positive than those tested with LCR, 
consistent with the lower sensitivity of culture in detecting CT 
(Table 2). When stratifying by test type, variables associated with 
infection did not differ between women tested with EIA and those 
tested with LCR (data not shown). 
Factors associated with an increased risk of chlarnydial infection 
in univariate analysis were explored in multivariate models. 
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TABLE 1. Characteristics of Women Tested by Type of Clinic, Region X, 1998-2000 
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STD Clinics FP Clinics Other* Clinics 
Characteristic In 34,228, (n 304,183, %) In 71,471, %) 
percent positive for chlarnydia 7.3 4.1 3.8 
Age (yrs) 
<20 28.0 37.3 35.8 
20-24 28.1 33.4 29.4 
25-29 15.9 14.7 13.4 
>29 28.0 14.6 21.5 
Race 
White 75.9 84.0 74.9 
Black 12.3 4.4 8.7 
American Indiari/AJaska Native 2.2 1.1 3.9 
Asian/Pacific Islander 3.9 4.2 5.2 
Other or More than one race 5.7 6.3 7.3 
Ethnicity 
Hispanic 12.0 15.6 24.7 
Test type 
EIA 47.1 43.0 36.0 
LCR 21.9 45.6 36.8 
DNA probe 11.1 6.9 25.1 
Culture 20.0 4.5 2.1 
New sex partner (past 60 days) 38.6 24.7 21.5 
More than I sex partner (past 60 days) 23.5 10.2 7.9 
Symptomatic sex partner 11.7 2.6 2.7 
No condom use Cast sex) 78.6 76.6 76.0 
Cervical signs (MPC, friability, ectopy) 17.4 8.5 11.5 
*Other clinics Include community, migrant, college health, public health nursing, and adolescent clinics. 
STD = sexually transmitted disease; FP = family planning; EIA = enzyme Immunoassay; LCR = ligase chain reaction; MPC = mucopurulent 
cervIcItis. 
Among all women attending STD clinics, factors remaining sig- 
nificantly associated with infection, in order of relative strength, 
were young age, exposure to CT, sex with a symýtomatic sex 
partner, cervical friability, and exposure to nongonococcal urethri- 
tis. Weaker, but statistically significant, associations were found 
with mucopurulent cervicitis, concurrent diagnosis of PID, expo- 
sure to Neisseria gonorrhoeae, multiple sex partners, and history 
of chlarnydial infection in the last year. Women tested with either 
EIA or LCR were more likely to be positive than those tested with 
DNA probe or culture, but no statistically significant difference 
between EIA and LCR was found (Table 2). 
Evaluation of the sensitivity and efficiency of selective screen- 
ing criteria revealed that the current Region X criteria were more 
sensitive than the target benchmark, detecting 95.6% of infections, 
but were less efficient than the 60% benchmark, requiring testing 
85.6% of women (Table 3). The sensitivity of these criteria re- 
mained Wgh and exhibited little variation across all clinics (range, 
94.5-97.5%). Even after stratifying by test type within clinical 
settings, the sensitivity of the current SSC in Region X showed 
little variation (range, 90.8-98.7%). The efficiency of the current 
criteria varied little between clinic types (range, 80.8-87.3%) and 
did not achieve our study's efficiency benchmark of 60%. When 
exploring the variation by test type, for all test types except DNA 
probe, the range of the criteria's efficiency was constant (82.6- 
89%). The efficiency of the current criteria was most variable 
when women were tested by DNA probe: 67.9% at other clinics, 
88.1% at family planning clinics, and 91.0% at STD clinics. 
Although SSC were not used in STD clinics where universal 
testing was used, the criteria would have been no more efficient 
there than at sites that selectively screened. 
Five sets of SSC developed from factors significantly associated 
with infection through univariate analysis and multivariate modeling 
showed marked differences in efficiency and sensitivity when com- 
pared with each other and with SSC from the USPSTF and those 
currently used in Region X. The sets of criteria were developed using 
an additive approach, beginning with just age (Table 3, criteria 3), 
which had good efficiency (56.1 % in STD clinics, 65.1 % in "othee, 
clinics, and 70.7% in FP clinics), but reduced sensitivity, detecting 
approximately 85% of infections. Ibe other criteria added addiflonal 
components to increase die likelihood of detecting infection in women 
over 24 years of age using the evidence generated from the analysis 
of risk factors (Table 3, criteria 4-6). Combining testing, all young 
women and women over 24, if there were clinical signs, eg, cervicifis 
or ectopy (Table 3, criteria 4), increased the sensitivity of the criteria, 
detecting almost 90% of all positives, with a slight reduction in 
efficiency, requiring testing of 64% to 74% of women. There were 
only incremental differences on varying the selection criteria for 
women over 24 using combinations of clinical signs, risk behaviors, 
and/or recent exposure to an infected partner (criteria 5 and 6). An 
additional diagnostic model was developed (Table 3, criteria 7), 
because the current SSC in Region X allowed for diagnostic tests to 
be included, principally, cervical signs of infection or recent exposure. 
Not surprisingly, this model performed best in STD clinics, detecting 
93.3% of positives, with the greatest efficiency, tesfing less than 70% 
of the women attending. However, the relative performance of this 
model was similar to the other criteria. The recently recommended 
criteria by the third U. S. Preventive Services Task Force had the 
lowest efficiency (Table 3), in part because the criteria recommend 
testing women who do not use condoms regularly, which comprised 
over 75% of our study population. 
Discussion 
Our study confirmed that the factors most strongly associated 
with chlamydill infection are young age, clinical findings sugges- 
tive of infection, report of contact to CT, and reported sex with a 
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TABLE 2. Univariate and Multivariate Factors Associated With Chlamyclial Infection Among Women Attending STD Clinics, Region X 
1998-2000 1 
Univariate Factors (N 34,228) Multivadate Factors (model n 24,780) 
Odds Ratios (95% confidence interval)t 
Age (yrs) 
: 517 8.0 (6.7-9.4) 7.8 (6.3-9.6) 
18-19 6.7 (5.6-7.9) 6.3 (5.1-7.8) 
20-24 5.0 (4.3-5.9) 4.8 (3.9-5.8) 
25-29 2.6 (2.2-3.2) 2.6 (2.0-3.2) 
>29 Referent Referent 
Fiace 
White Referent Referent 
Black 1.2 (1.1-1.4) 1.5 (1.3-1.8) 
American Ind1an/AJaska Native 1.8 (1.4-2.2) 1.7 (1.2-2.4) 
Asian/Paclflc Islander 2.1 (1.8-2.5) 2.3 (1.9-Z% 
Other/Multiracial 1.0 (0.9-1.2) 1.2 (0.9-1.5) 
Ethnicity 
Hispanic Referent Not included In model 
Non-Hispanlc 1.0 (0.9-1.1) 
Specimen type 
Cervical swab Referent Referent 
Urine 1.4 (1.1-1.8) 1.1 (0.8-1.6) 
Test type 
DNA Probe Referent Referent 
EIA 0.9 (0.8-1.1) 1.3 (1.1-1.6) 
Culture 0.7 (0.6-0.6) 1.0 (0.8-1.2) 
LCR 1.2 (1.0-1.4) 1.6 (1.3-1.9) 
Clinical exam findings 
Normal appearance of cervix 0.5 (0.5-0.6) 0.8 (0.7-0.9) 
MPC 3.5 (3.1-3.8) 1.8 (1.5-2.1) 
Friability 3.1 (2.7-3.4) 2.3 (1.9-2.7) 
Ectopy 3.2 (2.6-3.9) 1.1 (0.8-1.4) 
PID 1.7 (1.4-2.1) 1.5 (1.1-2.0) 
Exposure risk factors 
Exposure to CT 7.8 (7.0-8.7) 3.9 (3.3-4.5) 
Exposure to GC 3.7 (2.9-4.6) 1.5 (1.1-2.0) 
Exposure to NGU 2.3 (1.9-2.9) 2.0 (1.6-2.6) 
Exposure to unspecified STD 1.0 (0.8-1.1) Not Included In model 
Sex with symptomatic partner 4.3 (3.9-4.8) 2.2 (1.9-2.5) 
Behavioral risk factors 
CT last 12 months 2.5 (2.2-2.9) 1.3 (1.1-1.5) 
Other STD last 12 months 1.1 (1.0-1.3) Not Included In model 
Condom use at last sex (yes) 0.9 (0.8-1.0) Not included in model 
New sex partner 1.4 (1.3-1.5) 1.2 (1.0-1.3) 
Multiple sex partners 1.5 (1.4-1.6) 1.5 (1.4-1.6) 
*All odds ratios rounded to the nearest 10th percent and calculated at significance level P<0.05. 
EIA = enzyme Immunoassay; LCR = ligase chain reaction; MPC = mucopurulent cervicitis; PID = pelvic Inflammatory disease; CT 
Chlamydia trachomatis; GC = Neisseria gonorrhoeae; NGU = nongonococcal urethritis; STD = sexually transmitted disease. 
symptomatic partner. Behavioral risk factors were weakly associ- 
ated with infection, especially among women tested with more 
sensitive laboratory tests. Additionally, behavioral risk factors did 
not add efficiency to the selective criteria for screening. There 
were variations in the predictors' performance by test type. but 
differences were slight and did not outweigh the consistent per- 
formance of Young age, clinical findings, and recent exposure, as 
recent studies have confirmed. 37-43 
With the exception of universal screening, none of the selective 
criteria developed from our models were able to detect >92% of 
CT-positives outside an STD setting. Our analysis found some 
added efficiency in including exposure variables. eg, exposure to 
CT or sex with symptomatic partner, and cervical findings as indications for screening older women. Although these items are 
usually considered indications for diagnostic testing and/or pre- 
Sumptive treatment in STD clinics and other clinical settings, the 
inclusion of signs of cervicitis or exposure to an STD in Region X 
SSC has been maintained over the years for ease in clinical 
decision-making in non-STD settings. Our results showed that 
there was very little difference in criteria efficiency or sensitivity 
when these items were used in a diagnostic model or as part of 
screening criteria (Table 3, criteria 6 and 7). Behavioral risks such 
as a new sex partner or multiple sex partners increased the popu- 
lation screened to nearly 80% while only yielding a slight increase 
in the proportion of infections found. 
As an example, Figure I illustrates the predictive perfor- 
mance of changing the current SSC to items that reflect greater 
efficiency with minimal reduction in sensitivity, as suggested in 
the models in Table 3. In our study population, chlarnydia 
positivity was 5.3% among females tested in FP clinics. The 
goal of SSC is to detect those women most likely to be positive. 
Age was the best predictor of infection. If that were the first 
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TABLE 3. Sensitivity and Efficiency of Different Selective Screening Criteria for Chlarnydial Infection Among Women by Clinic Type, 
pegion X, 1998-2000* 
crtterla Set 
Current criteria In region Xý 
US preventive Services Task Force recommendation§ 
Age : s24 yrsl 
Age : 524 or age >24 yrs If any clinical signs, eg, 
cervicltis" 
Age : 524 or age >24 yrs If any clinical sign or behavioral 
risk, eg. recent partner change" 
Age : 524 or age >24 yrs If any clinical sign or recent 
exposure to a sexually transmitted diseaselt 
I)iagnostic model": 
STD (n = 34,228) FP (n = 304,183) Other* (n = 71,471) 
Study Thresholds = 60% Efficiency/90% Sensitivityt 
Eff. (%) Sens. (%) Eff. (%) Sens. (%) Eff. (%) Sens. (%) 
87.3 97.5 86.5 95.4 80.8 94.5 
93.3 97.5 95.2 98.2 93.4 97.7 
56.1 82.1 70.7 85.4 65.1 84.4 
63.7 69.5 73.8 88.8 69.6 88.3 
77.1 93.5 79.6 92.1 72.2 90.0 
67.0 92.0 74.7 89.9 70.7 89.3 
69.3 93.3 78.8 91.9 75.8 91.9 
STD = sexually transmitted disease clinic; FP = family planning clinic. 
*Other clinics Include community, migrant, college health, public health nursing, and adolescent clinics. 
tSee notes In text for definitions. 
$Screen 1) all women age 524 yrs, all pregnant women, and all women receiving an Intrauterine device (IUD), and 2) women >24 yrs If any 
clinical sign (cervicitis, MPC, friability, ectopy, or PID), any recent exposure (to chlamydia, gonorrhea, nongonococcal urethritis, or other STD, 
or reported sex with a symptomatic partner in the last 60 days), diagnosed chlamydial infection or other STD in the last year, or behavioral risk 
(Tw sex partner, 2 or more sex partners In the last 60 days). 
9Screen 1) all women age : s25 yrs, and 2) women >25 years if more than 1 sex partner, or diagnosed chfamydial Infection or other STD In the 
last year, or Inconsistent condom use. 
'Screen 1) all women age : 524 yrs, 
'Screen 1) all women age : 524 yrs and 2) women >24 yrs if any clinical sign (cervicitis with or without mucopus, cervical friability, or PID). 
"Screen 1) all women age : 524 yrs, and 2) women >24 yrs If any clinical sign (cervicitis with or without mucopus, or PID), or behavioral risk 
ý new sex partner or 2 or more sex partners in the last 60 days). 
tScreen 1) all women age : 524 yrs and all pregnant women, and 2) women >24 yrs If any clinical sign (cervicitis with or without mucopus, 
friability, ectopy, or PID), or any exposure (to chlamydial infection In the last 60 days or sex with a symptomatic sex partner). 
4Test 1) all women If any clinical sign (cervicitis with or without mucopus, friability, ectopy, or PID) and all pregnant women, and 2) screen 
women age : s24 yrs, and 3) test all women if any exposure (to chlamydia, gonorrhea, or nongonococcal urethritis, or sex with symptomatic 
sex partner), or history of a positive chlamydia test In the last year. 
criterion for screening, 85% of all positives (10,621 of 12,437) 
would have been detected, whereas testing two thirds of the 
female population (Fig. 1) over the 3-year period of our study. 
Using additional selection criteria for women over 24, eg, 
clinical signs or conditions, or recent exposure to chlarnydia, 
15% of this older age group would have been tested, but the 
positivity in this group was 4.6% (Fig. 1). Therefore, these 
additional criteria would have identified a subset of women at 
highest risk. The remaining population of women over 24 had 
the lowest positivity, 1.6%. which some have suggested is 
below the threshold to make screening for chlarnydial infection 
cost-effectivc. 18.24.28-30.36 However, the number of positives 
missed would have been less than I positive per clinic per year. 
Ile current selective screening criteria used in the Region X 
Infertility Prevention Project are very inclusive; 80% to 87% of 
women screened in the last 3 years satisfied these criteria. This 
region, as the first large-scale population-based chlarnydia screen- 
ing program implemented in the United States, has been using 
these criteria for nearly 10 years. Even with the marked reductions 
in prevalence observed in this population and the increasingly 
widespread use of highly sensitive nucleic acid amplification tests, 
the current SSC were sensitive, although not particularly efficient. 
They required testing over 85% of women in various clinics to 
capture over 95% of all positives. Although Miller and colleagues 
recently suggested that 50% cfficiency and 80% sensitivity were 
good benchmarks for selectively screening women for chlarnydial 
infection, 35 the Region X Infertility Prevention Project Advisory 
Comriýttee argued that failing to detect nearly 207o of all positives 
was unacceptable (Committee minutes, January 2002, unpublished 
data). 
For most of the screening scenarios investigated, criteria 
efficiency ranged from 56% to 95%, and criteria sensitivity 
ranged from 82% to 98% across the 3 clinical settings. The 
limited variation in criteria sensitivity likely rcflects the relative 
stability over time of those factors associated with infection. 
The wide range of efficiency might suggest that criteria should 
be tailored to the clinical setting in which screening is occur- 
ring. In Region X, the SSC have always been consistent across 
all 4 states and non-STD clinics. This has facilitated program 
implementation and training of clinical staff through provision 
of clear, consistent messages and clinical protocols. Our study 
suggests that STD clinics might benefit most by using selective 
screening for chlarnydial infection, although potential tradeoffs 
in reducing the comprehensive diagnostic services currently 
offered in many of these settings would need to be considered 
carefully. 
Finally, our study showed that the current criteria in use in 
Region X could be optimýized. A selective screening approach that 
first tests all women 24 years and younger, then tests women over 
24 years if they have cervical signs implicative of infection or 
report recent exposure to CT or sex with a symptomatic partner 
(Table 3,6). would have been over 10% more efficient with only 
a modest 5% decrease in sensitivity. Had this been used in the STID 
clinic population, efficiency would have increased over 25% while 
still detecting 92% of all positives. 
There are at least 3 potential limitations with our evaluation. 
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All Women In FIR Clinics 
(n=304,183) 
Women <-24 years Women >24 years 
10,6211215.128 1.616 / 89,055 
4.9% CT+ 2.0% CT+ 
L 
TEST Cervicitis, mucopus, friability or eclopy or exposure None of the criteria 
to CT or other STI)s or sex with a symýtomatic 
partner, or CT in the last 12 months: or PID or 1,204 / 75.765 




Fig. 1. Predictive performance of modified selective screening criteria, * Region X. 1998 to 2000. *The modified selective screening criteria 
in Region X are: 1) screen all women 24 years and younger and 2) for women >24 years of age, test for chlarnydial Infection If at least 1 of 
the following exists: cervicitis, mucopurulence, fnability, ectopy, pelvic Inflammatory disease (PID), reported exposure to Chlarnydia tracho- 
matis (CT), sex with a symptomatic partner In the past 60 days, CT Infection In the last 12 months, PID, pregnancy, or planned Intrauterine 
device Insertion. 
First, selection bias could have been introduced by excluding a 
small proportion of tests among the screened population, not 
accounting for women who were tested frequently. during the 
3-year study period or by clinics not testing eligible women. 
However, less than 1% of all tests performed on women were 
excluded; women who are repeatedly tested would generally be 
included in the screening criteria (mostly because of age), and 
the Project has had a high participation rate among clinics since 
the program's inception in 1988. Second, almost all women in 
our study had a cervical sample used as the diagnostic specimen 
for CT; urine for nucleic acid amplification testing (NAAT) has 
become more widespread. However, the performance of NAAT 
performed on cervical samples is comparable to that on urine, 41 
so use of urine as the diagnostic modality in this study is 
unlikely to have changed our conclusions. Finally, the poor 
performance of our behavioral risk factors could be reflective 
of not having asked the right questions to detect asymptornatic 
infections in women over 24. It is possible that there are 
other characteristics of the over 24-year-old population of 
women that could aid in the development of more SSC for this 
group. 
Based on the results of our evaluation, the Region X Infertility 
Prevention Project has modified their selective screening criteria 
for women tested for chlarnydial infection at family planning and 
other non-STD clinics and began testing women accordingly in 
January 2003. Ilie criteria efirninated include the 2 items reflecting 
risk behavior (new sex partner or more than I sex partner in the 
past 60 days), recent exposure to a partner with an STI that is not 
CT, and history of an STI that is not CT. Iliese modified selective 
screening criteria in Region X are: 1) test all women under 25 
years old; and 2) for women ý!: 25 years of age, test for chlamydial 
infection if at least I of the following exists: signs of mucopurulent 
cervicitis, PID, reported exposure to chlamydia, sex with a symp- 
tomatic partner in the past 60 days, chlarnydial infection in the last 
12 months, PID, pregnancy, or planned IUD insertion. 16* As 
funding for large-scale screening initiatives becomes increasingly 
strained, incremental efficiency gained in selective screening cri- 
teria should translate into program savings. 
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Summary: Studies have suggested that positivity can be used to estimate the 
prevalence of Chlamydia trachoniatis in large-scale chlamydia screening programmes. 
A recent pilot of opportunistic screening in England estimated that the prevalence 
among 16-24-year-old women in Portsmouth and Wirral was 9.8% and 11.29., 
respectively. This study assessed the continued validity of positivity as an 
approximate for preval6nce. We re-analysed data from the Chlamydia Screening 
Pilot to estimate positivity, calculated as total positive tests divided by total tests, 
and compared these estimates. -with the previously reported prevalence, measured 
as the number of women testing positive divided by the total number of women 
screened. Overall positivity was 9.4% in Portsmouth and 11.0% in the Wirral; these 
estimates were not statistically different from prevalence, regardless of health-care 
setting, ag group or symptoms. We conclude that positivity can be used as a proxy 
for i ence. 
Keywords: Chlaniydla frachoniatis, ciflamydia, screening, positivity, prevalence 
Introduction 
Chlamydia trachoinatis is the most common bacterial 
sexually transmitted infection in the United King- 
dom; over 82,000 cases were diagnosed in geni- 
tourinary (GU) medicine clinics in 2002.1 The 
highest rates of chlamydia infection are amon q 
16-19-year-old women and 20-24-year-old men. 
Untreated chlamyclial infection can lead to serious 
sequelae in women, including pelvic inflarrimator 
)'2 ty'4, 
ý 
disease (PID ectopic pregnancy, ' and infertili 
Prevalence of genital chlamyclial infection in 
women in the UK varies widely depending on 
the age group under study, clinical setting, and 
laboratory test method. " Two recent studies, both 
using urine samples and ligase chain reaction 
(LCR) testing (LCx, Abbott Laboratories, Chicago, 
IL, USA), illustrate this variation. A national 
household probability survey of adults 1844 years 
of age in England showed a prevalence of 3.0% 
(95% confidence interval [CII: 1.7-5.1) among both 
Correspondence to: D Scott IaMontagne 
Email: scott. lamontagneghpa. org. uk 
25-34-year-old men and 18-24-year-old women. 10 A 
pilot of opportunistic screening based in clinical 
settings in two health authorities in England 
among women aged 16-24 years found a preva- 
lence of 9.8% in Portsmouth (95% Cl: 9.3-10.3) and 
11.2% on the Wirral (95% Cl: 10.3-12.1). " Taken 
collectively, these studies provide evidence that 
genital chlamydial infection, often found to be 
asymptomatic, affects a large proportion of the 
sexually active population and constitutes a reser- 
voir of hidden disease with potential long-term 
negative reproductive health sequelae. 
The results of an opportunistic screening trial - 
the 'Chlarnydia. Screening Pilot' - informed the 
national policy in England and led to the phased 
implementation of opportunistic chlamydia screen- 
ing for sexually active women and men under 25 
years of age at selected clinical services facilities 
throughout the country. 12 As necessary with any 
large-scale screening programme, monitoring of 
activities, outcomes, and impact is of key impor- 
tance. In the Chlamydia Screening Pilot, prevalence 
was reported as in outcome measure. To count 
individuals for the outcome measure, all testing 
323 
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episodes frorn the same participant were linked 
based on personal identifying details, such as 
name, date of birth, and residential postcode. 13 
Although all patients attending for health care as 
part of the National Health Service (NHS) are 
allocated a unique identifying number (NHS 
number), this was not captured in the screening 
trial, as patients do not routinely use their number. 
As such, matching testing episodes to individuals 
in the pilot was a time-consuming and difficult 
process. Given the challenges in measuring and 
monitoring chlarnydia prevalence in a large popu- 
lation-based cohort ...... the Department of Health (England)-funded National Chlarnydia Screening 
Programme has proposed to use positivity, rather 
than prevalence, as an outcome measure. 14 poSi_ 
tivity has been used in the United States (USA) as a 
surrogate measure for prevalence in clinic-based 
screening programmes and has been shown to be a 
useful tool in monitoring programme perfor- 
mance. 's This approach has been validated in only 
one published study, concluding that positivity 
was a useful proxy measure-16 However, in that 
study, data were collected from limited health 
settings, so questions regarding the generalizability 
of these conclusions remain. Re-examining the 
Chlamydia Screening Pilot data provides an ideal 
opportunity to crossvalidate this method, while 
informing the appropriateness and utility of using 
positivity to monitor the National Chlamydia 
Screening Programme in England.. 
Methods 
Using data collected as a part of the Chlamydia 
Screening Pilot, we selected all test records with a 
known test result from individual 16-24-year-old 
women tested for genital chlamydial infection via a 
urine sample at family planning (FP), GU medi- 
cine, general practice (GR and youth clinics 
(n=16,595). Tests from other clinical sites, those 
with equivocal or inhibitory results, and tests of 
cure were excluded. We calculated positivity, 
defined as the number of positive tests divided 
by the total number of tests and 95% Cls using 
SPSS 11.5 17 and STATA 8.0.1A Positivity by single 
years of age, health-care setting, symptornaticity, 
and geographic area were also calculated. We 
compared positivity estimates with prevalence. 
Prevalence for each health-care setting and by 
symptornaticity within the health-care setting has 
been published elsewhere; " however, prevalence 
by single years of age within only the four health- 
care settings of interest for this study (F-P, GP, GLJ 
medicine and Youth clinics) was recalculated 
because the published age-specific prevalence 
included all health-care settings. 
Definitions 
Positivity: Using test records, the number of positive 
tests (numerator) divided by the number of tests 
(denominator) among women 16-24 years of age for 
GP, FP, GU medicine, and Youth clinics combined. 
Prevalence; The total number of women 16-24 
years of age with a positive test during the full 12- 
month duration of the Chlamydia Screening Pilot 
(numerator) divided by all 16-24-year-old women 
(patients). " If a woman attended and tested 
positive at more than one health-care setting, she 
was counted as a part of the prevalence estimates at 
each setting. Age was defined as age at first test. 
SVinploinaticity: The original definitions of symp- 
tom categories' were applied to the test records 
used for this analysis. Diagnostic tests were those 
performed on patients with either reported symp- 
torns of chlamyclial infection and attended for this 
reason or attended for GU medicine screening. Tests 
performed for another reason but with symptoms 
reported on the intake form were classified as 'other 
reason but reported symptoms. ' Test records that 
were asymptomatic, i. e., no symptoms were repor- 
ted, were categorized as 'opportunistic screening! 
In addition to calculating Cls to assess differences 
between positivity and prevalence, two-sided bino- 
mial probability tests (using STATA 8.0) were also 
performed to further test our hypothesis, using the 
prevalence within each strata as the comparison mea- 
surement for the positivity within the same strata. 
Results 
We found an overall positivity of 9.4% (95% CI: 
8.9-9.9) in Portsmouth and 11.0% (95% Cl: 10.1-11.9) 
in the Wirral (Table 1). This was slightly lower than 
the prevalence in these areas, 9.8% (95% CI: 
9.3-10.3) and 11.2% (95% CI: 10.3-12.1), respectively, 
but was not statistically different. " Positivity by 
health-care setting did not differ from prevalence 
within these settings. For example, positivity among 
GP attenders in the Wirral was 83% (95% Cl: 
7.4-10.1) compared with prevalence at this location 
of 8.7% (95% Cl: 7.4-10.2). Absolute differences 
between positivity and prevalence within health- 
care settings ranged from -1.43 to 0.04 and the 
percentage difference between the two ranged from 
-8.58% to 0.47%, neither of which was statistically 
significant. ']'here were fewer attenders to youth 
clinics in Portsmouth than the Wirral, reflected in 
the greater variation between positivity and pre- 
valence estimates and associated Cls (Table 1). 
Additionally, positivity by single year of age did 
not vary from prevalence in either the Wirral or 
Portsmouth (Figure 1). Positivity tended to be 
slightly lower than prevalence for most age 
coliorts. The age distribution curve of positivity 
followed the saine pattern for prevalence in both 
the Wirral and Portsmouth. Positivity was highest 
among women aged 19 and 20 years in the Wirral 
and women 18 and 19 years old in Portsmouth. 
Positivity by reason for test within GP, FP, GU 
medicine, and youth clinic health-care settings was 
imilar to tlie prevalence in these locations (Table 2). ss 
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r4 N "s Cq W) C) 0 rn ý -2 but not statistically different from, E were less than z 
o 
r, M--- IT , ý;, prevalence. There are some slight variation in 
C U numerators and denominators when selecting tests Q) 
E -i a or selecting women by age for these estimates. For T 0 ý C prevalence, the age at the first test was used; 
0 0 T at every test. The effect is to ýE positivity used the age 6 
z 
5,00 ý0 r, C) 00 
M 00 rn :1;: W) 0 C) 0% .12 CCnII 
= bias the prevalence numerators towards younger 
. 2ý, ages. Since positivity uses age at test, there will 
a) Zz result a smaller numerator within the younger S ages, potentially reducing the percent positive. 
Y Lastly, if there is a high proportion of women with CP C: E I T repeat tests (more than 7% of our study popula r *6 
=R -ýu ý-U>og 0 ý_ U >' F2 ivity estimate b) tion), the denominator of the posit 
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Figure I Chlarnydia positivityaniong women comparedwith age-specilic prevalence(sce body of the texLf or definitions of positivity 
and age-specific prevalence). [Chlarnyclia Screening Pilot, Portsmouth and the Wimil, [n9land, 1999-2000) 
Table 2 Positivity among 16-24 year old women by reason for test* and health-care setting, [Chlamyclia Screening Pilot, Portsmouth 
and the Wirral, England, 1999-2000]ý 
Diagnostic Other jeason but fepoflod 5yrnplonis AsymptoinaLic 
Health-care 
setting No. of tests (+) Positivity (951y" CI) No. of tests (i ) Positivity (95'! Iý CI) No. of tests (+) Positivity (95% Cl) 
Portsmouth 
GP 337 (53) 15.7, ". ) (11.8-19.6) 21 18(220) 10.4% (9.1 A 1. /) 3910 (317) 8.1% (7.3-9.0) 
FP 71 (11) 1 S. 5 'Yo (6.9-2 4.1 ) 1015 (103) 10.1 % (8.3 -12.0) 1()46(179) 9.2% (7.9-10.5) 
GU medicine 925 (128) 13.8% (11.6-16.1) 29 (3) 10.3%. -1.4-22.1) 280(32) 13.2% (7.7-15.2) 
Youth 4(0) 0.0% 38(5) 13.2% 1,1.9-2,1.4) 117(20) 17.1% (10.2-24.0) 
Wirral 
GP 151 (24) 15.9% (10.0-21.8) 422(41) 9.7%, (t). 9-12.6) 743 (57) 7.7% (5.8-9.6) 
FP 14(0) 0.0% 315(32) 10.2% (6.8 -13.5) 671 (67) 10.0% (7.7-12.3) 
GU medicine 273 (40) 14.7% (10.4-18,9) 248(53) 21.4 %, (16.2-2 6.5) 74(9) 12.2% (4.5-19.8) 
Youth 16(2) 12.5% (- 5.7-30.7) 276(41) 14.9Y(, (10.6-19.1) 638 (69) 10.8% (8.4-13.2) 
*Reasaii for test was deNied in the origirml siticly (11inu-sita et (A, S. -v linnsm hofTJ 2003; 79 . '. 1-7") wal jumled . &-ozig i-fing episode% for this analysis (see Methods) 
Cl=conf', dence interval; GP=qeneral practice; R=farnilY planninq; GU-yeniloulinary 
would be increased, contributing to a reduction in 
the percent positive. 
Dicker and colleagues suggest that positivity 
would overestimate prevalence if a high proportion 
of the population was tested frequently. "' In this 
study, positivity was less than prevalence at R, GU 
medicine, and youth clinics in both tile Wirral and 
Portsmouth, suggesting underestimation of preva- 
lence. In these settings, the percentage of tests that 
were repeat was greater than 8%; seeming to 
support the conclusions by Dicker et al. in tile 
relationship between frequent testing with under- 
estimations of prevalence. 
Dicker et al. also conclude that positivity would 
underestimate prevalence if there was a high 
percentage of repeat tests that were positive. 16 
However, in all settings in our study, the percentage 
of repeat tests that were positive was higher than 
prevalence (ranging from 9.8% to 60%). Tile con- 
verse finding could be the result of factors that make 
these two studies different. First, tile test volume in 
our study is significantly less than the multi-year 
data used by Dicker and colleagues. The result is 
smaller numerators and denominators, from which 
percentages become more pronou nced. For example, 
14 women attending youth clinics in Portsmouth 
had multiple tests (31 tests in total). Among the 17 
repeat tests (second or third tests only) for these 14 
women, 10 (or 60%) were positive. Second, the 
opportunity for women to be tested more than once 
was reduced by the limited 12-month duration 
of Chlamydia Screening Pilot and the screening 
protocol that advised re-testing only if the woman 
changed sex partners. Lastly, in the Cl-damydia 
Screening Pilot, women testing positive were ac- 
tively followed tip to ensure treatment compliance. 
The multiple contacts by the health-care provider 
for treatment might have built relationships with 
higher risk women, creating an environment of trust 
and security, such that they might be more likely 
to re-attend through these established links. Regard- 
less of these differences and potential limitations, 
we found no statistically significant or interpretive 
difference between positivity and prevalence. 
The results of the Chlarnydia Screening Pilot 
guided the development and direction of the 
National Chlamydia Screening Programme in Eng- 
land, which is currently being implemented in 
phases across the country. In large-scale screening 
prograninies, assessing programme impact is ne- 
cessiry to ensure that [here is public health benefit 
to the population. For chlainydia screening, this 
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission. 
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often has been put in terms of cost-effectiveness, 
declines in prevalence over time, and decreases in 
incident cases of PID. The cost-effectiveness eva- 
luation of the Chlamydia Screening Pilot is on- 
going and two randomized control trials have 
shown that chlamydia screening can decrease PID 
incidence. 19,20 Therefore, the principal measure- 
ment of programme impact for the National 
Chlamydia Screening Programme in England will 
be illustrating a decline in infection over time 
where the screening programme is in operation. 14 
It is important to note the difficulties in precisely 
measuring and monitoring prevalence in the com- 
munity through a national screening programme 
for genital chlamyclial infection. The principal 
limitation is not all sexually active women are 
tested; thus, the infection status of women not 
tested remains unknown. At best, prevalence 
estimates can be made for only tile population 
tested and only if individual patients can be 
uniquely identified to prospectively track multiple 
testing and/or infection episodes across clinical 
settings attended and geographic areas lived in. To 
monitor that level of prevalence within a large-scale 
national programme would require a Herculean 
effort. As noted previously, the NHS assigns patient 
identification numbers that are unique to the 
individual, but these numbers are not -widely used 
by patients and clinical facilities are limited in their 
capacity to search the national database for these 
identification numbers. Therefore, it is envisioned 
that most local programmes monitoring chlamydia 
screening activities will need to use positivity 
within clinic settings as an alternate technique for 
investigating changes in prevalence. 
Monitoring positivity, in lieu of prevalence, 
would also minimize the reporting burden for 
clinical providers participating in the National 
Chlamydia Screening Programme to uniquely 
identifying individuals tested and would still allow 
for rigorous assessment of the programme's impact 
on decreasing disease in the population. This 
method will also allow for more rapid epidemio- 
logical assessment of populations affected and 
changes in the burden of disease. 
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Modelling the healthcare costs of an opportunistic 
chlamyclia screening programme 
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Objectives: To estimate the average cost per screening offer, cost per testing episode and cost per 
chlamyclia positive episode for an opportunistic chlamyclia screening programme (including partner See end of article for 
authors' affiliations management), and 
to explore the uncertainty of parameter assumptions, based on the costs to the 
....................... 
healthcare system. 
MetWs: A decision free was constructed and parameterised using empirical data from a chlamyclia Correspondence to: 
Elisal>4th J Adams screening pilot study and other sources. The model was run using 
baseline data from the pilot, and 
, Statistics, Modelling and univariate and multivaricte sensitivity analyses were conducted. 
Economics Dqpartment, Results: The total estimated cost for offering screening over 12 months to 33 215 females aged 16-24 
Communicab6 Disease 
Surveillance Centre Hea t 
was U93 412. The average cost (with partner management) was E1,41.88 per screening offer (90% 
, Protection Agency, 61 credibility interval JCQ 10.34 to 18,56), C21.83 per testing episode (90% Cl 18.16 to 24.20), and. 08.36 
Colindole Avenue, London per positive episode (90% Cl 33.97 to 42.25). The proportion of individuals accepting screening, the 
NW9 5EQ, UK; elisobeth. clinician (general practitioner/nurse) time and their relative involvement in discussing screening, the test 
adams@hpo. org. uk cost, the time to notify patients of their results, and the receptionist time recruiting patients had the greatest 
Accepted for publication impact on the outcomes in 
both the univanate and multivariate sensitivity analyses. 
I April 2004 Conclusions: Results from this costing study may be used to inform resource allocation for current and 
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future chlomydia screening programme implementation. 
G enital Chlamydia trachomatis infection is the most 
common sexually transmitted infection (STI) diag- 
nosed in genitourinary medicine (GUM) clinics in the 
United Kingdom. ' it is mainly asymptorniticand may leld to 
pelvic inflammatory disease (PID) in a proportion of 
untreated cases, which in turn may cause ectopic pregnancy 
and infertility in women .2 
Asymptornaticilly infected intlivi- 
duals may not have adequate opportunity or seek to be 
tested, leaving a reservoir of hidden infections and risk (if 
sequelac. Therefore, screening it-tisk populitions can iden- 
tify and treat asyrriptomatic infection, reduce sequelac, and 
perhaps impact the associated long term healthcare costs.; ' 
The decision to implement opportunistic chlainydil screen- 
ing may be based in part upon results from economic 
analysis, which have been undertaken using variow; screen- 
ing assumptions. " A rcvicw of other cost effccthcness 
studies by Honey et al- found that depending on the model 
assumptions, screening females for chlamydial infection call 
be cost effective under various baseline prevalence estimates, 
especially when age is used to select women anti DNA testing 
methods are used. in England, chlainydia screening is 
currently being implemented in phases across the country. ' 
It is, therefore, timely to assess the cost of such a screening 
programme and examine in detall the relative contribution of 
the cost elements, using a combination of' data such a% the 
time involvement of personnel, variable costs, and ovedicad 
costs. As screening encompasses more sit" across the 
country, information from this study may be particularly 
useful as it directly feeds back into programme inipleniclua- 
tion, and may hell) other sites that are planning and 
undertaking screening programmes elsewhere. 
In this study, a deci%ion analytical model wa% used to 
estimate the average cost per test offer, cost per testing 
episode, and cost per chlatuydia positive episode, based on 
the costs incurred by the healthcare system. The model 
structure gives the ability to change the model assumptions 
and run a series of "what if" scenarios (for example, %vital if 
the role of practice nurses is emphasised over doctors' roles in 
discussing screening). It also allows for detailed analyses of 
uncertaftay on how patients move through the screening 
process for both patient flow and the costs of the programme. 
The results from this analysis may help to advise on 
appropriate resource allocation to mininike screening costs 
and improve the efficiency of future screening programmes in 
the United Kingdom and elsewhere. 
METHODS 
Screening methodology 
Data on patient flow came from a pilot study funded by Elie 
Department of Health (England) to evaluate the costs, 
acceptability, arid feasibility of opportunisitic chlarnydia 
screening; these nicihods have becii fully described else- 
where. ' "' This analysis included 16-24 year old females who 
were off'cred screening when attending GUM clinics, family 
planning clinics, antenatal clinics, termination of pregnancy 
clinics, arid general practitioner (GP) surgeries. The study 
was undertaken between I September 1999 arid 31 August 
2000 in Portsmouth and Wirral, England. Although some 
men were also offered screening opportunistically at GUM 
arid youth clinics those data are not included here. In the 
pilot study, research nurses were responsible for managing 
patients and their partners. In this analysis, we have 
estimated the costs of a health adviser who would have a 
similar role with patient and partner management. Women 
who accepted a test offer wcre asked to submit a urine 
%aniple ior ligase chain reaction (LCR) testing (LCx Chlamydia 
trachomaiis assay, Abbott Laboratories Diagnostic Division). 
Patients in the pilot study with an insufficient diagnosis were 
advised to get another test, arid paiients with an equivocal 
result were given the option to be treated or retested. The 
......................................................... 
Abbreviations: Cl, credibility interval; GP, general practitioner; GUM, 
9enilourinary medicine; LCR, liguse chain reaction; PID, pelvic 
inflammatory disease; STI, sexually transmitted infection 
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model used in this analysis assumed that patients witha final 
diagnosis of positive, insufficient, or equivocal were asked to 
attend for treatment (azithromycin or doxycycline; alter- 
native regimcn use(] for pregivint women). The positive 
patients were also a%ked to report any sexual partners froin 
the past 3 months. For the reported partncrs, contact was 
attempted (either by the patient or the health adviser), and 
the partner(s) was asked to attend, receive prophylack 
treatment, and give a urine sample for LCR testing. A small 
subset of partners was tested using other methods (n = 20); 
these were not included in this analysis. 
Decision analysis model 
Two linked decision trees (Precision Tree, version 1.0.4, 
Palisade Corporation) were constructed to simulate the flow 
of fernale screening episodes from initial test offer to Patient 
treatment and partner reporting (fig IA), and conlacting 
partners and partner management (prophylaxis and testing) 
(fig 113). Two of the node% have branches with the same 
outcomes (or next steps), výhich arelinked in the model (that 
is, all insufficient/equivocal diagnoses are treated as positivcs 
and go to the treatment node. and individuals may have 
reported partners without receiving treatment). Each 11OLIC Of 
the model returns the number of paticni episodes aod the 
expected average valuc of the niodel at that point. 
Patient data extraction 
In the pilot screening model, patient testing and nianage- 
ment spanned across various healthcare settings. The 
methodology of the pilot study stated that patient% would 
be tested in a variety of setting,., but treatment and partner 
notification would be undertaken in GUM clinics, by health 
1) 904 
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advisers or at the site of testing. This analysis combined the 
number of patient episodes through each step of the tree 
across healthcare settings, instead of using individuals as the 
unit of measurement. Since some women were tested more 
than once and fit various clinical settings, ' each time thcy 
were offered a test they would have been included in the total 
rininber of patient episodes. This was thought to better 
estiniate the true costs to the screening programme. 
However, this may contribute to a different acceptance rate 
than if the results were estimated based on the number of 
women who accepted testing, instead of counting each 
occasion they were offered a test. Data were also combined 
from Portsmouth and Wirral to give in average estimate of 
the value of such a screening strategy. 
Two researchers (DSL ARJ) extracted the data for each 
branch of the decision tree using different methods to check 
for accuracy (Stata, version 8.2, Stata Corporation, and SPSS, 
%-ersion 11.0, SPSS Inc). in both methods, screening episodes 
from men, womcii aged < 16 years or >24 years and my test 
of core t-pisodcs ivcre excluded from the analysis. For both 
extraction methods, a stepwise approach was used following 
the i1ccision tree!, (figs IA, B) with the test records filtered at 
each node. 
Costs 
The overall healthcare costs of screening were estimated from 
direct cmts froin the pilot study (preliminary invoiced 
cxpensc forms. %upplied by the Department of Health, 
Economics anti Operational Research Division) and lddi- 
tional costs borne by the healthcare systcrn (that is, clinicians 
involved in screening who did not receive remuneration froin 
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Figure I Schematic diagram of the screening trees used in the analysis. (A) Patient free; (B) partner tree. for each branch option, the number who 
Rowed through that branch is given above the line, and the baseline cost is Wow. Triangles indicate a branch termination, and broken lines indicate a 
flow to another node. 
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Costs of chlamyclia screening 
Table 1 Total annual overhead costs used in the analysis 
based on invoiced expenses from the chlarnydia 
screening pilot study 
cost 
Total personnel ov"eads 36974 
Programme administrator 11 138 
Cansu" coordimator 14362 
Administration and clerical 11 474 
Total capital o"rh"d, 17164 
Refrigerators 4421 
Computers and printers 4851 
Office furnishings 262 1 
Accocrimodation: rent/alterotions 5271 
Total running overheads 22329 
Trafel and transportation 12" 
Telephone and lax 323 
Stationery and posloge U 178 
Mvertising 671 
Oqw costs 7913 
Source: Preliminary cost data provided by the Department of Health, 
Economics and Operaflonol Research Division, and dab from the 
questionnaire on time and patient flow. 
Tosts inflated to CUK at 2001 rates. 
costs was thought to more closely estimate the true costs ofa 
chiamydia screening programme, by taking oil the wider 
healthcare costs (but excluding the social costs and costs to 
the patient). The included costs were not all paid for directly 
by the screening study itself, anti therefore would not 
necessarily be funded in a nationally implemented pro- 
gramme. 
The planning and sct-up costs of the screening progroninic 
were included and were based on the pilot invoiced expenses. 
Costs deciried to be associated with the research side of tire 
pilot screening programme wcre excluded from the analysis 
(that is, personnel costs toy analysis relating to llie slukly 
evaluation, since the pilot IWIS a research studý to evaluate 
the feasibility and effect iven ess of chlaiiiydia screening). 
Recruitment of staff and laboratory upgrade costs (froin LIA 
to NAAT testing) were also excluded. 
In the pilot, a fee was paid to the clinicians for each 
chlamydia test initiated. However, this cost was excluded 
from the analysis, as it is unlikely to continue in the pliased 
implementation of the national prograrnine. Instead, their 
time costs have been acconmed foT in the analysis by 
estimating the cost of a con%ullafion xvith a licalilicare 
g to a potential patient (see 
bdow). clinician to offer screening 
All costs were inflated it) reflect 2001 prices (f: %terliniz), 
using the Hospital and Community Health Services inflation 
indices for either price.,, or pay. " The adjusted costs ilIdUded 
all overhead costs and sonic of the unit costs (noted in 
tables I and 2). 
Overheads 
There was an overhead fiXed COSJ for IIIC NCTMling 
infrastructure, personnel and running the programme 
(table 1). These costs were taken from the expenditure 
reports and include one off and recurring costs. 
While the patient flow data were taken over a 12 motuh 
period, the screening study and assmiated costs wcre 
incurred roughly over 2 year%. Therefore, the total cosLý were 
annualised to allow for tompari%on with the %tudy period 
data. One-off costs, including refrigerators, computers, and 
office furnishings. were as%igned an estimated lifespan of 
5 years, and an annual cost per item was estiniatc(I" ming a 
discount rate of 3.5%. " Only one of the sites supplied these 
onc-off costs, so these total annualiscd costs wcre doubled to 
account for both sites. The personnel (that is, administrators, 
screening coordinator, ctc) and running (that is, tc1cphoncs, 
365 
tra vel/tra ns port, etc) overhead custs from both the 
Portsmouth and Wirral sites (including -set up and pilot 
costs) v%erc halved to estimate in annual cost per itern. An 
ovcrhead cost per patient screening episode was estimated 
frorn the total overhead costs. 
Costs at each branch 
variable costs were added at each step in the decision tree 
(table 2). To estimate these, costs of materials and personnel 
were sunimed (derived from the rucan Portsmouth and 
Wirral costs when data were available). Personnel costs were 
derived from [lie estimated salary of a typical healthcare 
wojker who would see a patient or partner (receptionists, 
GPs, practice nur%es/health adviser,, and GUM con%ultants), 
and included qualification costs, ongoing training and other 
additional costs such as overhead costs, to estimate the actual 
opportunity cost%. " " In the pilot, women were screened at 
various clinical settings and would have spoken to various 
healthcare personnel. This analysis assumed that the salary 
of a practice nurse or health adviser jboth assumed to be a 
grade F nurse in the NHS pay scale") would give a lower cost 
estimate, and that of a Gil clinician an upper estimate. The 
relative involvement of both cliniciini was assumed to be 
50%, but was allowcd to vary in the sensitivity analysis (see 
below). These annual costs were used to derive the cost per 
patient related minute (except for receptionist, which was 
just a cost per minute), using data on the average number of 
wcek% worked per year, an([ the average number of hours per 
week. " 
These data were then combined with estimates of the time 
spent on different screening and related activities. To obtain 
this, a questionnairc was sent to the primary research nurses 
involved in the original chlainydia screening pilot in both 
sites, askingabout the time spent on specific activities during 
(lie screening process. These estimates were not directly 
nicasurctl while the pilot was conducted, and therefore are 
bawd on retrospective accounts. The baseline estimates 
represent an average when data front both sites were 
available. 
The total cost of a patient (or partner) flowing through 
various parts of the tree (with different outcomes) will simply 
be the %uni of the branch costs through which she or he 
flows. 
Outcome: estimated average cost of screening 
Three wain outconics were estimated: the average cost per 
screening offer; cost per testing episode (giving a urine 
%arnple and testing, regardless of the outcome), and cost per 
positive episode. The cost esfiniates are additive, such that 
the cost per testing episode include% the cost per screening 
offer and the co. %t per positive episode includes the cost per 
testing episode. These are simply the weighted average of all 
possible outcomes (anti associated costs) for that decision 
node and all subsequent. nodes. For example, the cost per 
offer is [tic weighted average of the cost of all the occasions a 
test offer was not accepied and the cost of all occasions a test 
was accepted and all of their subsequent downstream costs. 
Likewise, the cost per icstiiig episode is the weighted average 
of those testing negative and those with a diagnosis of 
positive, insufficient, or equivocal. For all outcomes, these 
cost% include those ofaccepting a test, the laboratory costs of 
testing, and the costs of notifying them of their results, and 
also inClUdC the Weighted costs of those testing positive that 
may include the additional costs of treatment and partner 
notification for a proportion of positives. 
All oulconic% included the costs of partner inanagenient 
(contacting, treatment, and testing) as these arc all part of 
the screening structure and contribute to the cost of the 
otitconics. These outcomes werc assessed froin the healthcare 
www. stijournal. com 
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Table 2 Total variable costs at each node of the decision tree (in bold) and their constituent inputs 
Baseline Unit Minimum Maximum Distribution* Sourcet Comment 
Overall. personnel . Receptionist 0.13 C/Minute Assumption 
Gp 1.01 r/Minutet Rel' II 
Practice nurse/6A odyiser§ 0.42 C/Minutet Re[ I], ]A 
Me" GUM Consultant 1.40 2/Minvtet Re[ 11,14 
(1) kcapt; th lost l n 1 3.77 E/Episode 1.50 5.42 
In6rmati . 
I1. 
01 0.31 c/lIern A Cost inflated to WK at 2001 roes 
Receptionist time 1.8 Minute 0.5 3 Uniform A Screening selection and invitation 
GP/nurse time to discuss screening 4.5 Minute 2 7 Triangular A Depends on sening/clinicion 
% GP firne compared to nurse rime 50 % 0 100 Uniform Assumption 
(2) Giving a sample 0.65 C/Episode 
Sample container 0.50 C/Item B Cost inflated to WK of 2001 rates 
Request form 0.15 C/Itern B Cost inflated to WK at 2001 rates 
(3) Testing and final diagnosis 12.97 E/Episode 10.71 15.25 Cost inflated to RUK at 2001 rates 
LCR lost materials and personnel 11.81 Vltem 10.49 13.14 Uniform B Average of both sites, cost inflated 
to EUK of 2001 rates 
Health adviser time to notify patient 2.8 Minute 0.5 5 Uniform A 
(4) Treaftnitrit 7.46 E/Episode 
Azithromycin 7.33 C/Treatment Ref 17 Recommended dosage" 
Do d, 4.98 C/Treatment Ref 17 Recommended dosage" = 
, 
=. 
r time for treatment 5 Minute A Partner notification not included 
% receiving azithromyrin compared to 15.6 0 100 Triangular C 
cloxycycline 
(5) porftw" repor%d 1.06 1! /Episode 0.85 1.27 
Health adviser time for eliciting partner 2.5 Knule 2 3 Uniform A 
information 
(6) Portrws conkKW 0.01 C/Pariner 0.00 0.13 
episode Health adviser time to contact partner I Minute 0 to Triangular A 
% partners contacted by health adviser 3 % C 
compared to patient contacted 
(7) Porhw oftridance and treatment 14.30 C/Poriner 7.16 10.74 
episode Time far partner clinic visit 12.5 Minute 10 )5 uniform A 
% partners seen by health adviser 70 % Ao 100 Uniform Assumption 
compared to GUM consultant (a) Partner kiled 11.81 C/Portner 10.49 13.14 Uniform B See No 3 above. 
episode 
*Distributions used in the sensitivity analysis. Uniform distributions were used to represent a large degree of uncertainty (any value over the range selected 
randomly), triangular distributions were u sed when the most likely value was known (the value drawn for each simulation was more likely to be closer to the mean 
value). 
t& dola from interview with primary research nurses in Portsmouth and Wirral; B, preliminary pilot expenses provided by the Department of Health, Economics 
and Operational Research Division; C, p ilot databas e. 
tPotent related minute, 
IMId-scole grade F nurse. 
provider pcrsl)Lctive, incorporating the costs of dic screening 
programme and the associated wider healthcare cost%. The 
baseline costs were uscd in the primary analysis. 
Sensitivity analyses 
Sensitivity analyses were undertaken to assess which costs 
and patient flow values %vere most important it) the 
outcomes, and to explore the rangc of possible outconics 
(given some parameter uncertainty) for this sci-cening 
programme. The costs of such a screening programme are 
variable and may depend oil the personnel involved in 
counselling and testing (that is, whether a general practi- 
tioner, health adviser, or GUM consultant discusses screening 
with a patient), the cost of tile LCR test (which often varies 
between liboratories), and the numbers of patients and their 
partners who flow through the screening and partner 
decision trees. 
Parameter values were drawn from %pecified distributions. 
The patient flow through the model was based oil data from 
the pilot and was binornially diStTibuICd (proportion ai each 
branch and the total number). The cost ind the time 
components were mainly drawn IrOT11 uniform distributions 
to represent a large degree of uncertainty (with any value 
randomly drawn from the range). Triangular distributions 
were assigned when there was considerable evidence that tile 
mean closely approxiniatcd the baseline valtic. Then, the 
value used for each simulation was more likely to be drawn 
from a value closer to the mean. The baseline an(] maximum 
and minimum values used are given in table 2 along with the 
assigned distribution. 
The screening programme modelled here is just one of 
many possible optiorm Therefore, univariate sensitivity 
analyses were performed, which varied one of the model 
,a -; sumptions at a time, and we then compared results to the 
baseline model outcomes. The input parameters were varied 
between the minimum and maximum values given in table 2. 
Additionally, several other "what if" scenarios were tested, in 
which one or two of the parameters were chinged. This 
included (a) changing the relative time a receptionist rather 
than GP spent with a patient during screening recruitment 
(that is, if a receptionist spends 3 minutes recruiting each 
patient then a GP spends only 3 minutes per patient; or no 
receptionist involvement then 10 minutes of GP time per 
patient), (b) excluding the cost of a consultation with a 
clinician for non-test acceptors, (c) varying the test accep- 
tance rate from 34% to 94ý,, (roughly a 5W,.; ý change from the 
baseline ul'641.. Iii), (d) including a lower LCR test cost estimate 
of C9, thought to be more realistic of the test costs for a larger 
scale screening programme, and (e) changing the chlamydia 
prcvalcri(e of tested patients. The prevalence range was based 
on a lower estimate (if 3% found in 18-24 )-car old females in 
a populmion based survey, " and on an tipper estimate of 18% 
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found in females aged 16-24 attending GUM clinics. "' The 
estimate for prevalence was driven by data from the decision 
analysis model, and it was assunied that positivity was art 
approximate estimate for prevalence. " It was estimated by: 
(positive + equivocal + insufficient tests. In this 
analysis (he baseline prevalence was estimated to be 11.4ý. 'o, 
based on the above equation and data on screening epi, odes, 
and differed slightly from the estimated prevalence in the 
pilot study. ", 
A probabilistic multivariate sciisitivity analysis wa% also 
performed using Cy. risk (version 4.0.5, Palisade Corporation) 
running within Excel (version 2000, Microsoft). The analysis 
was run 1000 times, and at caLh simulation parameter % afties 
were randomly drawn using 1-atin Ilypercube sampling- The 
parameters that varied weic the input costs and times with 
ranges given in table 2, the distribution of individuak flowing 
through the tree (drawn from binomial distribmions 
described above), and the acceptance rate (triangiflar 
distribution: minimum 341, %, inean (4%, maxi111L1111 94111', ). 
Distributions for the outcome variables (co%t/offer, coW 
tested, cost/positive) were generated along with non-para- 
metric 90% credibility intervals (CI%)-that is, 90'..,, of the 
model simulations fell within the upper and lower Cl. 
RESULTS 
The estimated overall annual cost of the opportuniitic 
screening programme based on offering screening to 33 215 
women aged 16-24 was E493-112. Of these costs, 80'A'*) 
(E394429) were the variable patient costs, . 5% (E22 515) 
were associated with partner management costs, and 15% 
(E76,468) were overhead costs for running the programnic. 
Thirty nine per cent of the costs were persomic) costs 
(including overheads and variable costs). About a third 
(37%) of the total costs were associated with the test kit cost 
(excluding testing personnel). These estimates are specific to 
the number of screening episodes examined in this analysis. 
The estimated average co-st per test offer given the flo%v of 
individual testing episodes in the pilot was E14.88 (90% Cl 
10.34 to 18.56), which included all of the downstream Co%ts 
of testing, notifying patient., of results, treatment an(] partner 
notification for positives, and all of the partner minagenient 
costs. The average cost per testing episode was E21.83 (90% 
Cl 18.16 to 24.20) including all downstream cost% and pariner 
management. The estimated average cost per positive episode 
was E38.36 (90% CI 33.97 to 42.25), which included a 
proportion of positive episodes having treatment and panner 
management. If the partner management costs were ignorcd, 
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the average cost per screening offer, testing episode, and 
positive cpisode %vere reduced to C14.18 (90% Cl 10.01 to 
17.80), L-10.57 (90% CI 17.18 to 22.63), and E27.35 (90% CI 
24.29 to 29.98). respectively. If the partner tree was examined 
alone, the expe(ted average cost per partncr contact was 
El 1.01 (90% CI 9.12 to 13.23), a %veiglitcd average of the costs 
of contact made with a proportion of parnius, and partner 
treatment and testing for a proportion of partners. 
Sensitivity analyses 
In the univariate witiftivity analysis, varying the proportion 
accepting the test offer had the greatest expected impact on 
the cost per screening offer compared to the baseline result 
(fig 2). As the test acceptance increased, so did the cost per 
offer, anti vice versa as the acceptance decreased (, E18.98 for 
94% icceptance; E10.74 for 34% acceptance). The relative role 
of the rck: el)tiorii%t in explaining screening (compared to GP 
involvement) also had a large impact (25% difference front 
baseline) )n the cost per offer. As the receptionist spent more 
time explaining screening and the clinicians spent less time, 
the average cost per offer declincd I. rom E18.59 to E13.98. 
Similarly, as the time associated with primary care clinicians 
(doctors or nurses) explaining screening to patients 
decreased, so did the average cost per offer. 
Several of the parameters had a moderate impact on the 
outcome% ( 12% or less change from (fie baseline results). 
These in(ludcd the relative involvement of Gl' versus practice 
nurse explaining screening to patients, excluding the 
licaltlicaic worker consultation for rion-test accepter, the 
test cost, art(] the prevalence of chlainydial infection. A two 
way analysis Of (he prevalence and the proportion accepting a 
test indicated that the prevalence had little impact on the 
outcome%, compared to the proportion accepting a test that 
had a large impact on the cost per test offer (fig 3). 
The distribution of the results front the multivariate 
sensitivitv analysis is shown in figure 4. The estimated 
average cost per positive individual was less certain (had a 
wider range of possible values) than the cost per offer and 
cost per individual tested. The inultivariate sensitivity 
analysis results indicated that the parameters that impacted 
most on the outcomes were (in Order of importance)-. the 
proportion accepting a screening offer, the relative impor- 
tance orGP versus nurse involvernent in discussing screening 
and the GP/nurse time to discuss patient recruitment, 
screening before test acceptince, the total laboratory test 
cost, the time 10 liodly patients of their results, and the 
receptionist time spent selecting and recruiting patients. 
figure 2 Results from the 
Receptionist time to %sled patients For screening 0.5 min 3 min univoriate sensitivity analysis. The 
GP/nurse time to explain screening 2 min 7 min difference (C) from the baseline cost 
GP Y nurse involvement explaining screening 0% GP i I 100% GP per test offer 
for various rometers 17 
, ir tested individually from 1 Test cost E9 F 13.14 minimum to maximum values. A 
Time to notify patients of their results 0.5 min 5 min negative difference denotes a cost 
Treatment regimen (azithro v doxy) 0% azithro 100% azithro, savings from the baseline. 
Health adviser time to elicit partner information 2 min 3 min 
Health advisor time to contact partner 0 min 10 min 
Partners seen by health adviser v GUM clinician 100% HA AO% HA 
Time to counsel partner 10 min 1 1 15 min 
Receptionist; GP/nurse time to explain screening 3 min: 3 min 0 min: 10 min 
Exclude consult with GP/nurse for norýcccepter 
Test acceptance 34% 1 94% 
Chlomyclict infection prevalence 3% 16% 
-5-4-3-2-10123A5 
Cost/offer 
Difference (E) from baseline 
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Figure3 Results from the two way sensitivity analysis of prevalence and 
acceptance rate; change in Ike cost JQ/Ar, 
DISCUSSION 
This analysis provides estimates of the average cost )f 
screening from the healthcare perspective. The average (ost 
per screening offer was about E15 including I)artner manage- 
ment, It was an additional estimated E7 more (E21 total) per 
person tested, and E16 more than that per person po, 'itive 
(total about E38). 
Varying the proportion that accepted a test had the largest 
effect on the cost per offer, since the participants largely drive 
the overall costs of the scicening programme. While a high 
test acceptance rate accounts for higher costs, it may hell) 
identify the greatest number of infections if the correct 
population is tested. Identifying cases through screening with 
the aim to reduce transmission and prevent sequelac inay 
save money in the longer term. This is an area of ongoing 
research, and can be better addressed with cost effectiveness 
studies. 
Since the laboratory test cost %%-a% important in the 
sensitivity analysis (fit part because more thai; onc third of 
the total screening cost came from LCR testing), determining 
the most accurate value for this variable will provide a better 
estimate of the overall costs of screening. Variations in 
laboratory cost may be explained by differences in the LCR 
test kit cost and laboratory personnel, and some local 
variation is expected. There are also various laboratory 
options, for the testing process including leasing equipment, 
Average cosViesf 
120 Mean - 21.83 
(90% Cl 18.16 to 24.20) 
100- 
Average cost/offer 
Mean - 14.88 
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buying cquipinciit, and renting reagents, that call be 
examine([ to see if test costs call be reduced to drive down 
the overall laboratory costs. 
Paimet iiianagenwrit contributed only 5% of the overall 
costs, yet it is an important part of a screening programme. 
While screening female% will detect their infection, partner 
notification will identify niale partners at risk who may not 
otherwise be tested, and treating partners may prevent both 
re-infection and onivard transmission of chlarnydia. The 
costs of partner management were included in the screening 
model, and it does not appear to make a difference to the cost 
per screening offer or cost per testing episode if it is included 
or riot, although it does inipact the cost per positive episode. 
The infrastructure in place for screening may remain (for 
example the ovcilicads), irrespective of the numbers being 
tested and treated, at least ill the short run. Roughly 25% of 
the overlicad costs %verc oric-off costs such as capital items 
(refrigerators, office furrikiiings, computer equipment) that 
would probably not IICCLI to be spent again if iriore tests were 
done. These costs would, however, be necessary if a new site 
were to implenicnt a screening programme. Screening start- 
ill) costs may be itself for these capital costs, unless they could 
be aCCOMITIodated and streamlined within the current 
healthcare infra struct tire. This could be explored in future 
analyses. 
Results from the multivariate and univariate sensitivity 
analyses highlight areas of uncertainty in the data that 
influence the costs of screening. For example, the thne spent 
by clinicians explaining screening had a large impact on the 
costs because of its high variability and impact on all 
screening offers. Refining this all(] other estimates may give 
more precise estimates of the costs involved. However, some 
of the costs incurred in the pilot study, such as clinician time 
explaining screening, may not be incurred in future screening 
paradigms' because patients will be expected to self select for 
screening in([ there would be minimal involvement of staff 
for rccruilincin. Time and motion studies call be conducted 
to better understand the flow of people through screening 
and the costs involved in each step. This infort-nation can be 
used to streamline the I)TOCCss and reduce costs within the 
existing infra%trut ture. 
The costs and resottrccs will be dictated at a local level to a 
certain extent, so variation in the outconics would be 
Average cost/positive 
Mean - 38.36 
(90% Cl 33.97 to 42.25) 
35 40 45 50 
Figure 4 Results from the multivaricte 
sensitiyity analysis; frequency 
distribution of outcomes for 1000 runs, 
including partner management costs. 
www. stijournol. com 
Costs of chlomyclia screening 
expected if this analysis were done for other sites. However, 
the results from this analysis may also provide a point of 
reference for evaluaiing future screening proposals. 
There arc several reasons %vliy this analysi% adds -IrUtly to 
the information about the cost of genital clilainydia s(rccii- 
ing. Firstly, the model hiput data on the patient and partner 
flow were taken directly front the pilot study. Secondly, izilich 
of the cost data also came directly from the pilot. invoiced 
expenses, so is thought to accurately represent the current 
costs of a screening programnic. Thirdly, tile fildi%idual 
patient data allow direct estiniates oftlic nican an([ variance 
in proportions it each node. This, combined with the flexible 
model structure anti ability it) simulate ilterilative scenarins, 
provides a powerful too] to explore the average cost% of' 
screening, the uncertainty in these estimates, and tile cost 
under different scenarios. 
Cost effectiveness studies of chlainydia screening iddrc. ý, s a 
different issue from tile one in this analysis, but they require 
similar screening costs. In [his analysis, the detailed costs at 
each step of the tree arc cxaniincd, and include costs frorn the 
wider healthcare system such as personnel who have contact 
with potential patients in settings where screening is offered 
(receptionists, nurses, general practitioners), overhead (osts 
of running a screening prograninic, screening set-up costs, 
and partner management costs. These may be included in 
other studies esdriiiiing the (ost effectiveness of screening, 
depending on the assumptions about the infrastructUle alld 
organisation of the -screening prograinnie. Sonic sttidic-ý have 
estimated the tinic and relative involvement of healthcare 
workers for different oiilcoziic-ý (PID, cciopic pregnancy, 
infertility), ' "" but this is tile only rcccrit iinalysk it) 
explicitly estimate the tinic and coits at each step of' a 
screening programme. Tile inethod presented here provides a 
more precise estimate of tile cost of patients with a specific 
outcome flowing through the screening tree. 
This analysis was done froin the health provider pei'spec- 
tive. It included screening cost% and also those of other 
healthcare personnel involved fit tile %creening process. 
However, there are other costs that arc not included, such 
as patient costs and the wider societal costs. For example, 
there may be costs to a positive patient in tcrin. % of tinic lost 
from work to travel to a clinic to receive treatment. and 
similar costs for a partner. Another large chlarnydia screening 
study is collecting patient costs as part of their study, %% hich 
should provide more inforniation when the re-stilLs are 
pubfished. " 
only the screening costs were included in this analysi,, and 




: This 'study esfimates the healthcare costs of opportu- 
- 
nisfic chlarnydio screening in clinical settings in 
iEnglond. It is based on empirical data from 0 recently 
completed chlornyclia screening pilot study and uses 
de0sion analytical modelling techniques to explore the 
uncertainty of results and the impact of changing key 
assumptions in the screening paradigm. 
0 The average cost per screening offer is approximately 
V5, (under baseline assumptions); these are costs 
incurred by both the screening programme and the 
healthcare system in which screening occurs. Sensitivity 
analyses highlight the elements at screening where 
costs could be targeted for reduction, including 
lowering the laboratory test costs and reducing 
clinician involvement in screening. 
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sequelac were estimated. For example, preventing PID or 
vctoplc piegnancy may be a restilt of ýcreejiing and treating 
aiymptomatic infection through a screening programme. 
Other co-; ts and modelling studies have included these 
w(luclae and [lie estimated coNt% saving from averting 
infection and/or c( ... plicafions. ' 6`" Rc. sults frorn this 
analysis combined with the identified costs of scquelae will 
be used in further modelling and economic studics. 
This analysis provided the average expected cost of 
screening, based on detailed data, and provides a novel 
frammoik for estimating the costs an(] uncertainty of a 
screening programme. The uncertainty analyses provided 
information about the relative importance of different 
components of the screening model that may direct what 
information should tie collected in future studies. Results 
may hell) advise in the phawd chlainydia screening iniplc- 
mcniation planned for future area% in England, and for 
screening programnics elsewhere. 
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Management of genital chlamydial infections at termination of 
pregnancy services in England and Wales: where are we now? 
D. Scott LaMontagne'a Jeanne M. Pimenta, b Kevin A. Fenton, a 
Harry Mallinson, ' Jenny Hopwood d 
Objective To determine the range of policies and practices related to the management of genital chlamydial 
infection employed at termination of pregnancy services in England and Wales. 
Design Cross-sectional descriptive study. 
Setting England and Wales. 
Population Termination of pregnancy providers. 
Methods Survey questionnaire administered to termination of pregnancy providers. 
Main outcome measures Policies and practices for the management of genital chlamydial infection in women 
seeking termination of pregnancy with comparison to the national guidelines of the chief medical officer 
(CMO) and the Royal College of Obstetricians and Gynaecologists (RCOG). 
Results One hundred and thirty-eight (48%) practices responded to the survey, with representation across 
England and Wales. Policies for screening and/or treatment of chlarnydial infection existed for 70% of 
providers. We found three practice patterns for the management of genital chlarnydial infection among 
termination of pregnancy attenders: 70% of providers tested their own attenders prior to termination and 
treated if necessary; about 25% of providers administered prophylaxis without testing, and a small number 
of providers (<5%) neither tested nor treated attenders. 
Conclusion These patterns may be the result of differences in the CMO and RCOG guidelines. Given the 
impact of untreated genital chlamydial infection in women attending for termination, consistent 
recommendations from the CMO and RCOG may encourage uniform practice for the management of 
chlamydial infection in this vulnerable population. 
INTRODUCTION 
Chlamydia trachomatis is the most common bacterial 
sexually transmitted infection in England and Wales. ' Un- 
treated infection can lead to pelvic inflammatory disease, 
infertility and ectopic pregnanCy. 2 Data from termination 
of pregnancy (TOP) services indicate a prevalence be- 
tween 4.9% and 14.0% (weighted average prevalence of 
7.6%). 3-14 In 2001, over 70,000 diagnoses among males 
and females attending genitourinary medicine. (GUM) 
clinics were recorded, an increase of 158% since 1993.1 
Factors associated with infection in these populations 
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Communicable Disease Surveillance Centre, London, UK 
b GlaxoSmithKline R&D, Worldwide Epidemiology, 
Middlesex, UK 
'Liverpool Public Health Laboratory, University Hospital 
Aintree. Liverpool, UK 
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Correspondence: Mr D. S. LaMontagne, HIV/STI Department, Health 
Protection Agency, Communicable Disease Surveillance Centre, 61 
Colindale Avenue, London NW9 5EQ. UK. 
include young age (<25 years), non-white ethnicity and 
presence of other genital tract infections. 3,5,15 
Around 180,000 medical or surgical terminations of 
pregnancy (TOP) are performed each year 16 and may place 
women at greater risk of ascending upper genital tract 
infection. 17.1 8 The incidence of pelvic inflammatory dis- 
ease in chlamydia-infected women following TOP is be- 
tween 25% and 63%. 17 The chief medical officer's (CMO) 
Expert Advisory Group on Chlaniydia trachomatis has 
advised screening all women attending for TOP, treatment 
of those found to be positive and contact tracing of partners 
for testing and treatment where needed. 19 Guidelines from 
the Royal College of Obstetricians and Gynaecologists 
(RCOG) allow for either (1) prophylaxis for attenders 
without testing for chlarnydial infection or (2) screening 
attenders and treatment if indicated . 
20 There is no mention 
of partner follow up in the RCOG guidelines. Furthermore, 
the Department of Health's recent phased roll out of the 
national Chlarnydia Screening Programme recommends 
opportunistic screening of all women attending for termi- 
nation of pregnancy, with appropriate treatment and partner 
notification for women who test positive. 21 
In this study, we explored current local policy and 
practice for chlarnydia testing and treatment among TOP 
providers in England and Wales. We examined variations 
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in policy and practice by region of the country, service size 
and the degree to which the national recommendations 
regarding testing and treatment for infection have been 
implemented in termination of pregnancy services. 
METHODS 
The most recent (1999) list of termination of pregnancy 
service providers was obtained from the Department of 
Health (England) and included the name, location, and 
annual number of terminations performed for each service. 
This was used as the sampling frame to identify participat- 
ing services. All services on the Department of Health list 
were contacted by telephone to confirm current service 
provision and to verify contact details. 
A survey questionnaire was designed, which requested 
detail on current policies for screening and treating genital 
chlamydial infection; assessment of testing and treatment 
services to client populations; information on follow up for 
women testing positive; and perceived barriers to imple- 
menting chlamydia screening. The survey requested provider 
practice for those persons attending for surgical termination 
separately from those persons attending for medical termi- 
nation. Questionnaires were sent to either the director of 
gynaecology or the lead clinician at each service with a 
response paid envelope addressed to the study administrator. 
A second mailing was sent to non-responders after four 
weeks. Larger centres (performing more than 100 termina- 
tions annually) were contacted directly by telephone two 
weeks after this to encourage survey completion. The culoff 
for responding was 10 weeks after the original mailing. 
Data were entered into a secure, password-protected 
Microsoft Access database. A categorical coding frame 
for each free text question was developed. Several survey 
questions were recoded for meaningful analysis. Service 
size was categorised by the annual number of terminations 
reported: fewer than 200 terminations per year (small 
services); 201-600 (medium sized services); or more than 
600 annual terminations (large services). Respondents were 
categorised into either NHS or non-NHS (private and non- 
specialised combined) services based upon the primary 
source of funding reported. Data were analysed using SPSS 
11.5 (SPSS, Chicago, Illinois) and STATA 7.0 (Stata, 
College Station, Texas). Descriptive statistics and bivariate 
analyses with X2 test (as appropriate) were generated. 
Ethical approval for the study was not required as the 
study was a policy survey related to information at the 
service and not patient level. 
RESULTS 
In total, 380 services in England and Wales reported 
terminations in 1999. Seventy-eight services were excluded 
due to duplication on the list, service closure, incomplete 
contact information or changed service mix that no longer 
included terminations. Eighteen services were excluded as 
they were represented by the British Pregnancy Advisory 
Service or Marie Stopes International. As national policies 
exist for these organisations, one survey questionnaire was 
sent to the central office of each organisation. In total, 284 
services were invited to participate in the study. Re- 
sponses were acquired from 156 (55%) services. Eighteen 
providers indicated that they no longer provided a service. 
Results are presented for 138 services (48% response 
rate). 
All regions except the West Midlands were evenly 
represented in services of different size (Table 1). One 
hundred and twenty services (87%) were NHS funded 
and 16 (12%) were non-NHS funded. Two respondents 
(1%) did not provide funding information. Eleven respon- 
dents reported more than one funding source: eight pro- 
vided more than 200 terminations funded by the NHS and 
were classified as such; the other three were classified as 
non-NHS. 
Ninety-six services (70%) reported a written policy for 
screening and/or treatment of genital chlarnydial infection. 
For providers with policies regarding chlamydia screening, 
the most common content areas within the policy included 
testing (82/96), treatment (67/96) and referral of positives 
to GUM clinics (65/96) (Table 1). 
Actual practice showed no difference between attenders 
receiving a medical termination vs those receiving a surgi- 
cal termination (data not shown). For medical terminations, 
providers in Yorkshire and Humberside and East Midlands 
were more likely to employ prophylaxis without testing 
(P < 0.05). For surgical terminations, services in Yorkshire 
and Humberside and the North East were more likely to 
provide prophylaxis without testing (P < 0.05). 
NHS services were more likely than non-NHS services 
to have a screening and/or treatment policy (75% vs 38%, 
P<0.05); screen all or some of their surgical ten-nination 
attenders (74% vs 50%, P<0.05); and treat all or some of 
their medical termination attenders (97% vs 71%, P<0.05). 
Additionally, NHS services were more likely to report more 
than 50% of their attenders were screened for chlamydial 
infection (91% vs 30%, P<0.05). 
Medium and large services were more likely than small 
services to have a written policy for screening and/or 
treatment (79% vs 51%, P<0.05). More small services 
did not screen wornen attending for surgical tern-driations 
(41% vs 26% [medium] vs 22% [large], P<0.05). Small 
services were less likely than medium or large services to 
telephone test results to women who were screened (12% vs 
33% vs 51%, P<0.05). Small services were also less 
likely to report a formal policy of onward referral of 
chlarnydia positive patients (50% vs 69% fmedium] vs 
84% [large], P<0,05). 
Both the RCOG and CMO guidelines recommend 
screening attenders and treating those who are positive. 
Over one-third of services administered treatment without 
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Table 1. Characteristics of 138 services that responded. Values are given 
as n (%). 
Service provider characteristics Number and 
percentage of service. s 
Region 
Fast Midlands 15 (11) 
Eastern 13 (9) 
London 13 (9) 
North East 11 (8) 
North West 20(15) 
South East 16 (12) 
South West 18 (13) 
Wales 15(11) 
West Midlands 3 (2) 
Yorkshire and Humberside 14(10) 
Annual number of terminations (11 135) 
<200 (small) 39(28) 
201-600 (medium) 48 (35) 
600 or more (large) 48 (35) 
Existing policy (n = 136) 96(70) 
Policy covers 
Testing for genital CT infection 82(85) 
Specimen collection and delivery 45(47) 
Receipt of laboratory results 50(52) 
Treatment of women testing positive 67(70) 
Counselling regarding STIs 43(45) 
Partner notification 26(27) 
Referral to GUM services 65(68) 
Treatment of all attenders 14(15) 
Termination practice* 
Surgical tenninations 133 (96)t 
Medical terminations 109 (79)t 
Actual screening and Surgical TOP Medical TOP 
treatment practice for CT 
Neither screens nor treats 3(2) 5(5) 
Prophylaxis without screening 35(26) 25 (23) 
Screening and treatment 95 (71) 79(73) 
Among TOP providers that screen (Table 1, final row), 
93% screened all attenders, regardless of surgical or med- 
ical termination. Half of the services that screen adminis- 
tered antibiotic treatment for those testing positive (52% 
and 56% of surgical or medical termination) and half 
treated all those screened (48% and 44%). Among services 
that screen for chlamyclial infection then treat, if positive, 
over 90% of providers tested attenders before the termina- 
tion procedure, regardless of the procedure, and over 80% 
administered treatment on-site. Treatment mostly occurred 
during or after termination (70% surgical and 63% medical 
terminations). Adherence to the RCOG-recommended first- 
line therapy was reported by 42% of surgical and 48% of 
medical termination providers. 
Very few providers performed partner notification ac- 
tivities themselves (<5%). Approximately half the services 
(48% of surgical termination providers and 51% of medical 
termination providers) referred women who test positive 
onto GUM. 
Cervical swabs were used exclusively by over half of 
screening services, and a combination of swabs and urine 
was employed by nearly a third, regardless of type of 
termination procedure. Fewer than 10% of providers were 
using urine only for specimen collection. Full employment 
of nucleic acid amplification tests was less than 25%; an 
additional 50% of providers used only non-amplified tests, 
such as enzyme immunoassays; and about 20% used a 
combination of these. 
The most common factors reported to limit the delivery of 
chlamydia testing were lack of financial support (46/138) 
and time constraints in clinic (38/138). Several service 
providers stated that prophylactically treating all TOP at- 
tenders was easier, more reliable and more cost effective 
(data not shown). 
CT = Chlamydia trachomatis, STIs = sexually transmitted infections. 
GUM = genitourinary medicine. 
Totals and percentages may not add to total respondents due to non- 
responses on some questions. Percentages may exceed 100% due to 
rounding or multiple responses. 
* Surgical and medical termination categories arc not mutually 
exclusive; 106 providers are represented in both categories. 
t Excludes two services that did not respond to testing and treatment 
practice questions and three services that did not provide surgical 
tem-dnations. 
I Excludes I service that did not respond to testing and treatment 
practice questions and 28 services (hat did not provide medical 
terminations. 
screening (Table 1, next to last row). Eighty percent (28/35) 
of surgical termination providers reported administration of 
treatment during or after the procedure and 60% of these 
reported that they administered the RCOG recornmended 
first-line therapy. Medical termination providers, which 
provided prophylaxis without testing for chlarnydial infec- 
tion, showed a similar pattern of treatment. 
DISCUSSION 
Our study found significant heterogeneity in the behav- 
iour of termination of pregnancy services in their approach 
to testing and treating for genital chlarnydial infection. 
Three distinct patterns emerged: (1) TOP providers that 
screened attenders prior to termination and treated if 
necessary, (2) providers that administered prophylactic 
antibiotics without testing; and (3) providers that did not 
screen or treat. A possible explanation for these patterns 
might be uncertainty in best practice due to the overlapping 
and diverging recommendations of the RCOG and the 
CM0. 
Among the nearly 70% of providers that engaged in 
screening before termination, over 90% tested everyone. 
The RCOG and CMO guidelines are most similar on this 
point but the RCOG guidelines do not explicitly recom- 
mending testing all patients. Consistency in this policy 
directive between the two bodies may be warranted. 
Most screening providers tested prior to termination, as 
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recommended, and collected an appropriate sample. How- 
ever, less than half were using the more sensitive nucleic 
acid amplification test that is the current diagnostic 
standard .21 As TOP providers are likely to become increas- ingly involved in routine testing for genital chlamydial 
infection, it is necessary that laboratory capability also 
improves to provide the best diagnostics for this population. 
For all services, differences in the treatment regimen 
administered were apparent. Inconsistency in the recom- 
mended treatment regimens between the RCOG and CMO 
policies may be influencing these providers' practices. The 
majority of these providers were in compliance with one 
guideline or the other, but this lack of explicit and consist- 
ent direction for treatment is of some concern. Lack of 
consistency between guidelines was demonstrated in that 
about 25% of the providers offered prophylaxis to TOP 
attenders without testing, a practice that is only encouraged 
by the RCOG guideline. 20 Additionally, less than two- 
thirds indicated using the RCOG recommended treatment 
regimen. 
Although very few providers reported they neither 
screened nor treated any TOP attender, the fact that any 
provider reported this practice is disturbing. There is 
significant evidence of the health risks associated with 
untreated genital chlarnydial infection 17.19 and these risks 
are much greater for women who have a termination. 
Our study has several limitations. Only about one-half of 
all providers responded to our survey. This is an important 
source of bias, the direction of which is not possible to 
predict. Secondly, we do not know to what *extent the 
responses of the central offices for the British Pregnancy 
Advisory Service and Marie Stopes International represent 
the practice of providers within their networks. FinallY, 
there may have been practice changes in the intervening 
years between our survey and this publication, especially in 
light of the large amount of national coverage for the 
Department of Health's phased roll out of the national 
Chlamydia Screening Programme in England. 
In conclusion, we found that over 95% of responding 
TOP providers reported practice consistent with either the 
RCOG or CMO guidelines on Chlaniydia trachonialis, 
although there were discrepancies. Specifically, guidelines 
need clarifying on (1) whether antibiotic prophylaxis 
should be offered to all TOP attenders without testing; 
(2) what is the appropriate treatment regimen for both 
prophylaxis without testing and test then treat policies; 
and (3) what should be the laboratory test standard for all 
women submitting a sample for chlarnydia testing. Addi- 
tionally, the absence of any guidance regarding partner 
notification and contact tracing for women testing positive 
in the RCOG recommendations should be addressed. Syn- 
chronising the RCOG and CMO guidelines would be 
beneficial in harmonising a universal standard for chla- 
mydia testing and treatment for all women, increasing the 
compliance of providers and may encourage providers to 
begin a testing programme within their service. 
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